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A new exofacial photoaffinity label for studying glucose transporters has been 
developed. This compound is 2-N-[4-(l-azi-2,2,2-trifluoroethyl)benzoyl]-l ,3-bis-(D- 
mannos-4-yloxy)-2-propylamine (ATB-BMPA). Binding of ATB-BMPA to the 
erythrocyte glucose transporter (GLUT1) renders the protein less susceptible to 
proteolysis by trypsin and thermolysin than both unlabelled GLUT1 and cytochalasin 
B-labelled GLUT1. The GLUT1 18 kDa tryptic fragment has a lower affinity for 
ATB-BMPA and a higher affinity for D-glucose than untreated, native GLUT1.
The ability of GLUT1 mutants expressed in CHO cells to transport 2-deoxy-D- 
glucose and to bind the external and internal ligands, ATB-BMPA and cytochalasin 
B has been investigated. Mutation of glutamine 282 to leucine in transmembrane 
segment (TM) 7 of GLUT1 selectively perturbs binding of the external ligand, ATB- 
BMPA to the mutant GLUT1. The mutation of tyrosine 293, at the top of TM7, to 
isoleucine renders the mutant GLUT1 unable to transport 2-deoxy-D-glucose or to 
bind the internal ligand, cytochalasin B. A GLUT1 mutant in which proline 385, in 
TM10, is substituted with isoleucine loses the ability to transport 2-deoxy-D-glucose 
and to bind ATB-BMPA. The ability of GLUT1 to bind the external ligand, ATB- 
BMPA, is lost upon deletion of 25 residues from the C-terminal of GLUT1. The 
results obtained are interpreted in terms of the possibility of a close association of 
transmembrane segments 7 and 12 in the 3-dimensional structure of GLUT1. The six 
transmembrane segments of the C-terminal half of GLUT1 may be arranged 
concentrically, with TM7 next to TM12, to form a channel. The outside site would 
be occupied by an upward movement of TM7 and TM12 which may move a
II
proteolytic cleavage site into an inaccessible location. Tyrosine 293 may form part 
of a hydrophobic region at the external binding site. Mutation of tyrosine 293 may 
prevent the conformational change that is required to transport a substrate and to 
subsequently expose the internal binding site. The proline-rich region of TM10, 
particularly proline 385, may play an important role in the conformational changes of 
the glucose transporter protein.
The impermeant photolabel ATB-BMPA has been used in conjunction with 
specific antibodies to GLUT1 and to the insulin-responsive isoform (GLUT4) to 
investigate the insulin-stimulation of glucose transport activity in rat adipocytes. 
GLUT4 is found to be the major isoform in rat adipocytes and accounts for « 90 % 
of the cell-surface glucose transporters in insulin-stimulated cells. Insulin is found to 
increase cell-surface GLUT4 by ~ 15-20-fold and cell-surface GLUT1 by « 4-fold. 
These levels of stimulation are contrasted with the increase in glucose transport 
activity which is * 30-fold. The appearance of both GLUT1 and GLUT4 at the cell- 
surface precedes the transport stimulation which shows a lag period of * 47 sec. The 
discrepancies between transport stimulation and transporter translocation may be due 
to an « 2-fold intrinsic activation of the transporters.
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CHAPTER 1 : INTRODUCTION
1.1. The Glucose Transporter Family
The uptake of glucose into cells is a very important process and is achieved 
by a protein present in the cell membrane. The hexose transporter in most mammalian 
cells is the passive, facilitative diffusion type in which net transport always occurs in 
the direction of high to low sugar concentration. However, a number of cell types 
such as kidney, small intestine and bacterial cells contain an active transporter 
protein that can transport sugars against their concentration gradient by co-transporting 
ions such as H+ or Na+. The transporters display a strong specificity for D- 
stereoisomers of pentose and hexose monosaccharides adopting the chair configuration 
of the pyranose ring such as D-glucose, D-galactose or D-mannose. A family of 
glucose transporters have now been identified (Table 1) which display a high degree 
of sequence homology and are all predicted to have a similar structure within the 
membrane, consisting of 12 membrane spanning domains. However, they vary greatly 
in their tissue distribution, specificity and regulation. In order to have a better 
understanding of the way that the protein transports sugars, the conformational 
changes of the glucose transporter upon binding of external and internal ligands have 
been investigated in the native erythrocyte glucose transporter and in a number of 
mutant glucose transporter proteins. The regulation of glucose transport in the adipose 
cell, where two different glucose transporter isoforms are both differentially regulated 
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Table 1 Properties o f the Mammalian Facilitative Diffusion Glucose 
Transporter Family
3
1.1.1. The Erythrocyte, HepG2-tvt>e Glucose Transporter (GLUT1)
The erythrocyte glucose transporter is known to be an integral membrane 
protein with an approximate molecular weight of 55 kDa, as shown by SDS-PAGE. 
An antibody generated against this protein was used by Mueckler et al, (1985), to 
screen a cDNA library prepared from the human HepG2 hepatoma cell line. A cDNA 
encoding a 492 amino acid glucose transporter protein was isolated. The predicted 
amino acid sequence corresponded with partial amino acid data obtained for the 
erythrocyte transporter.
Bimbaum et al, (1986), cloned and sequenced glucose transporter cDNA from 
adult rat brain and found 97.6 % identity to the HepG2 glucose transporter. GLUT1 
mRNA has been identified in most tissues, the highest levels being in fetal tissues and 
placenta. The highest levels in adults are found in brain, kidney and colon, with only 
low levels in liver and skeletal muscle, two important sites of glucose uptake. GLUT1 
is also expressed in most cultured cell lines, generally at much higher levels than in 
the original cell type. Elevated levels of GLUT1 have also been observed in a range 
of tumours (Yamamoto et al, 1990).
1.1.2. The Liver-Type Glucose Transporter (GLUT2)
Bimbaum et al, (1986) noted that very little mRNA was detected in rat liver 
when screened for rat brain glucose transporter mRNA compared with the large levels 
of glucose transport observed and so concluded that a different glucose transporter 
must be present in rat liver. In 1988, two groups cloned a unique glucose transporter
4
from human and rat liver. Thorens et al, (1988), screened a rat liver cDNA library 
with rat brain glucose transporter cDNA and found a protein of 522 amino acids with 
55 % identity with GLUT1. They expressed the protein in an E. Coli mutant deficient 
in glucose transport activity and showed that the protein transported glucose.
Fukumoto et al, (1988), obtained a human GLUT2 cDNA from kidney and 
liver cDNA libraries and found a protein of 524 amino acids with a 55.5 % identity 
with GLUT1. There is 82 % identity between human and rat GLUT2. GLUT2 is 
expressed at highest levels in liver and pancreatic 6-cells, and at lower levels in 
kidney and small intestine.
GLUT2 differs from GLUT1 in that it transports fructose, with an apparent K,,, 
of 100 mM (Gould et al, 1991). It is also unable to bind the internal ligand forskolin 
(Hellwig & Joost, 1991) and binds cytochalasin B only weakly (Ciaraldi et al, 1986, 
Hell wig & Joost, 1991).
Insulinoma cells express GLUT1 rather than the GLUT2 which is normally 
present in the pancreatic 6-cell (Thorens et al, 1988). Thorens et al, (1988) suggest 
that this abnormal expression of GLUT1 may be related to an inability of the 
insulinoma cells to secrete insulin in response to elevated glucose levels.
1.1.3. The Brain-Type Glucose Transporter (GLUT3)
The GLUT3 glucose transporter isoform was first identified by probing a 
human fetal skeletal muscle library with GLUT1 cDNA (Kayano et al, 1988). The 
GLUT3 cDNA was found to encode a protein of 496 amino acids having 64 % and 
52 % identity with GLUT1 and GLUT2 respectively. GLUT3 mRNA is present in
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all tissues but is most abundant in adult brain, kidney, gall bladder and placenta. 
GLUT3 has been expressed in CHO cells (Asano et al, 1992), where it was found to 
be localized mainly to the plasma membrane. GLUT3 has similar characteristics to 
GLUT1, but has a lower and Vmax for 3-O-methyl-D-glucose transport (Asano et 
al, 1992c). GLUT3, like GLUT1, has been found to be overexpressed in cancer tissue 
(Yamamoto et al, 1990).
1.1.4. The Insulin-Responsive Glucose Transporter (GLUT4)
GLUT4 was first identified using a monoclonal antibody (mAb IF8) prepared 
against a low-density microsomal fraction of rat adipocytes (James et al, 1988). The 
antibody was used to immunodetect a 43 kDa protein in the plasma-membrane of rat 
adipocytes, whose concentration was increased 5-fold after cellular insulin exposure. 
James et al, (1989), obtained GLUT4 cDNA from both rat adipocyte and heart 
libraries. Bimbaum (1989) cloned GLUT4 cDNA from a skeletal muscle library. 
GLUT4 was found to be a 509 amino acid protein with 65 % identity with GLUT1.
The highest levels of GLUT4 mRNA are in insulin-responsive tissues such as 
cardiac and skeletal muscle, heart and brown and white adipose tissue (James et al, 
1989). GLUT4 mRNA is also expressed in 3T3-L1 adipocytes but only after 
differentiation of the fibroblastic cell line into adipocytes (James et al, 1989).
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1.1.5. The Small Intestine Glucose Transporter (GLUT5)
The GLUT5 cDNA was isolated from a human small intestine cDNA library 
by Kayano et al, (1990). GLUT5 encodes a protein of 501 amino acids and has 41.7 
%, 40 %, 38.7 % and 41.6 % identity with GLUT’s 1, 2, 3 and 4, respectively. The 
mRNA is found at high levels in small intestine and at much lower levels in kidney, 
skeletal muscle and adipocytes. Burant et al, (1992), have expressed GLUT5 in 
Xenopus oocytes and have shown that it is a high affinity fructose transporter that is 
not inhibited by cytochalasin B or D-glucose.
Although both GLUT2 and GLUT5 are in small intestine, GLUT2 is located 
on the basolateral membranes of the absorptive cells and GLUT5 is located on the 
apical membranes of the absorptive cells. Therefore Burant et al, (1992), suggest that 
GLUT5 is the most important transporter for fructose uptake from the lumen of the 
small intestine.
1.1.6. The Glucose Transporter Pseudogene (GLUT6)
A glucose transporter pseudogene was identified by Kayano et al, (1990), and 
is part of an 11 kilobase transcript that is expressed in all tissues examined. A portion 
of this pseudogene (1.5 kilobase pairs) has 79.6 % identity with GLUT3. Because of 
the presence of multiple stop codons and frame shifts the sequence can not encode a 
functional glucose transporter protein. However, this pseudogene was termed GLUT6.
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1.1.7. The Microsomal Glucose Transporter (GLUT7)
GLUT7 was identified when Waddell et al, (1992) used antibodies raised 
against a 52 kDa rat liver microsomal glucose transport protein (a component of the 
glucose-6-phosphatase system) to screen a rat liver cDNA library. Two of the positive 
clones were found to be GLUT2 but the other 4 clones encoded a unique microsomal 
glucose transporter protein. The largest GLUT7 clone encoded a protein of 528 amino 
acids with 68 % identity to GLUT2. GLUT7 has an additional 6 amino acids at its 
C-terminal compared with GLUT2 and these amino acids contain a consensus motif 
for membrane-spanning proteins targeted to the endoplasmic reticulum. When GLUT7 
was expressed in COS-7 cells (Waddell et al, 1992), it was found in the endoplasmic 
reticulum and nuclear membrane and was shown to be functionally active in glucose 
transport.
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1.2. The Structure of the Glucose Transporter Protein
1.2.1. The Two-Dimensional Membrane Topology of the Glucose Transporter
Analysis of the hydropathy profile of the GLUT1 amino acid sequence led 
Mueckler et al, (1985) to suggest a model for the glucose transporter in which it has 
12 integral membrane spanning segments with both N- and C-termini located in the 
cytoplasm (Fig. 1). There is a large hydrophilic loop of 65 amino acids between 
transmembrane segments (TM) 6 and 7 and an extracellular loop of 33 amino acids 
between TM1 and TM2, containing an asparagine which is glycosylated by a 
mannose-rich carbohydrate moiety (Mueckler et al, 1985).
The two-dimensional structural topology of the glucose transporter protein in 
the membrane has still not been totally proven. The cytoplasmic location of the C- 
terminal and the central hydrophilic loop have been confirmed by studies with 
proteolytic enzymes (Cairns et al, 1987) and specific peptide antibodies (Davies et al, 
1987, 1990). Davies et al, (1990) produced anti-peptide antibodies to a number of the 
predicted intracellular and extracellular extramembranous domains but only those 
against the large central loop and C-terminal recognized the native transporter. The 
exofacial location of cysteine 429 (predicted to be in TM12) has been confirmed by 
studies in which the substitution of cysteine prevented inhibition of glucose transport 
by sulphydryl-reactive agents (Wellner et a l  1992). Also the loop between TM1 and 
TM2 is known to be extracellular because it contains the single site of N-linked 
glycosylation of the transporter (Cairns et alt 1987).
Analysis of the amino acid sequences of the other members of the glucose 
transporter family suggest that they all have a similar membrane topology to that of
9
Fig. 1. Predicted model for the arrangement o f the G LU Tl/H epG 2 glucose 
transporter in the plasma membrane as proposed by M ueckler et a l (1985). The
glucose transporter is predicted to have 12 membrane spanning segments with the N- 
and C-termini facing into the cytoplasm. The glucose transporter is glycosylated on 
asparagine 45 in the extracellular loop between transmembrane segments 1 and 2. 
Regions of the glucose transporter involved in the binding of the exofacial photolabel 
ATB-BMPA (Ala 301-Arg 330) and the endofacial photolabel cytochalasin B (Phe 
389-Trp 412) are shown (Davies et al, 1992).
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GLUT1. GLUT2 varies greatly from GLUT1 in two domains (Fukumoto et al, 1988, 
Thorens et al, 1988). GLUT2 has a larger extracellular loop (between TM1 and TM2) 
with an extra 32 amino acids. Both transporters are glycosylated in this region. The 
C-termini of GLUT1 and GLUT2 are not well conserved and GLUT2 has a potential 
cAMP dependent-protein kinase phosphorylation site in its C-terminal portion 
(Fukumoto et al, 1988).
GLUT4 has a slightly longer N-terminal region before TM1. GLUT1 and 
GLUT4 sequences vary most in the predicted soluble domains, particularly the large 
cytoplasmic C- and N-termini and central loop regions and also within the predicted 
transmembrane segment 3 (James et al, 1989).
1.2.2. Glycosylation of the Glucose Transporter
The heterogeneity of the glucose transporter on SDS-PAGE, where it runs as 
a broad band corresponding to an approximate molecular weight of 45-65 kDa, is due 
to glycosylation of the transporter on asparagine 45 (Mueckler et al, 1985). Removal 
of the carbohydrate by endoglycosidase F treatment produces a single band on SDS- 
PAGE of 46 kDa (Gorga et al, 1979). Feugeas et al, (1990) found that N-glycanase 
treatment of the human erythrocyte glucose transporter resulted in an inhibition of 
glucose transport activity and so concluded that glycosylation is essential for glucose 
transport activity. However, partial removal of the carbohydrate with endo-6- 
galactosidase did not reduce glucose transport activity (Wheeler & Hinkle, 1981).
Mutation of asparagine 45 to either aspartate, tyrosine or glutamine resulted in 
the mutant GLUT1 clones having an increased for 2-deoxyglucose uptake and a
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much lower affinity for both the internal ligand, cytochalasin B, and the external 
ligand, ATB-BMPA, than the wild-type GLUT1 (Asano et al, 1991). Subsequent 
studies by Asano et al (1993) have shown that the lack of N-glycosylation causes 
improper targeting of the protein to the cell surface. The stability of the 
glycosylation-deficient GLUT1 protein is also decreased (Asano et al, 1993).
1.2.3. The Three-Dimensional Structure of the Glucose Transporter
The three-dimensional structure of the glucose transporter is not at present 
known due to the difficulties in obtaining crystals, and so crystallographic data, for 
this membrane-associated protein. Chin et al, (1987) reported circular dichroism 
measurements that indicated that the purified erythrocyte glucose transporter protein 
(GLUT1) contains mainly (> 82 %) a-helical structure with small amounts of B-tum 
of ~ 10 % and of random coil of * 8 % but with no B-strands. Fourier Transform 
Infrared Spectroscopy of this glucose transporter (Alvarez et al, 1987, Cairns et al, 
1987) suggested that it is mainly a-helical with a little B-sheet and random coil 
conformation. The cytoplasmic C-terminal portion removed by trypsin was also found 
to contain a-helical structure (Cairns et al, 1987).
A speculative model for the 3-dimensional arrangement of the 12 membrane 
spanning segments is shown in figs. 2 & 3. The duplication of sequences in the N 
and C-terminal halves of the transporter has led to speculation that a gene duplication 
event may be responsible for the present structure of the glucose transporter and that 
the two halves might be arranged in a similar manner (Maiden et al, 1987).
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Fig. 2. A speculative model for the 3-dimensional arrangement of the 12 
membrane spanning segments of the glucose transporter protein. The model 
predicts that the N- and C- terminal halves of the glucose transporter might be 
arranged in a similar manner. Transmembrane segments 7, 8 and 11 are predicted 
to be amphipathic and may form part of a hydrophilic channel (Mueckler et al, 1985).
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Side View Top View
Human GLUT1 Model
Fig. 3. A putative model of GLUT1 (produced by Dr P. Hodgson, University of 
Bath). A putative model of GLUT1 based on molecular dynamic simulations. The 
N- and C-terminal halves are shown in green and orange, respectively. The 
cytoplasmic central loop and C-terminal are shown in blue.
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Transmembrane segments 7, 8 and 11 are predicted to be amphipathic and may form 
part of a hydrophilic channel (Mueckler et al, 1985).
All evidence presently available suggests that glucose is transported through 
the C-terminal half of the protein only. The photoaffinity ligands, cytochalasin B, 
ATB-BMPA and IAPS-forskolin all bind, in a glucose displaceable manner, to the C- 
terminal half only (Karim et al, 1987, Clark & Holman, 1990, Wadzinski et al, 1990, 
Hell wig et al, 1992). Katagiri et al (1992) replaced the intracellular C-terminal 
domain of GLUT1 with that of GLUT2 and found that the C-terminal domain 
conferred GLUT2-like properties on the transporter, suggesting that the diversity of 
the C-terminal domains of the glucose transporter isoforms may contribute to the 
diversity of the differing characteristics of the glucose transporter isoforms.
Although the N-terminal half does not appear to bind transporter ligands, it is 
essential for glucose transport activity and is probably involved with transporter 
regulation. It has been suggested that the N-terminal of GLUT4 is necessary for 
sequestration of this isoform within the cell (Piper et al, 1992, 1993). The external 
ligand, ATB-BMPA, only binds to the bacillovirus-expressed C-terminal half of 
GLUT1, when the N-terminal half of GLUT1 is also expressed (Cope, Holman & 
Wolstenholme, manuscript in preparation). Mutation of asparagine 45, which prevents 
the normal glycosylation of GLUT1 in the N-terminal half of the protein, has been 
found to alter GLUT1 targeting and stability (Asano et al, 1991, 1993).
1.2.4. The Higher Order Structure of the Glucose Transporter
Whether the glucose transporter protein is present in the membrane as a
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monomer or as an oligomeric form is still not known. Radiation inactivation studies 
have been carried out by a number of groups. Jacobs et al, (1987), suggest that the 
adipocyte glucose transporter (now known to be GLUT4) occurs as a monomer in the 
plasma membrane, whilst existing as a homodimer, or as a stoichiometric complex 
with a protein of approximately equal size, in the intracellular membrane pool. Jarvis 
et al, (1986), suggest that the human erythrocyte glucose transporter exists as a dimer 
in the membrane with an apparent M,. of 124 ± 11 kDa, whereas Cuppoletti et al, 
(1981) obtained a M, of 185 kDa, suggesting a tetramer. Hebert & Carruthers, (1992) 
suggest that the native glucose transporter is a homotetramer which is stabilized by 
intramolecular disulphide bonds and that it can be transformed to dimeric GLUT1 by 
alkaline reduction.
Pessino et al, (1991) expressed chimeric glucose transporters with the C- 
terminal of GLUT1 replaced with the C-terminal of GLUT4 in CHO cells harbouring 
endogenous GLUT1. They found that endogenous GLUT1 could be immuno- 
precipitated with an anti-GLUT4 peptide antibody and therefore suggested that GLUT1 
may exist as a dimer or higher order oligomer. Burant & Bell, (1992) coexpressed 
two different glucose transporter isoforms in Xenopus oocytes and found that the 
oocytes produced kinetic properties that reflected the parental transporters rather than 
a protein with intermediate properties. Also when varying amounts of a normal and 
functionally inactive transporter were coexpressed, they found no inhibition of glucose 
transport. They therefore concluded that a monomer is the functional unit of transport 
activity (Burant & Bell, 1992).
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1.3. Glucose Transporter Kinetics and Substrate Recognition
1.3.1. Glucose Transporter Kinetics
The erythrocyte glucose transporter exhibits asymmetrical kinetics, the K,,, and 
Vmax values for zero-trans efflux being considerably greater than those for influx 
(Lowe & Walmsley, 1986). The transporter also exhibits fraAts-acceleration, that is, 
the stimulation of the unidirectional flux of labelled sugar across the membrane by the 
presence of unlabelled sugar on the opposite side of the membrane. Glucose transport 
in erythrocytes is highly temperature dependant. Lowe and Walmsley (1986) found 
that the inequalities in the maximum rates of i&xo-trans efflux and influx and 
equilibrium exchange, decrease as the temperature rises and almost disappear at 
physiological temperature. At low temperatures, the marked asymmetry arises mainly 
from the high proportion of inward-facing transporters and transporter-glucose 
complexes. At physiological temperatures, the transporter is fairly evenly distributed 
between outward- and inward-facing conformations and the affinity for glucose is 
about 2.5 times greater outside than inside (Lowe & Walmsley, 1986).
Whereas transport in erythrocytes is asymmetric, in the rat adipocyte glucose 
transport properties were found to be symmetrical in both the basal and insulin- 
stimulated states (Taylor & Holman, 1981).
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1.3.2. The Alternating Conformation Model
Glucose transport in the erythrocyte is purely passive and does not require any 
input of energy, from either a concentration gradient of a second carried substrate or 
a chemical reaction , such as the hydrolysis of ATP. In 1952, Widdas demonstrated 
that human erythrocyte and sheep placental glucose transport were characterised by 
simple Michaelis-Menten saturation kinetics. His studies led to the proposal of the 
alternating conformation model for sugar transport (Fig. 4).
The glucose transporter is proposed to contain mutually exclusive saturable 
sugar influx and efflux sites. When sugar binds to one of these sites to form the 
carrier-sugar complex, a conformational change is promoted that results in sugar 
translocation, dissociation of the sugar from the carrier at the opposite side of the 
membrane, and the exposure of the glucose transport site at the opposite side of the 
membrane. The carrier is now available for transport in the opposite direction or can 
isomerize back to its original state with the sugar binding site exposed at the original 
side of the membrane.
Appleman & Lienhard (1989) measured the rates of interconversion of the 
transporter conformers T} and T0 in the presence and absence of D-glucose using 
intrinsic fluorescence. The values of the individual rate constants obtained were 
consistent with the alternating conformation model (Appleman & Lienhard, 1989).
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Fig. 4. The alternating Conformation Model for Sugar Transport In the absence 
of substrate (S), the transporter (T) can exist as only 1 of 2 possible interconverting 
isomers: T0 where the binding site faces the outside of the cell, and where the 
binding site faces the inside of the cell. On addition of intracellular or extracellular 
sugar (S), a transporter-sugar complex is formed which undergoes a conformational 




A number of more complex models for glucose transport have been proposed 
in which multiple substrate binding sites are simultaneously present on the transporter 
(Helgerson & Carruthers, 1987, Hebert & Carruthers, 1992). The glucose carrier is 
proposed to contain saturable sugar influx and efflux sites that exist simultaneously. 
In order to explain the trans-phenomena in glucose transport, these investigators 
suggest that the two sites display negative cooperativity.
Hebert & Carruthers (1992) propose that the glucose transporter protein is 
tetramer and is stabilized by intramolecular disulphide bonds. According to their 
model, in a multisubunit transporter the transfer of substrate to an inside site is 
conformationally coupled to the exposure of an external site on another subunit of the 
transporter. This would allow external and internal ligands to simultaneously occupy 
the oligomeric transporter.
Hellwig & Joost, (1991) investigated the affinities of various ligands for 
GLUT1, GLUT2 and GLUT4 glucose transporter isoforms in a number of different 
tissues. They suggest that the complex differences they found result from the 
interaction of more than one heterogeneous binding site on the glucose transporter 
with the ligand.
Nishimura et al, (1992a) using monoclonal antibodies directed against 
erythrocyte GLUT1 found that D-glucose binding inhibited the binding of these 
monoclonal antibodies by 50 %. A high concentration of cytochalasin B inhibited the 
binding of one of these monoclonal antibodies to the erythrocyte GLUT1. However, 
a low concentration of cytochalasin B enhanced the binding of another of the 
monoclonal antibodies which presumably recognised a different epitope. Nishimura
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et al, (1992a) therefore suggest the existence of high and low affinity binding sites for 
D-glucose and cytochalasin B. They suggest that the binding of these ligands cause 
different conformational changes within the glucose transporter depending on whether 
they occupy a low or a high affinity site.
1.3.4. Side Specificity of the Glucose Transporter
Side specificity of the glucose transporter in erythrocytes has been investigated 
using D-glucose analogues (Barnett et al, 1973a, b, 1975). Introduction of bulky 
groups into the hydroxyls at the C4 and C6 positions of D-glucose produced analogues 
which were tolerated by the external site of the transporter. However, substitution at 
C l of D-glucose resulted in loss of binding. The reverse occurred when glucose 
derivatives interacted with the internal site of the transporter. Here, C l alkyl 
substituted compounds bound well, but C4 and C6 derivatives did not. Barnett et al 
(1973a,b) concluded that there must be a structural link between the inside and outside 
sites which forces the sugar to enter the transporter from the outside with C l first and 
C4/C6 trailing. This polarization of the sugar is maintained throughout the transport 
channel (Fig. 5). 4,6-O-ethylidene-D-glucose is a good outside specific hexose while 
propyl B-D-glucopyranoside is inside specific (Barnett et al, 1973b).
Spacial requirements for hexose binding to the outside site of the rat adipocyte 
glucose transporter have also been investigated (Holman et al, 1981). The spacial 
requirements were found to be similar to those of the erythrocyte glucose transporter 
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Fig. 5. Possible model for sugar transport in the erythrocyte (Barnett et al, 
1973a, b). Glucose is proposed to enter the transporter with Cl first and C4/C6 
trailing and this polarization is maintained throughout the transport channel. 4,6-O- 
ethylidene-D-glucose is a good outside-specific hexose while propyl-6-D-glucoside is 
inside-specific.
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constants for the various analogues were similar in basal and insulin-stimulated cells 
indicating that insulin does not cause a major structural change in the transporter, but 
instead increases the availability of sites of identical specificity (Holman et al, 1981).
1.3.5. Photoaffinitv Labels for the Glucose Transporter
1.3.5.1. Cytochalasin B
Irradiation of 3H-cytochalasin B (Fig. 6) in the presence of purified glucose 
transporter or erythrocyte membranes results in stereospecific, D-glucose inhibitable, 
low efficiency (1-5 %), covalent incorporation of labelled ligand into the glucose 
transporter (Shanahan, 1982). GLUT1 and GLUT4 have a strong affinity for 
cytochalasin B. The dissociation constants (K̂ ,) for cytochalasin B binding to the 
glucose transporter in erythrocytes (KD =190 nM) and in adipocytes (KD =160 nM) 
are similar (Hellwig & Joost, 1991).
Cytochalasin B is thought to bind at the internal surface of the glucose 
transporter in the region of TM10 and TM11 between Phe 389 and Trp 412 (Holman 
& Rees, 1987, Davies et al, 1992). Cytochalasin B is permeable to cells. It is not 
specific for the glucose transporter and so labelling is carried out in the presence of 
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Fig. 6. The structure o f the exofacial and endofacial photoaffinity labels fo r the 
glucose transporter. ATB-BMPA binds to the exofacial surface of the glucose 
transporter and cytochalasin B is inside-specific.
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1.3.5.2. Forskolin
Forskolin is a potent glucose transporter inhibitor and binds to the erythrocyte 
glucose transporter in a cytochalasin B-inhibitable manner (Shanahan et al, 1987). 
Tritiated forskolin and 3-[125I]iodo-4-azidophenylamido-7-0-succinyldeacetylforskolin 
(IAPS-forskolin) are used as photoaffinity reagents for the glucose transporter in 
erythrocytes (Shanahan et al, 1987, Wadzinski et al, 1990) and adipocytes (Zorzano 
et al, 1989, Hellwig et al, 1992). The dissociation constant (KD) for forskolin binding 
to GLUT1 (Kd = 2360 nM) is significantly higher than for binding to GLUT4 (KD = 
200 nM) (Hellwig & Joost, 1991).
The forskolin binding site in the human erythrocyte glucose transporter has 
been localized to TM10 by Wadzinski et al, (1990) who suggest that tryptophan 388 
may be involved. The forskolin binding site in GLUT4 from adipocytes has been 
localized to a site between TM7 and TM9, possibly in the proximity of TM9 (Hellwig 
et al, 1992). They tentatively suggest that forskolin may bind to more than one site 
in a region spanning transmembrane segments 9 and 10.
1.3.5.3. Bis-Mannose Derivatives as Photoaffinitv Labels
A bis-mannose compound (l,3-bis-(D-mannos-4-yloxy)-2-propylamine, BMPA) 
was designed by Midgley et al, (1985) to be an impermeant external ligand for the 
glucose transporter. Two D-mannose residues were cross-linked through their C4 
hydroxyl positions by a 2-propylamine bridge. It has been shown that bulky 
substitutions at the C4 position can be tolerated by both the glucose transporter protein
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in erythrocytes (Barnett et al, 1973a) and adipocytes (Holman et al, 1981).
Radiolabel was introduced into the 2-position of the bridge by reductive 
amination. Various photoreactive substituents were attached to the bis-mannose via 
the amine in the bridge. By synthesizing tritiated derivatives, Midgley et al, (1985) 
showed that the BMPA derivatives were not significantly taken up by either 
erythrocytes or adipocytes over a period of 90 min, neither via the transporter nor 
through the lipid bilayer. The compounds had a higher affinity for the glucose 
transporter protein than the parent compound, D-mannose, but had much lower 
affinities than alternative labelling reagents such as cytochalasin B and IAPS-forskolin. 
Therefore it was important that the photolabile substituent was selective. A 4- 
azidosalicylate derivative of BMPA (ASA-BMPA) was shown by Holman et al, 
(1986) to label the glucose transporter in intact erythrocytes. However, when used 
with isolated membranes, ASA-BMPA gave some labelling of erythrocyte membrane 
band 3 and spectrin. A benzophenone derivative of BMPA (BB-BMPA) has been 
used to label both erythrocyte and adipocyte glucose transporters (Holman et al, 
1988). However, relatively long irradiation times were required for activation of the 
photolabile group, in which time damage to the cells may occur.
1.3.5.4. An Azitrifluoroethylbenzovl-Substituted Bis-Mannose Photolabel
The main properties desired of a photoactivatable group are chemical stability 
prior to photoactivation, rapid photolysis at an appropriate wavelength and a very high 
reactivity of the photogenerated species (Bayley & Knowles, 1977). Carbenes react 
very rapidly with a variety of chemical functions: by coordination to nucleophilic
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centers (to give carbanions), by addition to multiple bonds (including those of 
aromatic systems), by insertion into single bonds (including carbon-hydrogen bonds), 
and by hydrogen abstraction (to give two free radicals that may then couple) (Bayley 
& Knowles, 1977).
The diazirine group as a carbene precursor has many advantages. Diazirines 
are relatively stable in acid. The addition of an electron-withdrawing group such as 
fluorine stabilizes the parent diazo compound and also decreases the tendency to 
Wolff rearrangement after photolysis (Bayley and Knowles, 1977). Brunner et al, 
(1980) synthesised 3-trifluoromethyl-3-phenyldiazirine as a carbene precursor and have 
used this to investigate the hydrophobic regions of membrane proteins (Brunner & 
Richards, 1980).
The structure of the diazirine derivative of BMPA (2-N-[4-(l- 
azitrifluoroethyl)benzoyl]- l,3-bis(D-mannos-4-yloxy)-2-propylamine (ATB-BMPA) is 
shown in Fig. 6. Diazirine substituted hexoses have been used as transported 
substrates for the glucose transporter (Midgley et al, 1985). ATB-BMPA was 
produced in order to get improved labelling of the erythrocyte and adipocyte glucose 
transporters and using a shorter irradiation time.
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1.4. Conformational Changes of the Glucose Transporter Protein
1.4.1. Chemical and Physical Studies on Glucose Transporter Conformational Changes
A number of approaches have been used to investigate the conformational 
changes that occur within the glucose transporter protein. When sugar analogues were 
added to fix the glucose transporter in an inward or outward facing conformation, 
shifts in the a-helical and 6-structure absorptive band were observed (Alvarez et al, 
1987). In the presence of an excess of glucose the a-helical content was reduced and 
there was a significant increase in the random structure content, whereas in the 
presence of cytochalasin B there was no significant change (Chin et al> 1987).
Rampal & Jung, (1987) studied the effect of glucose binding to the erythrocyte 
glucose transporter on its inactivation by alkylating agents such as N-ethylmaleimide 
and found that the substrate-induced conformational change mostly occurred within 
the transmembrane hydrophobic domain. The hydrophilic extracellular domains did not 
show marked changes.
A number of groups have investigated glucose transporter intrinsic 
fluorescence, using several ligands including D-glucose and internal- and extemal-site 
specific ligands. The extent of quenching of tryptophan fluorescence varied depending 
on the liganded state of the transporter. Chin et al, (1992) suggested possible 
interactions between Trp 388 and His 337, Trp 412 and Cys 347 and Trp 412 and Glu 
380, and stressed the importance of helices 9, 10 and 11 in the transport catalysis 
process. Pawagi & Deber, (1990) suggested that the region around Trp 388 could be 
a dynamic segment, which could be located alternately in an aqueous or membrane 
domain. No change in fluorescence quenching was observed with cytochalasin B
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binding (Pawagi & Deber, 1990).
1.4.2. Studying Glucose Transporter Conformational Changes using Proteinases
Proteolysis by enzymes and chemicals has been used to investigate the 
conformational changes that take place within the erythrocyte and adipocyte glucose 
transporter upon binding of ligands at internal and external surfaces.
Non-transported exofacial ligands like phloretin and 4,6-O-ethylidene-D- 
glucose (Gibbs et al> 1988, Yano & May, 1993) and ASA-BMPA (Holman & Rees,
1987) decrease the extent of cleavage by trypsin and thermolysin. This protection can 
not be due to steric hindrance as the native transporter is cleaved solely at its 
cytoplasmic face, within the large loop between TM6 and TM7 and within the C- 
terminal extramembranous region (Cairns etal, 1987). Therefore the exofacial ligands 
are thought to stabilize a conformation in which parts of the cytoplasmic loop and C- 
terminal (which contain the proteolytic cleavage sites) are withdrawn from the 
cytoplasmic surface.
Compounds that are known to bind internally such as methyl and propyl 
glucosides, have been shown to increase the susceptibility of the glucose transporter 
to thermolysin (King eta l, 1991, Yano & May, 1993) and therefore may be stabilizing 
an inward-facing conformation in which the cleavage sites are accessible to the 
protease. When cytochalasin B is covalently bound to the internal surface of the 
erythrocyte glucose transporter it also increases susceptibility to proteolysis (Holman 
& Rees, 1987). Noncovalently bound cytochalasin B does not however alter the 
susceptibility of GLUT1 to proteinases but does reverse the effects of exofacial
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ligands which stabilize the exofacial conformation (King et al, 1991, Gibbs et al,
1988). Surprisingly, cleavage of erythrocyte GLUT1 is decreased by noncovalently 
bound cytochalasin B at higher temperatures of 45-50 °C (Gibbs et al, 1988). In 
contrast, binding of cytochalasin B was found to increase the cleavage of GLUT4 in 
adipocyte microsomal membranes (Yano & May, 1993). The authors suggest that this 
may reflect a greater tendency of the unloaded GLUT4 transporter to assume an 
outward-facing conformation in the absence of cytochalasin B than observed for the 
erythrocyte GLUT1 protein.
D-glucose has been shown to increase the cleavage of the erythrocyte glucose 
transporter by papain (Asano et al, 1992b), thermolysin (King et al, 1991) and trypsin 
(Gibbs et al, 1988) within the cytoplasmic loop and the C-terminal. The observed D- 
glucose effect was thought by King et al, (1991) to be due to the D-glucose at 
equilibrium forming a complex with the internal site. However, this may reflect an 
increased susceptibility of the protein to cleavage during the transport process itself 
(Baldwin, 1993). However, the asymmetric carrier model predicts a small increase in 
the steady state of the proteinase-resistant outward-facing carrier conformation in the 
presence of glucose (Lowe & Walmsley, 1986). By contrast, D-glucose slowed the 
rate of tryptic cleavage of adipocyte GLUT4 (Yano & May, 1993). This suggests that 
the D-glucose-bound GLUT4 transporter has a different conformational stability than 
the unliganded protein.
1.4.3. Site-Directed Mutagenesis of GLUT1
Site-directed mutagenesis studies on GLUT1 have so far implicated a number
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of amino acids as being important or essential for glucose transport activity, specificity 
for substrate and targeting to the cell surface. Garcia et al, (1992) studied mutants of 
GLUT1 using the Xenopus oocyte expression system. They found that mutation of 
tryptophans 388 (at the bottom of TM10) and 412 (at the bottom of TM11) of GLUT1 
to glycine or leucine resulted in an inhibition of glucose transport activity. Binding 
of the internal ligand, cytochalasin B, was partially reduced when either tryptophan 
388 or 412 were mutated which suggests that these tryptophans may comprise part of 
an inside hexose binding site (Garcia et al, 1992, Katagiri et al, 1991). Substitution 
of a leucine for tryptophan 412 did not effect binding of the exofacial ligand, ATB- 
BMPA, (Katagiri et al, 1991).
Substitution of asparagine 415 (TM11) for aspartate resulted in an increase in 
Kjj, and a decrease in the turnover of the mutant transporter compared to the wild-type 
(Ishihara et al, 1991). They suggest that the asparagine may play a role in 
determining the rate of the conformational change between an inward-facing form and 
an outward-facing form of the glucose transporter.
Marshall-Carlson et al, (1990) investigated some glucose transport deficient 
mutants from Saccharomyces Cerevisiae. A conservative amino acid change of valine 
402 to isoleucine in TM8 caused a defect in the glucose transporter function. They 
also found that mutation of glycines 112 and 153, predicted to be near the middle of 
transmembrane segments 1 and 2, perturbed transport suggesting that both are 
important residues. Both glycines are highly conserved.
Wellner et al, (1992) investigated the importance of cysteines 421 and 429 in 
GLUT1 using the Xenopus oocyte expression system. Neither of the residues were 
found to be essential for glucose uptake. Replacement of cysteine 421 at the exofacial 
end of TM11 resulted in partial protection from cytochalasin B inhibition of 3-0-
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methyl-D-glucose transport. Therefore this cysteine may play a role in stabilizing an 
adjacent local tertiary structure necessary for the full activity of cytochalasin B 
(Wellner et alt 1992).
Oka et al, (1990) found that a GLUT1 mutant lacking the C-terminal 37 amino 
acids was not able to transport glucose or bind the external ligand, ATB-BMPA. 
However, the truncated GLUT1 was able to bind the internal ligand, cytochalasin B. 
These results suggested that the glucose transporter was locked in an inward-facing 
conformation with only the inner glucose binding site available. Deletion of only the 
first 12 amino acids from the C-terminal of GLUT1 produced a functional glucose 
transporter that showed no reduction in glucose transport activity or ligand binding 
(Lin et al, 1992).
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1.5. Insulin-Stimulation in Rat Adipocytes
1.5.1. The Translocation Hypothesis for Insulin-Stimulation of Glucose Transport
Insulin increases 3-O-methyl-D-glucose transport in isolated rat adipocytes by 
at least 30-fold. In 1980, two groups simultaneously and independently proposed that 
glucose transporter proteins were recruited from an internal pool to the plasma 
membrane in response to insulin (Fig. 7). Cushman & Wardzala, (1980) measured 
glucose transporter proteins in plasma membrane (PM) and low-density microsome 
(LDM) fractions by D-glucose inhibitable [3H]-cytochalasin B binding. Suzuki & 
Kono, (1980) reconstituted plasma membrane and low-density microsome proteins into 
artificial lipid membranes and measured their glucose transport capacity. Both groups 
demonstrated that plasma membrane from basal adipocytes contained 3-7 fold lower 
glucose transporter content than plasma membrane from insulin-stimulated adipocytes. 
This increase in the glucose transporter content in the plasma-membrane was 
paralleled by a decrease in the glucose transporter content in the low-density 
microsome fraction. It has been shown that stimulation of glucose transport by insulin 
does not involve new protein synthesis but that ATP is required for the translocation 
of glucose transporters to and from the cell surface (Kono et al, 1981).
Initial evidence for glucose transporter translocation was based on fractionation 
studies described above. More direct evidence (not involving subcellular fractionation) 
has come from cell-surface labelling experiments. Holman et al, (1988) used a cell- 
impermeant glucose transporter-specific exofacial photoaffinity reagent (BB-BMPA) 
to label cell-surface glucose transporters in basal and insulin-stimulated rat adipocytes.
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Fig. 7. The translocation hypothesis for insulin-stimulationof glucose transport 
(from Gould & Holman, 1993). The majority of GLUT4 glucose transporters are 
sequestered within the cell in specialized vesicles in the absence of insulin. After 
insulin addition, transporters are translocated to the plasma membrane. After arrival 
of GLUT4 at the membrane an approximate two-fold activation is apparent which 
may be due to dissociation of trafficking proteins. Upon removal of insulin, the 
GLUT4 is endocytosed back into the cell and restored in vesicles.
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BB-BMPA labelling was at least 7-fold greater in insulin-treated versus basal 
adipocytes. Following incubation and washing at 37 °C in the presence of insulin, 30 
% of the transporters photolabelled at the plasma membrane were internalized and 
were found in the LDM fraction of the cell (Holman et al, 1988).
Calderhead and Lienhard, (1988) labelled cell-surface carbohydrate in 3T3-L1 
adipocytes with 3H borohydride then selectively immunoprecipitated GLUT 1-like 
glucose transporters to show a 2.6-fold increase in plasma-membrane glucose 
transporters in response to insulin.
The apparent discrepancy between the extent of GLUT1 recruitment compared 
to the large increase in transport rate was at least partially explained in 1988 when an 
insulin-responsive glucose transporter was discovered. James et al, (1988) produced 
a monoclonal antibody IF8 that recognised an insulin responsive glucose transporter, 
later named GLUT4. These antibodies were used to show that GLUT4, which was 
barely detectably in the plasma membranes of basal adipocytes, was recruited to the 
plasma membrane on addition of insulin, resulting in a 7-8-fold increase in the 
membrane content of this protein.
Slot et al, (1991a) have used electron microscopy to localize GLUT4 in rat 
brown adipose tissue. They found that under basal conditions, 99 % of the GLUT4 
labelling was located within the cell, predominantly in the trans-golgi reticulum and 
tubulo-vesicular structures. In insulin-stimulated cells approximately 40 % of the 
GLUT4 labelling was at the cell surface, where it was randomly distributed, except 
for occasional clustering in coated pits.
The stimulation by insulin of glucose transporter translocation from an internal 
pool to the plasma membrane has also been shown to occur in other tissues including 
heart muscle (Wheeler, 1988), diaphragm muscle (Wardzala & Jeanrenaud, 1981),
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skeletal muscle (Klip et al, 1987) and cardiac muscle (Slot et al, 1991b).
1.5.2. The Internal Pool of Glucose Transporters
Both GLUT1 and GLUT4 glucose transporter isoforms are sequestered in the 
low-density microsome fraction in rat adipocytes (Zorzano et al, 1989, Holman et al, 
1990). GLUT1 and GLUT4 are localized in different vesicle populations in rat 
adipocytes (Zorzano et al, 1989), although both translocate to the plasma-membrane 
in response to insulin to varying extents. GLUT4 was localized to a unique vesicle 
population that consists of less than 3 % of the total low-density microsome fraction. 
These vesicles were analyzed and were found to be of limited protein composition. 
They contained neither the insulin-like growth factor II receptor or the transferrin 
receptor, both of which are translocated to the plasma membrane in response to insulin 
(Zorzano et al, 1989).
Del Vecchio & Pilch, (1991) have identified phosphatidylinositol 4-kinase (PI4- 
kinase) as a component of the GLUT4-containing vesicles (GTV). PI4-kinase was 
also identified in the other LDMs, and the high density microsome and plasma 
membrane fractions and its location was not altered upon insulin-treatment. Cormont 
et al, (1991) found low molecular weight GTP-binding proteins colocalized with 
GLUT4 in GTV*s. Schurmann et al, (1992a) found that although G-proteins were 
localized in the low density microsome fraction, they were not tighdy associated with 
the GTV’s. Cain et al, (1992) screened GTV’s for various synaptic vesicle proteins 
and found that one protein, VAMP (also known as synaptobrevin), was highly 
enriched in GTV’s and also translocated to the plasma membrane in response to
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insulin. Rab3 was the only other synaptic vesicle protein detected but this was also 
observed in the non-GLUT4-containing vesicles. A set of three polypeptides of M, 
« 36-40 kDa (named GTV3) have also been localised to GTV’s (Thoidis et al, 1993). 
The GTV3 proteins may be related, if not completely identical to SCAMPS (secretory 
component-associated membrane proteins) which may be involved in the secretory 
process. Streptozotocin-induced diabetic rats which show a marked reduction in 
GLUT4 levels also have a marked reduction in GTV3 expression.
1.5.3. 3T3-L1 Adipocytes: A Good Model for Studying Insulin-Stimulated Glucose 
Transport
3T3-L1 cells are used for studying insulin action on glucose transport because 
they can be differentiated using isobutylmethylxanthine (IBMX), dexamethasone and 
insulin (Frost & Lane, 1985) to produce differentiated 3T3-L1 adipocytes that respond 
to acute insulin with increases in glucose transport of 10-20-fold above basal level. 
3T3-L1 fibroblasts contain only GLUT1 but during the differentiation period the cells 
produce the insulin-responsive glucose transporter GLUT4. The GLUT1 and GLUT4 
mRNA and protein levels reach a maximum after 8-11 days of differentiation 
(Tordjman et al, 1990, Yang et al, 1992).
The ratio of cell-surface GLUT1: GLUT4 in acutely insulin-stimulated 3T3-L1 
adipocytes is approximately 1:1 (Yang et al, 1992b) compared to 1:9 in insulin- 
stimulated rat adipocytes (Holman et al, 1990). Therefore GLUT1 makes a greater 
contribution to the transport activity in 3T3-L1 adipocytes than in rat adipocytes. 
Calderhead et al (1990) found that GLUT1 and GLUT4 were colocalized in the same
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low-density microsome vesicles in 3T3-L1 adipocytes. Vesicles immunoprecipitated 
with antibodies to GLUT1 contained 95 % of the GLUT4 and vesicles 
immunoprecipitated with antibodies to GLUT4 contained 85 % of the GLUT1 
(Calderhead et al, 1990). Piper et al (1991) immunoabsorbed GLUT4-containing 
vesicles from a partially purified preparation of low density microsomes and absorbed 
90 % of the GLUT4 and only 30 % of the GLUT1. GLUT1 was also found to 
colocalize with both the transferrin receptor and the insulin-like growth factor II 
receptor, which also translocate to the plasma membrane in response to insulin 
(Tanner & Lienhard, 1989). Treatment of 3T3-L1 adipocytes with phenylarsineoxide 
(PAO) results in GLUT1 and GLUT4 exhibiting different trafficking properties during 
recycling. Following PAO treatment of fully insulin-stimulated 3T3-L1 cells, GLUT4 
showed a greater tendency to internalize to the intracellular transporter pool (Yang et 
al, 1992a).
1.6. Regulation of Glucose Transport
1.6.1. The Insulin Receptor
Insulin-stimulation of glucose transport in adipocytes is mediated by the 
interaction of insulin with cell surface insulin receptors (This topic is reviewed by 
Kahn & White, 1988 and Carruthers, 1990). The receptor is a heterotetrameric 
assembly of two a- and two 6- subunits. The a-subunits reside on the extracellular 
surface of the membrane and are linked by interchain disulphide bonds to the 6- 
subunits which span the membrane once and contain a longer C-terminal sequence.
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The mechanism by which insulin binding to its receptor causes a translocation of 
glucose transporters from an internal pool to the plasma membrane is still not 
understood. The purified insulin receptor displays insulin-dependent receptor 
autophosphorylation on tyrosine residues of the 6-subunit and the ability to 
phosphorylate tyrosine residues of exogenous substrates.
Certain mutations within the tyrosine kinase domain of the insulin receptor 
result in markedly reduced or complete loss of insulin-stimulated tyrosine 
phosphorylation. These mutations also produce little or no ability to mediate insulin- 
stimulated glucose transport (Ellis et al, 1986). Synthetic inhibitors of in vivo insulin 
receptor tyrosine kinase activity are known to inhibit insulin-stimulation of glucose 
transport (Saperstein et al, 1989). However, Forsayeth et al, (1987) showed that 
monoclonal antibodies directed against the insulin receptor could produce glucose 
transport stimulation in the absence of insulin receptor tyrosine phosphorylation both 
in vivo and in vitro. It is possible, that the conformations of the tyrosine- 
phosphorylated and antibody-liganded insulin receptor are similar and that it is this 
conformation that results in signal transduction.
1.6.2. Post-Receptor Signalling
Insulin has been shown to stimulate tyrosine phosphorylation of a protein band 
of a molecular weight between 165 kDa and 185 kDa, collectively called ppl85 or 
IRS-1 (insulin receptor substrate-1) (White et al, 1985). The IRS-1 is a minor 
cytoplasmic phosphoprotein found in most cells and tissues and its phosphorylation 
is decreased in cells expressing mutant receptors defective in signalling. IRS-1 has
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been cloned by Xiao et al, (1991) and has been shown to contain over ten potential 
tyrosine phosphorylation sites, nine of which are in YXXM motifs.
During insulin stimulation of CHO cells expressing the human insulin receptor, 
the IRS-1 protein undergoes tyrosine phosphorylation and binds phosphatidylinositol 
3-kinase (PI3-kinase)(Backer et al, 1992). PI3-kinase is composed of a catalytic 
subunit (pi 10) and a putative regulatory subunit (p85) that contains two SH2 (src 
homology-2) domains and one SH3 (src homology-3) domain. Binding of PI3-kinase 
to IRS-1 is thought to be mediated through the SH2 domains of p85 and 
phosphorylated YXXM motifs of IRS-1 as formation of the complex is inhibited by 
synthetic peptides containing phosphorylated YXXM motifs. Furthermore, 
overexpression of IRS-1 potentiates the activation of PI3-kinase in insulin-stimulated 
cells and tyrosyl phosphorylated IRS-1 or peptides containing phosphorylated YXXM 
motifs activate PI3-kinase in vitro (Backer et al, 1992). The expression in CHO cells 
of mutant p85, which is deficient in coupling to the 110 kDa subunit of PI3-kinase, 
inhibits the insulin-induced complex formation of PI3-kinase with IRS-1. Expression 
of this mutant p85 has been shown to inhibit insulin-stimulated glucose uptake by 
preventing the translocation of GLUT1 to the cell-surface (Hara et al, 1993).
PI3-kinase is known to be an important enzyme involved with signalling 
pathways (Panayotou & Waterfield, 1992). The function of PI3-kinase is to attach a 
phosphate group to the 3’-hydroxyl group of the inositol ring of PI and/or its 
phosphorylated derivatives PI(4)P and PI(4,5)P2, to produce PI(3)P, PI(3,4)P2 and 
PI(3,4,5)P3. The p i 10 domain of PI3-kinase has a high degree of sequence homology 
to the yeast protein VPS34 which is implicated in the targeting of proteins to the yeast 
lysosome-like vacuole (Herman et al, 1992) and therefore by analogy, PI3-kinase may 
be involved in membrane trafficking in higher eukaryotes. The products of PI3-kinase
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could be involved directly in the process of membrane invagination or in the recruiting 
of adaptor proteins involved in vesicle formation. Also, targeting of vesicular 
structures to their cellular destination, as well as interactions with the cytoskeletal 
protein network, could be mediated by the phospholipids. Alternatively, other 
downstream signalling molecules could be activated by the products of the PI3-kinase, 
initiating a cascade that would generate further distinct second messengers (Panayotou 
& Waterfield, 1992).
The subcellular distribution of PI3-kinase has been investigated in basal and 
insulin-stimulated rat adipocytes (Kelly et al, 1992). They found that insulin increased 
the activity of PI3-kinase in adipocytes and that this increased activity was primarily 
located in the LDM’s and to a lesser extent in the plasma membrane.
1.6.3. Movement of Glucose Transporter-Containing Vesicles
Antibodies against the N- and C-termini of GLUT4 have been used to localize 
GLUT4 in basal and insulin-stimulated rat adipocytes (Smith et al, 1991). From their 
results, Smith et al (1991) concluded that the C-terminal epitope of GLUT4 may be 
masked when GLUT4 is inside the cell and that this may be due either to a 
conformational change within the glucose transporter protein or a change in protein 
or lipid surrounding it.
Recently, synaptobrevin has been found in GTV’s (Cain et al, 1992). This is 
of particular interest as a simple docking mechanism has been reported in which an 
N-ethylmaleiimide sensitive factor (NSF) and SNAPs (soluble, NSF accessory 
proteins) link synaptobrevin in synaptic vesicles to syntaxin, an integral membrane
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protein in the presynaptic membrane (Sollner et al, 1992, Warren, 1992). Therefore 
a similar mechanism may take place in insulin-sensitive tissues and allow docking of 
GTV’s onto the plasma membrane. Docking must be a regulated process and this 
regulation may involve the Rab family of GTP-binding proteins. The Rab family of 
proteins have been implicated in many aspects of membrane trafficking (Van Der 
Sluijs et al, 1991). Non-hydrolysable analogues of GTP mimic insulin in inducing the 
translocation of GLUT4 from the low density microsomes to the plasma membrane 
in a-toxin permeabilized rat adipocytes (Baldini et al, 1991). A small GTP-binding 
protein, Rab 3D, has been found to be abundant in 3T3-L1 adipocytes and its mRNA 
levels have been found to increase during differentiation in a similar pattern to the 
increase in GLUT4 levels (Baldini et al, 1992). These investigators suggest that as 
Rab 3D is a close homolog of Rab 3a (involved in regulated secretion by 
neurosecretory vesicles), it may play a role in the exocytosis of GLUT4-containing 
vesicles.
Clathrin may also be involved in the exocytosis and/or endocytosis of GLUT4. 
Clathrin coated vesicles are part of the trafficking process of a number of proteins and 
receptors (Pearse & Robinson, 1990, Keen, 1990). Insulin has been shown to 
stimulate the assembly of cytosolic clathrin onto the plasma membrane of rat 
adipocytes (Corvera, 1990). Poku et al, 1992, have found GLUT4 in clathrin-coated 
vesicles, while Kim & Jung (1992) have found that GLUT4 is associated tightly with 
clathrin and some clathrin-coat components in the plasma membrane of rat adipocytes. 
Exposure of the cells to insulin resulted in a decrease in GLUT4 concentration in 
clathrin-coated vesicles (Poku et al, 1992) and no change in the relative abundance of 
clathrin-associated GLUT4 in the plasma membrane (Kim & Jung, 1992). GLUT4 has 
been visualized in clathrin lattices in 3T3-L1 adipocytes by electron microscopy
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(Robinson et al, 1992). An interaction between phosphoinositol components of the 
phosphoinositol pathway and plasma membrane-associated clathrin assembly protein 
has been reported (Beck & Keen, 1991).
1.6.4. Mechanism for the Sequestration of GLUT4 within the Cell
Jo et al, (1992) introduced purified erythrocyte GLUT1 into rat adipocytes by 
PEG-induced vesicle-cell fusion. More than 85 % of the GLUT1 that was inserted in 
the correct physiological orientation in the adipocyte plasma membrane was moved 
to the LDM fraction whereas 90 % of wrongly inserted GLUT1 was retained in the 
plasma membrane. Although more than 70 % of the LDM-associated erythrocyte 
GLUT1 was found in the small subset of LDM’s that contained 80 % of LDM- 
associated GLUT4, insulin did not recruit GLUT1 to the plasma membrane under 
conditions where GLUT4 plasma membrane content increased 4-5 fold. Therefore Jo 
et al, (1992) suggest that the adipocyte plasma membrane content is kept low by a 
mechanism where a cell-specific constituent interacts with a cytoplasmic domain 
common to GLUT1 and GLUT4, while the insulin-dependent recruitment requires a 
cytoplasmic domain specific to GLUT4.
When GLUT1 and GLUT4 are expressed in CHO cells, 3T3-L1 fibroblasts and 
Xenopus oocytes, expressed GLUT1 is normally directed to the plasma membrane and 
GLUT4 retained within the cell (Shibasaki et al, 1992, Piper et al, 1992, Thomas et 
al, 1993). Chimeric glucose transporters containing parts of GLUT1 and GLUT4 were 
transiently expressed in CHO cells by Piper et al, (1992). They found that 
replacement of the N-terminal 30 amino acids of GLUT1 with the 41 N-terminal
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amino acids of GLUT4 resulted in the sequestration of the glucose transporter within 
the cell. Deletion of only the N-terminal 8 amino acids of GLUT4 or a single amino 
acid substitution of phenylalanine at position 5 to alanine was sufficient to cause a 
marked accumulation of GLUT4 at the cell surface (Piper et al, 1993).
Asano et al, (1992a) replaced portions of GLUT4 with GLUT1 and expressed 
the chimeras in CHO cells. They found two domains to be important for correct 
targeting of the GLUT4. One domain included TM2 and TM3 and contained a 
leucine zipper sequence. These investigators suggested that a dimer structure of the 
glucose transporter may be required for its correct targeting. They suggested that 
another targeting sequence was a 28 amino acid domain around TM7 and TM8 
containing 9 amino acids that vary between GLUT1 and GLUT4.
1.6.5. Glucose Transporter Activation
Although translocation of glucose transporters to the plasma membrane appears 
to account for most of the effect of insulin on glucose transport activity, there is still 
a small discrepancy which may be due to some activation of the glucose transporter 
protein. Some agents (such as lipolytic agents) may regulate glucose transporter 
intrinsic activity, possibly by phosphorylation of the transporter (section 1.6.6.). 
Agents such as protein synthesis inhibitors have been reported to stimulate transport 
without apparently affecting the subcellular distribution of GLUT1 or GLUT4, as 
detected by Western blotting of plasma membrane fractions (Clancy et al, 1991). A 
discrepancy between transport activity and transporter abundance has been noted in 
comparing 3T3-L1 fibroblasts with differentiated adipocytes (Harrison et al, 1991,
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Yang et al, 1992b). The ratio of transport activity to GLUT1 abundance has been 
calculated to be higher in fibroblasts than in differentiated cells. Therefore, it has 
been suggested that the low basal transport rate observed in the adipocytes may reflect 
a suppression of the intrinsic activity of GLUT1 by 40-50 % (Yang et al, 1992b) and 
by 90 % (Harrison et al, 1991).
Tanti et al, (1992) found that anti-GLUTl peptide antibodies, when loaded into 
fibroblasts transfected with human insulin receptor cDNA, produced a 60 % increase 
in basal 2-deoxyglucose and 3-O-methyl-D-glucose transport. This increase was not 
observed with nonimmune serum and only occurred at low glucose concentrations, 
suggesting that binding of the specific antibody to the C-terminal caused an increase 
in the intrinsic activity of the glucose transporter rather than changing its maximal 
capacity.
1.6.6. Phosphorylation of the Glucose Transporter
Although insulin does not promote GLUT4 phosphorylation, GLUT4 can be 
phosphorylated in vitro by a number of protein kinases. Lawrence Jr. et al, (1990a) 
incubated microsomal membranes with c AMP-dependant protein kinase and found that 
all the phosphorylation was on Ser 488 in the C-terminal of GLUT4. As Ser 488 is 
unique to GLUT4, Lawrence Jr. et al, (1990a) suggest that GLUT4 may be uniquely 
regulated by phosphorylation. Nishimura et al, (1991) observed that there was no 
change in phosphorylation of GLUT1 upon insulin-stimulation of rat adipocytes.
Schurmann et al, (1992b) found that phosphorylation of adipocyte membranes 
with protein kinase A produced a stimulation of reconstituted glucose transport activity
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in plasma membranes and low-density microsome fractions provided the cells had 
been treated with insulin prior to isolation. They concluded that glucose transport 
activity can be modified by protein phosphorylation in an insulin-dependent 
mechanism but that phosphorylation of GLUT4 itself does not correlate with changes 
in reconstituted glucose transport activity.
Isoproterenol, a lipolytic agent, has been shown to stimulate glucose transport 
at low concentrations and inhibit insulin-stimulated glucose transport at high 
concentrations, but only in the absence of antilipolytic agents (Nishimura et al, 1991). 
Isoproterenol treatment can produce a phosphorylation of GLUT4 in preparations of 
rat adipocytes. However, isoproterenol-induced phosphorylation occurs both in the 
presence and in the absence of adenosine receptor agonists whereas isoproterenol 
treatment inhibits insulin-stimulated glucose transport only in their absence. 
Nishimura et al, (1991) therefore suggested that the phosphorylation of GLUT4 that 
is induced by isoproterenol treatment does not account for the inhibition of transport 
activity produced by this treatment.
The inhibitory effects of isoproterenol in glucose transport activity do not result 
from changes in the subcellular distribution of the glucose transporter as measured by 
cytochalasin B binding (Kuroda et al, 1987). These authors suggested that the reduced 
transport could be due to a change in the intrinsic activity of the glucose transporter 
within the plasma membrane. However recent data obtained with the exofacial 
glucose transporter labelling reagent ATB-BMPA suggests that isoprenaline induces 
an alteration, but not a loss, of GLUT4 in the plasma membrane of intact cells 
(Vannucci et al, 1992). These authors suggest that an occluded form of GLUT4 is 
produced that can neither bind photolabel nor transport glucose but can still be
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detected with cytochalasin B and Western blotting.
Okadaic acid, an inhibitor of type I and Ha protein phosphatases, has been 
shown to stimulate glucose transport in adipocytes by increasing the amount of 
GLUT4 in the plasma membrane (Lawrence Jr. et al, 1990b, Corvera et al, 1991). 
Okadaic acid treatment partially inhibited insulin-stimulated glucose transport. The 
transport activity observed following treatment with both insulin and okadaic acid was 
similar to that of okadaic acid alone. Incubation of cells with okadaic acid results in 
a 3-fold increase in the phosphorylation of GLUT4 and also in an increase in 
phosphorylation of at least three other glucose transporter vesicle (GTV) proteins. As 
insulin does not increase phosphorylation of GLUT4, the phosphorylation of one of 
the GTV proteins may be the signal for vesicle translocation (Lawrence Jr. et al, 
1990b). Lawrence Jr. et al, (1990b) suggest that the reduction, by okadaic acid, of 
the levels of glucose transporter present in the plasma membrane may be due to 
phosphorylation of GLUT4 which promotes its internalization.
Increased phoshorylation of GLUT4 has also been found in rat adipocytes from 
streptozotocin-induced diabetic rats (Begum & Draznin, 1992). In adipocytes from 
these rats the phosphorylated GLUT4 appears to be more resistant to phosphatases. 
This may be due to the glucose transporter being phosphorylated on sites that are not 
normally phosphorylated. Begum & Draznin, (1992) suggest that this greater 
phosphorylation may render GLUT4 less sensitive to acute regulation by insulin.
1.6.7. The Role of Protein Kinase C in Glucose Transport
The role of protein kinase C (PKC) in the stimulation of glucose transport by 
insulin is still controversial. Most, if not all, PKC activators stimulate glucose 
transport. However, in some cells these PKC activators are less effective than insulin. 
The phorbol ester, phorbol 12-myristate 13-acetate (PMA) stimulates 3-O-methyl-D- 
glucose transport in intact rat adipocytes in association with the subcellular 
redistribution of glucose transporters from the low density microsomes to the plasma 
membranes. However the effect of PMA on glucose transport is only approximately 
13 % of that for insulin (Holman et al, 1990, Saltis et al, 1991). The stimulation of 
glucose transport activity correlates closely with the appearance of GLUT4 at the 
plasma membrane in response to both PMA and insulin, but does not correlate with 
the sum of GLUT1 and GLUT4. These results are consistent with GLUT4 being 
inherently more active than GLUT1 due to a higher TK (tumover/K^) (Holman et al, 
1990, Saltis et al, 1991).
PKC depletion caused by 20-24 hour treatments with phorbol esters or other 
PKC activators such as glucose and/or insulin inhibit subsequent acute effects of 
insulin and phorbol esters (Ishizuka et al, 1991) on glucose transport. Therefore PKC 
may be involved in insulin-stimulation of glucose transport but additional factors must 
also be required to give the full insulin effect.
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1.7. Aims of this Study.
1) To use the impermeant ligand, ATB-BMPA, to selectively label the 
exofacial binding site of the erythrocyte glucose transporter.
2) To investigate the different conformations of the glucose transporter upon 
external (ATB-BMPA) and internal (cytochalasin B) ligand binding, by investigating 
its susceptibility to a number of proteinases.
3) To investigate the conformations of the native erythrocyte glucose 
transporter and the 18 kDa tryptic fragment of the transporter, by investigating their 
affinities for external and internal ligands.
4) To investigate the role of a number of conserved residues within the glucose 
transporter by investigating the ability of mutants with single amino acid substitutions 
to transport glucose and to bind external and internal ligands.
5) To use the impermeant ligand, ATB-BMPA, in combination with specific 
antibodies to investigate the role of the two glucose transporter isoforms, GLUT1 and 
GLUT4, in insulin-stimulation of glucose transport in rat adipose cells.
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CHAPTER 2 : METHODS
2.1. Materials
2.1.1. General Materials
Radiolabelled sugars and cytochalasin B were from Amersham International. 
Nonaethylene glycol dodecyl ether (Thesit) was from Boehringer Mannheim. Protein 
A-Sepharose, phloretin, trypsin and thermolysin were from Sigma. All other reagents 
were of analytical grade and were purchased from Sigma, BDH or Fisons.
2.1.2. Preparation of ATB-BMPA and ATB- f 2-3Hl BMP A
ATB-BMPA and ATB-[23H]BMPA (specific activity : 10 Ci/mmol) were prepared 
by Dr G.D.Holman using the method previously described (Clark & Holman, 1990). 
Tritiated ATB-BMPA (5 mCi/ml in PBS, pH 7.2) was aliquoted and stored at -20 °C.
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2.2. Preparation and use of Anti-Peptide Antibodies
2.2.1. Peptide Synthesis
A 15 amino acid peptide (CGEELFHPLGADSQV) was synthesised. This 
corresponded to the 13 amino acids at the C-terminal of GLUT1 (Mueckler et al, 
1985), with a cysteine attached to the N-terminal via a glycine spacer. The cysteine 
allowed easy and efficient coupling of the peptide to the carrier protein Keyhole 
Limpet Haemocyanin (KLH). A 14 amino acid peptide (CSTELEYLGPDEND) 
corresponding to the C-terminal 13 amino acids of GLUT4 (James et al, 1989), with 
a cysteine attached at the N-terminal, was made. These peptides were synthesized by 
the Na-fluorenylmethoxy-carbonyl-polyamide solid phase method (Atherton & 
Sheppard, 1985).
2.2.2. Estimation of Thiol Groups
Ellmans reagent (Ellman, 1958) was used to estimate the number of cysteines 
on each peptide that were in a reduced state and so able to react with m- 
maleimidobenzoyl-N-hydroxysuccinimide ester (MBS). For the standard curve, 0, 2, 
5, 10 and 25 [A of standard cysteine solution (1 mg/ml in 0.1 M Na2HP04 buffer, pH 
8.0) were made to 1 ml with the same buffer and 100 fA of Ellmans reagent (5,5' 
dithiobis (2-nitrobenzoic acid, DTNB, Sigma), 4 mg/ml in 0.1 M Na2H P 04 buffer, 
pH 8.0) was added. 25 and 50 //I of peptide solution (4 mg/ml in 10 mM NaHP04 
buffer, pH 7.2) were made to 1 ml with 0.1 M Na2H P04 buffer, pH 8.0 and 100 ji 1
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of Ellmans reagent was added. Absorbance was read at 412 nm in a 
spectrophotometer and the concentration of cysteines on each peptide was calculated 
using the standard curve.
2.2.3. Conjugation of Peptides to Keyhole Limpet Haemocyanin
The peptides were conjugated to KLH (Sigma) using m-maleimidobenzoyl-N- 
hydroxysuccinimide ester (MBS, Pierce). MBS (1.4 mg in 120 ji\ of dry 
dimethylformamide (DMF)) was added dropwise to KLH (8 mg in 0.5 ml 10 mM 
NaP04 buffer, pH 7.2) to ensure that the local concentration of DMF was kept low, 
as KLH is insoluble in > 30 % DMF. The mixture was stirred for 30 min at RT and 
then passed through a Sephadex G25 column (8 mm dia. x 80 mm, equilibrated with 
50 mM NaP04 buffer, pH 6.0) to remove free MBS. The KLH-MBS conjugate was 
not retained by the column. Fractions of column eluate were monitored by absorbance 
at 280 nm and the peak fractions were pooled. Peptide (10 mg in 2 ml NaP04 buffer, 
pH 7.2) was added to the pooled KLH-MBS and stirred for 3 hrs at RT. The protein 
content was then determined and aliquots were stored at -20 °C until required.
2.2.4. Immunization Procedure
Antibodies were raised in rabbits by intramuscular injection of peptide 
conjugates. The conjugates (200 jug protein) in 0.5 ml of PBS (154 mM NaCl, 12.5 
mM Na2HP04, pH 7.2) were emulsified with 1 ml of Complete Freunds Adjuvant
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(Sigma). A booster injection of conjugate (200 fig) in Incomplete Freunds Adjuvant 
was made after 4 weeks. Booster injections of conjugate in Alum were then made 
every 4 weeks. Conjugate (200 fig) in 0.5 ml PBS, pH 7.2, was mixed with 0.5 ml 
of Imject Alum (Pierce) for 30 min at RT before injection. A 5 ml test bleed was 
taken in week 6 then every 4 weeks after that to monitor the titre of specific 
antibodies. Preimmune sera was obtained prior to the first injection.
2.2.5. Isolation And Treatment Of Antisera
Rabbits were bled from the ear vein for routine test bleeds. 30 ml bleeds were 
obtained by cardiac puncture under anaesthetic, then after 4 bleeds the rabbits were 
bled out. Rabbit blood was allowed to clot for 1 hr at RT then overnight at 0 °C. 
The serum was removed following sedimentation of the clot by centrifugation at 3000 
revs/min (IEC-Centra-3 bench centrifuge) for 10 min. The titre of specific antibodies 
was monitored by ELISA and aliquots were stored at -20 °C.
2.2.6. Purification of Anti-peptide Antibodies
Anti-peptide antibodies to GLUT1 and GLUT4 were purified essentially 
according to the method of Oka et al, (1988).
2 ml of Reacti-gel(6X) (l,l'-carbonyldiimidazole activated 6 % cross-linked 
beaded agarose, Pierce) was filtered through Whatman number 1 filter paper on a 
Buchner funnel under gentle suction and washed thoroughly with double-distilled water
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at 0-4 °C to remove any acetone. The reactigel was added to 5.5 mg of peptide in 
2 ml of sodium borate buffer, pH 8.5 and then mixed for 48 hr at 0-4 °C by rotation 
(stirring is known to damage the beads). The mixture was then filtered and the beads 
were added to 2 ml of 1.0 M ethanolamine in sodium borate buffer, pH 8.5 and mixed 
for 3 hr at RT. The beads were then packed into a column (8 mm dia. x 50 mm) and 
washed successively with 1 M NaCl, double-distilled water and PBS, pH 7.2. 5 ml 
of antiserum was then loaded onto the column and circulated at least 3 times. The 
column was then washed extensively with PBS, then with 2 M NaCl in 5 mM NaP04 
buffer, pH 7.2 to remove any weakly bound antibodies. The anti-peptide antibodies 
were then eluted with 3.5 M sodium thiocyanate in 10 mM NaP04 buffer, pH 6.6 and 
immediately dialysed against PBS, pH 7.2. The antibody solution was concentrated 
using polyethylene glycol 4000 (PEG) and then aliquoted and stored at -20 °C. At 
each stage of the purification, samples were taken and monitored for the presence of 
specific antipeptide antibodies by ELISA.
2.2.7. Enzyme Linked Immunosorbant Assay (ELISA)
ELISA1 s were done in 96 multi-well plates (Labsystems). For assaying anti- 
GLUT1 antibodies, wells were coated with protein-depleted erythrocyte membranes 
(section 2.3.2., 1 fig in 100 (A of coating buffer (50 mM NaHC03 buffer, pH 
9.6)/well) overnight at 4 °C. For assaying anti-GLUT4 antibodies, wells were coated 
in GLUT4 peptide (20 ng in 100 \i 1 of coating buffer/well) overnight at 4 °C. 
Unoccupied protein binding sites were blocked by three, 10 min incubations at RT 
with 100 [A of blocking buffer (1 % casein, 0.05 % Tween 20 (polyoxyethylene-
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sorbitan monolaurate, Sigma) in PBS (154 mM NaCl, 12.5 mM Na2HP04, pH 7.2). 
The wells were incubated with 100 /A antisera (serial dilutions from 1:100 to 1:6400, 
in blocking buffer) for 2 hr at 37 °C. Unbound antisera was removed by three, 10 
min washes in 100 fA of blocking buffer then 100 (A of a 1:2000 dilution of goat anti­
rabbit peroxidase conjugate (Sigma) in blocking buffer was incubated with the wells 
for 2 hr at 37 °C. Excess conjugate was removed by four, 5 min washes in 0.05 % 
Tween 20 in PBS, pH 7.2. 100 /A of freshly prepared substrate (0.1 M sodium 
acetate, pH 6.0, : 10 ml, tetramethylbenzidine (10 mg/ml in DMSO) : 100 jA, 
hydrogen peroxide (30 % v/v) : 1.5 /A) was added and incubated at RT until a bright 
blue colour had developed (approximately 10 min) then the reaction was stopped by 
the addition of 25 /A of 1 M H2S04. The resulting bright yellow colour was read at 
450 nm in a microtitre plate reader (Labsystems).
2.2.8. Western blotting
2.2.8.1. Transfer of Proteins onto Nitrocellulose
Samples were nm on 1.5 cm SDS-polyacrylamide gels as described in section 
2.6.2.. The stacking gel was removed and the resolving gel was put in continuous 
transfer buffer (39 mM glycine, 48 mM Tris, 0.0375 % (w/v) SDS, 20 % methanol, 
pH 8.8). Proteins were transferred using a Multiphor II NovaBlot electrophoretic 
transfer unit (Pharmacia LKB Biotechnology). The semi-dry transfer method involved 
soaking sheets of filter paper, nitrocellulose sheets and the gel in the continuous 
transfer buffer then layering them on the anode electrode (presoaked in distilled
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water). Nine sheets of filter paper were placed on the anode electrode, followed by 
the nitrocellulose (Biotrace, Gelman Sciences), then the gel, then 9 sheets of filter 
paper. The cathode electrode (presoaked in distilled water) was then placed on top 
and a current applied (0.8 x gel area, mA) for 1 hr 45 min. Great care was taken 
when setting up the trans unit to cut all the sheets to the same size, to soak the sheets 
evenly and to remove all the trapped air bubbles when layering the sheets together. 
Once the transfer was complete the nitrocellulose was washed in distilled water and 
the proteins were stained in the temporary stain, Ponceau S (0.1 % Ponceau S in 3 
% trichloroacetic acid) to enable the nitrocellulose to be cut and marked as required.
2.2.8.2. Blotting of GLUT1 and GLUT4 with 125I-Protein A
The nitrocellulose was first washed 2 times in blocking buffer (3 % bovine 
serum albumin (BSA), 0.2 % Tween 20, in TBS buffer (10 mM Tris, 0.9 % NaCl, 
pH 7.4)) to remove the Ponceau S, then incubated in blocking buffer overnight at 0-4 
°C. It was then incubated at RT for 1 hr in the same buffer. The nitrocellulose was 
incubated with antisera (1:200 dilution in 1 % BSA, 0.2 % Tween 20, TBS buffer) 
for 2 hr at room temperature, then washed by three 5 min and one 15 min wash in 50 
ml TBS/Tween (0.2 % Tween 20 in TBS buffer). 125I-labelled Protein A (affinity 
purified, Amersham) was then added at 0.1 in TBS/Tween for 2 hr at room
temperature, then the nitrocellulose was washed extensively with at least six 5 min 
washes in TBS/Tween. The nitrocellulose was dried and wrapped in cling-film then 
exposed to X-ray film (Fuji) for 24-72 hr. The glucose transporter band was excised
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from the nitrocellulose and counted in a Gamma counter. A background (the average 
count from a band of equivalent size cut from above and below the glucose transporter 
band) was subtracted to get glucose transporter-specific counts.
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2.3. Ervthrocvte Glucose Transporter Studies
2.3.1. Preparation of Ervthrocvtes and Ervthrocvte Membranes
Erythrocytes from 1-3 week old transfusion blood were washed five times at
0-4 °C in PBS (154 mM NaCl, 12.5 mM Na2HP04, pH 7.2). The cells were pelleted 
at 3,000 revs/min (IEC Centra-3). Care was taken to remove the " buffy coat " of 
white cells and platelets. To obtain erythrocyte membrane ghosts, the cells were then 
lysed for 20 min at 0-4 °C in haemolysis buffer (5 mM Na2HP04, 1 mM EDTA, 20 
fig/ml PMSF, pH 7.8). The membranes were centrifuged at 20,000 g in an Ole Dich 
bench centrifuge for 20 min. The pellets were resuspended and washed once in 
haemolysis buffer then once in 5 mM Na2HP04 buffer, pH 7.2 before being 
resuspended at 1 mg/ml in 5 mM Na2P 04 buffer. It was important to keep the cells 
cold and to wash them rapidly to remove the haemoglobin before the ghosts resealed.
2.3.2. Preparation of Protein-Depleted Erythrocyte Membranes
Protein-depleted membranes were prepared by the method of Gorga & 
Lienhard, (1981). Erythrocyte membranes were washed once in 5 mM Na2P04 
buffer, pH 7.8 and collected at 20,000 g for 20 min. The pellet was resuspended at 
4 mg/ml then treated with 5 volumes of a freshly prepared alkaline buffer (15.4 mM 
NaOH, 2 mM EDTA, 0.2 mM DTT) for 15 min at 4 °C. The membranes were spun 
at 20,000 g for 20 min and then resuspended in 50 mM Tris-HCl pH 6.8 and spun 
again before being resuspended at 4 mg/ml in 50 mM Tris-HCl pH 6.8.
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2.3.3. Photolabelling of Erythrocytes with ATB~r2-3HlBMPA
200 jli\ of a washed erythrocyte suspension (20 % cytocrit) was mixed with 10- 
30 fiCi of ATB-[2-3H]BMPA in 200 (A of PBS (usually containing 600 mM D- 
mannitol or D-glucose) in 1 mm-pathlength cuvettes. The cuvettes were covered with 
a 10 mm-pathlength quartz cell containing a chemical filter of 1 % cumene in 2, 2, 
4-trimethylpentane. Samples were irradiated for 60 sec in a Rayonet RPR-100 
photoreactor containing RPR-3000 lamps. After irradiation, the cells were washed 
five times in PBS. The membranes were then obtained by hypo-osmotic lysis (section
2.3.1.).
2.3.4. Photolabelling of Ervthrocvte Membranes with F4-3HlCytochalasin B and ATB- 
T2—Hi BMP A
300 [A of erythrocyte membrane suspension at 1 mg/ml in 5 mM Na2P 0 4 
buffer, pH 7.2, was mixed with 1.6 /nCi of [4-3H]cytochalasin B in the presence of 
10"4 M cytochalasin E or with 10 /uCi of ATB-[2-3H]BMPA and was irradiated for 30- 
60 sec in 1 mm-pathlength cuvettes. After irradiation, membranes were diluted in 3.0 
ml of Na2P 0 4 buffer and centrifuged at 20,000 g for 20 min. The pellets were 
resuspended and washed twice more in Na2P04 buffer to remove unbound radiolabel.
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2.3.5. Immunoprecipitation of GLUT1 From Ervthrocvte Membranes
Labelled erythrocyte membranes (100 fig) were solubilized in 300 fA of 0.5 % 
Mega 10 solution (0.5 % decanoyl-N-methyl-glucamid (Mega 10), 2 mM DTT in 5 
mM Na2P 0 4 buffer, pH 7.2), for 20 min at RT then centrifuged at 20,000 g for 20 
min to remove any unsolubilized material. Protein A-Sepharose CL-4B (Sigma) was 
swollen in 5 mM Na2P 0 4 buffer for 15 min at 0-4 °C then incubated with affinity 
purified anti-GLUTl antibodies (135 jug antibody/30 fA of protein A-Sepharose) for 
2 hr at 0-4 °C. The protein A-Sepharose-antibody conjugate was pelleted by 
centrifugation at low speed (6,500 revs/min) for 1 min in a MSE microcentaur bench 
microfuge and any unbound antibodies were removed by washing the pellets in 1 ml 
of 5 mM Na2P 0 4 buffer, pH 7.2. The solubilized membranes were incubated with 
the antibody-protein A-Sepharose conjugate for 2 hr at 0-4 °C. The antibody-protein 
A-Sepharose complex was then pelleted by centrifugation and the supernatant removed 
and retreated to obtain a second immunoprecipitate. The pellets were washed by 
resuspension 2 times in 50 fA of 0.5 % Mega 10 solution and the washings were 
combined with the first supernatant. Protein released from the immunopellets and 
from the supernatant was run on 10-12 % acrylamide gels (section 2.6.2.).
2.3.6. Estimation of the Affinity Constant for ATB-BMPA
The affinity of the erythrocyte glucose transporter for ATB-BMPA was 
investigated. The affinity constant (or half-maximal inhibition constant) for ATB- 
BMPA was determined in two ways: Either from the inhibition of the uptake of 100
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/xM D-galactose or from the inhibition of the reversible binding of the exofacial label 
ASA-BMPA.
2.3.6.1. Transport Inhibition Determination
50 /xl of an erythrocyte suspension (40 % cytocrit) was mixed with 10 /xl of 
PBS, pH 7.2 containing the indicated concentrations of ATB-BMPA and 10 /xl of D- 
[1-14C]galactose (100 /xM final concentration). The assay tubes were kept in subdued 
light until the erythrocyte suspension had been added. Transport was stopped after 
10 sec by the addition of 3 ml of stopping buffer (0.3 mM phloretin in PBS, pH 7.2). 
An equilibrium value (a) was determined by measuring transport for 60 sec. A blank 
value (b) was determined by adding 3 ml of stopping buffer before addition of the 
erythrocyte suspension. The erythrocytes were collected by centrifugation at 3000 
revs/min for 45 sec in a refrigerated bench centrifuge (IEC Centra-3). The 
supernatant was carefully aspirated and then the cells were resuspended in stopping 
buffer and recentrifuged. The supernatant was removed and any remaining liquid was 
removed from the sides of the tube with tissue paper. 500 /xl of 10 % TCA was 
added to precipitate the protein and then any unsolubilized material was spun down 
at 3,000 revs/min. Two 200 /xl aliquots of supernatant were counted.
The reciprocal of the uptake rate constant (s/v) was calculated from the 
fractional filling (f) and was: v/s = -ln(l-f)/t where f = cpm10-b/cpma-b, 
cpm10 was the amount of labelled sugar transported in 10 sec, cpma was the 
equilibrium value determined by measuring transport for 60 sec and b was the blank 
value determined by adding stopping buffer before the labelled sugar. If the substrate
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concentration added is much less than the Km :
s/v = Km(l+I/K i)/V max Equation 1
The Kj was determined by non-linear regression fitting to Equation 1. As the 
substrate concentration used (100 /xM) was approximately 10-times lower than the Km, 
the error in the Kj should not be greater than 10 %.
2.3.6.2. Erythrocyte Binding Experiments
200 /xl of an erythrocyte suspension at high cytocrit (80 %) was mixed with 
10 /xl of buffer containing 0.1 /xCi (10 pmol) of ASA-[2-3H]BMPA and 0.02 /xCi of 
[U-14C]sucrose and non-labelled ATB-BMPA at a range of dilutions. Samples were 
mixed and incubated for 5 min and then spun in a microcentrifuge. These operations 
(including centrifugation) were carried out at either 20 °C or 0-4 °C. A 5 /xl sample 
of the supernatant was then counted on a program that counted both tritium and 
14carbon. Extracellular space and the final total concentrations of ATB-BMPA were 
then calculated from the [14C]sucrose in this sample. Bound/free ASA-BMPA was 
calculated as [(Hmix/Cmix)/(Hspl/Cspl)]-l. Bound ASA-BMPA was calculated as
l-[(Hspl/Cspl)/(Hmix/Cmix)]xTot (where Hmix is 3H dpm in the isotope mixture 
without cells, Cmix is the 14C in the isotope mixture, Hspl is the 3H in the sample 
equilibrated with the cells, Cspl is the 14C in the sample and Tot is the added 
concentration of ligand). In additional samples, 50 /xM cytochalasin B was added to 
estimate the non-specifically bound ASA-BMPA ( —10 % of the total). The small 
bound/free ratio in the presence of cytochalasin B was subtracted from that obtained 
in its absence. The free/bound ratio in the presence of ATB-BMPA was multiplied 
by the bound/free ratio in the absence of inhibitor (n) and was plotted against the
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ATB-BMPA concentration. The Kj was calculated by non-linear regression fitting to 
Equation 2.
(free/bound) xn = 1 + [ATB-BMPA]/Kj Equation 2
2.3.7. Treatment of Erythrocyte membranes with Trypsin and Thermolvsin
Erythrocyte membrane suspension at 1 mg/ml in 5 mM Na2P 0 4 buffer, pH 7.2 
was treated with either trypsin at 100 units/ml for 30 min at 20 °C or thermolysin at 
0.4 units/ml for 30 min at 20 °C. After treatment with trypsin, the enzyme was 
removed by dilution of the membranes in 3.0 ml of 5 mM Na2P 0 4 buffer and by 
centrifugation at 20,000 g for 20 min at 4 °C. The pellet was then resuspended and 
washed again in the same buffer. After thermolysin treatment the enzyme was 
removed by dilution of the membranes in 3.0 ml of 5 mM sodium phosphate buffer 
with 27 mM EDTA and by centrifugation at 20,000 g for 20 min. After washing of 
trypsin and thermolysin treated samples, the membranes were resuspended in 
phosphate buffer without enzymes.
2.3.8. 2-Nitro-5-thiocyanobenzoic Acid Treatment
Labelled membranes were dissolved in a buffer comprising 42 mM Tris-acetate 
pH 8.0, 0.8 mM EDTA, 1.7 % (w/v) SDS and the sample was gassed with nitrogen. 
NTCB was then added to a final concentration of 10 mM and the reaction was kept
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at 37 °C for 30 min. An equal volume of 0.1 M sodium borate pH 9.3 was added 
and the pH readjusted to pH 10 by the addition of 1 M NaOH. The mixture was then 
maintained at 37 °C for 42 hr. 2-mercaptoethanol (30 /Alm\) was then added. The 
samples were desalted by repeatedly filtering through Ultrafree-MC filter units 
(Millipore) and diluting with a 1 mM Tris-HCl buffer containing 0.1 % (w/v) SDS, 
pH 6.8. The samples were then either analysed by electrophoresis on Tricine gels 
(section 2.6.2.3.) or were solubilized in 2 % Thesit detergent buffer and 
immunoprecipitated with antibodies to the C-terminal and cytoplasmic loop of GLUT1 
as described in section 2.3.5. Anti-peptide antibody against the large cytoplasmic loop 
(residues 231-246) of GLUT1 was kindly provided by S. A. Baldwin.
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2.4. Studies on GLUT1 Mutants Expressed in (CHO-K1) cells
Ham's F-12 medium, penicillin/streptomycin and glutamine were from 
ICN/Flow laboratories. Foetal calf serum, trypsin/EDTA and geneticin (G-418 
sulphate) were from Gibco BRL. 35 mm and 90 mm tissue culture dishes were from 
Nunc/Gibco BRL. 2-deoxy-D-[2,6-3H]glucose, sodium boro[3H]hydride and [4- 
3H]cytochalasin B were from Amersham International. Phloretin, cytochalasin E, 
cytochalasin B, galactose oxidase, neuraminidase, protein A-Sepharose, proteinase 
inhibitors and 2-deoxy-D-glucose were from Sigma. 4,6-O-ethylidene-D-glucose was 
from Koch-light Laboratories. Nonaethylene glycol dodecyl ether (Thesit) was from 
Boehringer Mannheim.
2.4.1. Production and Expression of Wild-Tvpe and Mutant GLUT1 Glucose 
Transporters in CHO-K1 cells
The CHO-K1 cells expressing wild-type and mutant GLUT1 glucose 
transporters were prepared by Dr Mitsuru Hashiramoto using the method previously 
described (Hashiramoto et a l, 1992).
2.4.2. Culture of CHO-K1 cells
The CHO cell line CHO-K1 were used as they have a low endogenous glucose 
transporter activity (Hasegawa et a l, 1990). They were maintained in Ham's F-12
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medium containing 10 % foetal calf serum, 100 unit/ml penicillin, 100 jug/ml 
streptomycin, 2 mM glutamine and 600 figlml geneticin (G-418 sulphate). The 
medium was changed every 2 days and when the cells reached confluence they were 
trypsinized and split 1:10 for further maintenance in culture. For transport and 
photolabelling experiments, cells were seeded into 35 mm and 90 mm culture dishes 
and were generally confluent 2-3 days later.
2.4.3. 2-Deoxv-D-Glucose Transport in CHO-K1 Cells
The measurement of 2-deoxy-D-glucose uptake was performed essentially as 
described by Harrison eta l, (1990). Cells in 35 mm dishes were grown to confluence 
for 2-3 days. Cells were then washed three times with 2 ml of Krebs-Ringer Hepes 
Buffer (KRH:140 mM NaCl, 4.7 mM KC1, 2.5 mM CaCl2, 1.25 mM MgS04, 2.5 
mM Na2H P04, 10 mM Hepes, pH 7.4). The cells were incubated with 0.9 ml of 
KRH for 10 min at 37°C, then with 50 fA of inhibitor (0-50 mM, final concentration) 
for a further 10 min. 2-deoxy-[2,6-3H]D-glucose (0.3 /uCi) was then added to give 
a final assay concentration of 0.1 mM and cells were maintained at 37°C for 5 min. 
Uptake was terminated by the addition of 2 ml/well of ice-cold PBS containing 0.3 
mM phloretin and three rapid washes with ice-cold PBS/phloretin. Cells were 
solubilized with 1 ml of 0.1 M NaOH and the extract was added to scintillant for 
estimation of radioactivity. Nonspecific 2-deoxy-D-glucose uptake was measured in 
the presence of 50 /uM cytochalasin B and 0.3 mM phloretin and was subtracted from 
each determination to obtain specific uptake.
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2.4.4. Labelling of Cell-surface Carbohydrate with Tritiated Sodium Borohydride
The CHO-K1 clones transfected with either wild-type or mutant GLUT1 were 
grown to confluence in 35 mm culture dishes. The cells were then simultaneously 
treated with 10 units of galactose oxidase and 1 unit of neuraminidase in 1 ml of PBS 
for 30 min at 18 °C. The dishes were then washed three times with 2 ml of PBS and 
then 2 mCi of sodium borohydride (specific activity 13.7 Ci/mmole) in 40 /A of 50 
mM NaOH was rapidly mixed with 20 [A of 45 mM HC1 and added immediately to 
the cells in 1 ml of PBS. After maintaining the cells at 18°C for 10 min the dishes 
were washed four times in PBS and then the cells were solubilized in 1 ml of 2 % 
Thesit detergent buffer and immunoprecipitated with anti-GLUTl antibodies as 
described below.
2.4.5. Immunoprecipitation of GLUT1 From CHO-K1 Cells
Labelled CHO-K1 cells were solubilized in 2 % Thesit detergent buffer (2 % 
C12E9 , nonaethylene glycol dodecyl ether, with the proteinase inhibitors antipain, 
aprotinin, pepstatin A and leupeptin, each at 1 jig!ml, in 5 mM Na2P 0 4 buffer, pH
7.2). Following centrifugation at 20,000 g for 20 min the supernatants were subjected 
to immunoprecipitation with 20 /A of protein A-Sepharose coupled to 100 jA of anti- 
GLUTl antiserum for 2 hr at 0-4 °C. C-terminal deletion mutants were 
immunoprecipitated with an anti-peptide antibody raised against the large cytoplasmic 
loop (residues 231-246) of GLUT1 (kindly provided by S.A. Baldwin). The 
immunoprecipitates were then washed 4 times with 1 ml of 0.2 % Thesit buffer (0.2
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% Thesit, with the proteinase inhibitors antipain, aprotinin, pepstatin A and leupeptin, 
each at 1 juglml, in 5 mM Na^C^ buffer, pH 7.2). The glucose transporter-antibody 
conjugate was removed from the protein A-Sepharose by incubating the immunopellet 
for 20 min with "whirly mixing" in electrophoresis sample buffer (10 % (w/v) SDS, 
6 M Urea and 10 % (v/v) 2-mercaptoethanol) and analysed by electrophoresis (section 
2.6.2 .).
2.4.6. Photolabelling of CHO-K1 Cells with ATB-BMPA
Confluent cells in 35 mm culture dishes were washed with PBS and were then 
incubated at 18°C with 100 fxCi of ATB-[23H]-BMPA (specific activity 10 Ci/mmol) 
in 200 jul of PBS for 2 min and then irradiated for 1 min in a Rayonet RPR-100 
photochemical reactor with 300 nm lamps. Following irradiation the dishes were 
washed five times in PBS. In some experiments, the cells were solubilized in 250 jul 
of 2 % Thesit buffer, then chloroform/methanol precipitated (section 2.6.3.). Protein 
was measured on the precipitate, and the pellets were solubilized in electrophoresis 
sample buffer and analysed by SDS-PAGE. In later experiments the cells were 
solubilized directly in 250 jul of electrophoresis sample buffer.
2.4.7. Photolabelling of CHO-K1 Cells with Cytochalasin B
CHO-K1 cells were grown to confluence in 90 mm culture dishes and washed 
3 times in 5 ml of TES (20 mM Tris-HCl, 1 mM EDTA and 255 mM sucrose, PH
7.2). The cells were homogenized in 2 ml of TES and then spun at 900 g for 2 min 
to pellet a fraction containing mainly mitochondria and nuclei. The supernatant was 
then centrifuged at 20,000 g for 20 min to obtain a plasma membrane fraction. 
Plasma membrane (200 fig) in 400 fA of TES containing 100 fiM  cytochalasin E, was 
labelled with 1.4 juCi of [4-3H]-cytochalasin B by irradiation for 45 sec in a Rayonet 
photochemical reactor. Following irradiation, the membranes were washed twice by 
centrifugation at 35,000 g for 20 min and resuspension in 3 ml TES. The final pellet 
was resuspended in 100 fA of TES, solubilized in electrophoresis sample buffer and 
analysed by electrophoresis.
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2.5. Studies on the Rat Adipocvte Glucose Transporter
2.5.1. Preparation of Albumin Solution
100 g of bovine serum albumin (Fraction V, Sigma) was dissolved in 500 ml 
of double-distilled water at 0-4 °C. This was dialysed for 24 hr against 2 changes of 
10 volumes of double-distilled water at 0-4 °C. The volume of the solution was then 
made up to 1000 ml with double-distilled water (to give a 10 % solution) and the 
solution was filtered, first through Whatman 41 filter paper, then Whatman 42 filter 
paper, and finally through Millipore type A membrane filters (0.8 fxm pore size). The 
pH of the solution was adjusted to 7.4 with 10 M NaOH and the solution was divided 
into 15 ml aliquots and stored at -20 °C until required. Once thawed, the solution 
was not refrozen.
2.5.2. Preparation of Buffers and Insulin Stock Solution
All buffers, unless otherwise stated, contained the following, Hepes buffer: 140 
mM NaCl, 4.7 mM KC1, 2.5 mM CaCl2, 1.25 mM MgCl2, 2.5 mM NaH2P 0 4, 10 
mM Hepes. The pH was adjusted to 7.4 at 20 °C. Albumin was added as required. 
Buffer stock solutions were prepared as 10 X concentrates, one containing Hepes and 
NaH2P 0 4 (pH 7.6), and the other containing NaCl, KC1, CaCl2 and M gS04 and were 
stored at 4 °C for up to 1 month.
Monocomponent porcine insulin was a gift from Dr. Ronald Chance, Eli Lilly
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laboratories. 1.0 mg of insulin was dissolved in 1.0 ml of 0.03 M HC1 and the 
solution made up to 3.0 ml with double-distilled water. 1.0 ml of this solution was 
then diluted to 50 ml with 1 % albumin/Hepes buffer, pH 7.6. The resulting insulin 
solution (1 jxM) was divided into 1 ml aliquots and stored at -20 °C until required. 
The solution was not refrozen once it had been thawed.
2.5.3. Preparation of Isolated Rat Adipose Cells
Isolated adipose cells were prepared from the whole epididymal fat pads of 
male Wistar rats (175-190 g) by the method of Taylor & Holman (1981). The rats 
were stunned and the necks dislocated. The epididymal fat tissue was quickly 
removed and rinsed in 1 % albumin/Hepes buffer at 37 °C. The washed tissue was 
then placed into Hepes buffer (3.5 ml/2 pads) containing 3.5 % albumin, 0.5 mM 
glucose, and 0.85 mg/ml collagenase (Worthington) in a 75 x 23.5 mm clear 
polystyrene flat-bottomed tube (Sarstedt), and minced finely with scissors. The tissue 
suspension was shaken rapidly in a shaking waterbath at 37 °C for approximately 50 
min until most of the tissue lumps were digested. The resulting cell suspension was 
filtered through nylon mesh (250 ym  mesh size, Lockertex), and allowed to float at 
37 °C. The infranatant buffer was removed using a needle (2 mm dia. x 100 mm) 
attached to a 20 ml plastic syringe, and 10-15 ml of 1 % albumin/Hepes buffer was 
added. The cells were resuspended and allowed to float. This washing procedure was 
repeated 4 times and was carried out at 37 °C. The cell suspension was then adjusted 
to 40 % cytocrit (using a 25 y\ capillary tube which was centrifuged at 1500 g for 30 
sec, and expressed as the ratio of the length of the packed cell fraction in the tube to
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the total length of the suspension in the tube).
2.5.4. Treatment of Rat Adipocytes with Insulin
Either 2 or 10 nM insulin (1 fiM stock, section 2.5.2.) was used to stimulate 
isolated rat adipocytes. The time course for activation of insulin stimulated glucose 
transport was studied using 2 nM insulin and 0.5 mg/ml bacitracin. 2 mM potassium 
cyanide (150 mM stock) was added at the specified times to stop any further 
translocation. Deactivation of insulin-stimulated glucose transport was achieved in two 
ways which gave the same results. Either the cells were washed 4-6 times during the 
reversal period with 1 % albumin/Hepes buffer at 37 °C to wash away the insulin, or 
collagenase (final concentration: 0.25 mg/ml, 50 x stock in albumin-free Hepes buffer) 
was added to remove the insulin.
2.5.5. 3-O-Methyl-D-Glucose Transport in Rat Adipocytes
Uptake of 3-O-methyl-D-glucose was determined by the method of Whitesell 
& Gliemann, (1979). 50 fi 1 of a 40 % adipocyte suspension was added to 10 (A of 
200 fiM  3-O-methyl-D-glucose (to give a final concentration of 50 fiM), containing 
0.15 f i d  of 3-0-[14C]methyl-D-glucose in albumin-free Hepes buffer in a 4 ml (50 
mm x 13 mm) polypropylene tube (Nunc/Gibco BRL). Uptake was terminated by 
rapidly adding 3 ml of 0.3 mM phloretin in albumin-free Hepes buffer (the phloretin 
was first dissolved in ethanol such that the final concentration of ethanol was 0.5 %).
Timings of 10 sec or less were carried out using a metronome set at 2 beats/sec. 
Uptake was measured for 3 sec in insulin-stimulated cells and 120 sec in basal cells 
(these times should give fractional filling values (f) of approximately 0.5). "Blank" 
values (b) (indicating extracellular trapped radioactivity) were determined by adding 
3 ml of 0.3 mM phloretin in albumin-free Hepes buffer to the sugar before the 
addition of the cells. "Infinity" values (a) (indicating equilibrium distribution of 
radioactivity) were determined by incubating insulin-treated cells with sugar for 12-15 
min. 1 ml of silicon oil (Dow Coming 100/200 cs, obtained from BDH) was layered 
on top of the buffer, and the tubes were centrifuged (MSE bench centrifuge, swing- 
out rotor) at 2,500 revs/min for 45 sec. The cell layer was removed from the top of 
the oil using small pieces of pipe-cleaner (5 mm), and placed in a scintillation vial. 
8 ml of scintillation fluid was added. The rate constant of sugar uptake (v/s) was 
calculated from the fractional filling (f).
f = cpmr b/cpma-b v/s = (-ln[l-f])/t
2.5.6. Photolabelling of Glucose transporters in Rat Adipocytes
1 ml of cells (40 % cytocrit) were added to 333-500 /xCi of ATB-[3H]BMPA 
in albumin-free Hepes buffer in 35 mm-diam. polystyrene dishes (Nunc/Gibco BRL) 
and irradiated for 1 min in a Rayonet RPR-100 photoreactor containing RPR-3000 
lamps. Following irradiation, the cells were washed into polystyrene centrifuge tubes 
(Sarstedt) with 8 ml 1 % albumin/Hepes buffer at 18 °C and spun in a bench
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centrifuge (IEC centra-3) to 1,000 revs/min then immediately stopped. The 
infranatant buffer was removed using a needle (2 mm dia. x 100 mm), and the cells 
were resuspended in 8 ml of 1 % albumin/Hepes buffer and washed twice more.
2.5.7. Subcellular Fractionation of Rat Adipocytes
This procedure was carried out essentially as described by Weber et al, (1988), 
with a few modifications. 2.5 ml of cells were washed once in TES buffer (20 mM 
Tris-HCl, 1 mM EDTA and 255 mM sucrose, pH 7.2) at 20 °C and then resuspended 
in 2 ml of TES buffer at 18 °C. The cells were then rapidly homogenized (basal 
first) with 10 strokes of a 55 ml Potter-Elvehjem homogenizer, (Thomas Scientific, 
with a specific clearance of 0.15 mm) then rapidly centrifuged at 1000 rev/min for 1 
min (MSE refrigerated bench centrifuge) to pellet any remaining red blood cells and 
separate the fat. All further centrifugations were done in a Beckman TL-100 benchtop 
ultracentrifuge with a TLA-100.3 fixed rotor and a TLS-55 swing-out rotor. The 
infranatant was removed with a syringe and hypodermic needle (21 g x 1.5") and 
centrifuged at 18,000 revs/min for 20 min. The supernatant was removed and used 
for fractionation of the microsomal membranes. The pellet containing plasma 
membranes, mitochondria and nuclei was resuspended in 2 ml of TES by 
homogenization (5 strokes of a 10 ml homogenizer, Braun) and respun at 18,000 
revs/min then resuspended in 300 /u\ of TES. This suspension was loaded onto 0.6 
ml of a sucrose cushion (1.12 M sucrose (38.3 %), 20 mM Tris, 1 mM EDTA, pH
7.2) and spun at 35,000 revs/min for 20 min in a swing-out rotor. The mitochondria 
and nuclei were recovered as a pellet. The plasma membranes were collected at the
cushion interface and were resuspended in 3 ml of TES and then centrifuged at 37,000 
revs/min for 9 min. They were then homogenized in 1 ml of TES at 0-4 °C with 5 
strokes of a 10 ml homogenizer. The homogenizer was washed out with a further 1 
ml of TES which was added to the membranes and centrifuged at 37,000 revs/min for 
9 min. The plasma membrane pellet was then resuspended in 100 fA of TES. The 
microsomal membranes were obtained from the 18,000 revs/min spin supernatant. 
This was centrifuged at 30,000 revs/min for 30 min to pellet the high-density 
microsomes. The supernatant was then centrifuged at 100,000 revs/min for 17 min 
to pellet the low-density microsomes. Both microsomal fractions were resuspended 
in 100 fA TES.
2.5.8. Immunoprecipitation of GLUT1 and GLUT4 from Rat Adipocytes
Immunoprecipitation of GLUT1 and GLUT4 from subcellular fractions and 
directly from whole rat adipose cells was carried out. In the case of 
immunoprecipitation of GLUT1 and GLUT4 from subcellular fractions, plasma- 
membrane and low density microsome fractions were solubilized in 2 % Thesit 
detergent buffer (2 % nonaethyleneglycol dodecyl ether, with proteinase inhibitors 
(antipain, aprotinin, leupeptin and pepstatin A, each at 1 fig/ml) in 5 mM Na2P04 
buffer, pH 7.2) for 20 min at 20 °C. For direct immunoprecipitation experiments, 
labelled cells were washed in 1 % albumin/Hepes buffer 3 times then cells were 
solubilized in 2 % Thesit detergent buffer for 20 min at 20 °C. Any unsolubilized 
material was then spun down at 20,000 g for 20 min. Protein A-Sepharose CL-4B 
(Sigma) was washed and swollen in PBS, pH 7.2 for 15 min then incubated for 2 hr
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at 4 °C with either affinity-purified antibodies or antiserum to GLUT1 or GLUT4 in 
PBS. When using affinity-purified antibodies, 10-20 fig of affinity-purified antibodies 
were mixed with 8 fA of swollen protein A-Sepharose. When using antiserum, 75-100 
/A of antiserum was mixed with 20 fA of protein A-sepharose. Unbound antibodies 
were removed from the protein A-Sepharose pellets by washing the pellets 2 times in 
1 ml of PBS. The protein A-Sepharose was always pelleted by centrifugation at low 
speed (6,500 revs/min) in a MSE microcentaur microfuge for 1 min. The solubilized 
membranes and cells were then incubated with either the GLUT1 or GLUT4 antibody- 
protein A-Sepharose conjugate for 2 hr at 4 °C. The immunoprecipitate was then 
pelleted and the supernatant incubated with the other antibody conjugate for 2 hr at 
4 °C. The immunopellets were washed 4 times with 1 ml of 0.2 % Thesit detergent 
buffer in PBS containing proteinase inhibitors (antipain, aprotinin, leupeptin and 
pepstatin A, each at 1 fig/ml). The glucose transporter-antibody conjugate was 
removed from the protein A-Sepharose by incubating the immunopellet for 20 min 
with whirly mixing in electrophoresis sample buffer and was analysed by SDS-Page 
(section 2.6.2.).
2.5.9. Trvpsin-Treatment of Immunoprecipitated GLUT4
Immunoprecipitated, ATB-BMPA-labelled GLUT4 was treated with 10 units 
of trypsin in 100 fA of PBS for 30 or 45 min at RT. Then, either electrophoresis 
sample buffer was added directly to the sample, or the pellet and supernatant were 




2.6.1.1. BIO-RAD Protein Assay
For the standard protein curve, 0, 5, 10, 15, 20 and 25 fA of standard bovine 
serum albumin (BSA) solution (200 figlml in double-distilled water) were made to 775 
fA with 5 mM Na2H P04 buffer, pH 7.2, then 25 /A of 0.1 M NaOH was added. An 
aliquot of the membrane or protein sample to be assayed (generally 5 to 50 fA aliquots 
depending on the expected protein content) was made to 775 fA with 5 mM Na2H P04 
buffer then 25 jA of 0.1 M NaOH was added. 200 (A of BIO-RAD reagent (BIO­
RAD) was added to the standard protein samples and the protein samples to be 
assayed. After incubation of the samples for 10 min at RT the absorbance was read 
at 595 nm in a spectrophotometer.
2.6.1.2. BCA Protein Assay
The BCA protein assay was carried out in microtitre plates. 100 (A standard 
BSA solution (2 mg/ml in double-distilled water) was mixed with 100 ûl of 0.2 M 
NaOH. For the standard protein curve, 0, 2, 4, 6, 8 and 10 fA of this solution was 
made to 10 fA with 0.1 M NaOH. 5 fA of the membrane or protein sample to be 
assayed (diluted if necessary) was mixed with 5 jA of 0.2 M NaOH. 10 ml of reagent
A (1 % BCA detection reagent (bicinchoninic acid, sodium salt, Pierce), 2 % Na2C 0 3, 
0.16 % sodium tartrate, 0.4 % NaOH, 0.95 % NaHC03, (pH = 11.25 with 1 M 
NaOH) and filtered through a 0.7 /urn filter (Millipore)) was mixed with 200 (A of 
reagent B (4 % CuS04, filtered through a 0.7 /um filter (Millipore)). 200 /ul of this 
solution was added to the standard protein samples and the protein samples to be 
assayed and incubated for 30 min at 37 °C. The absorbance was read in a microtitre 
plate reader (Labsystems) at 562 nm (filter 6 and 3).
2.6.2. SDS-Polyacrvlamide Gel Electrophoresis
Ammonium persulphate and TEMED were from BIO-RAD. All other reagents 
were of analytical grade and were purchased from Sigma, BDH or Fisons.
2.6.2.1. Sample Preparation for Electrophoresis
Samples were dissolved in electrophoresis sample buffer (10 % (w/v) SDS, 6 
M urea, 0.05 % (w/v) bromophenyl blue and 10 % (v/v) 2-mercaptoethanol) for 20 
min at RT with mixing, then unsolubilized material was pelleted and the supernatant 
was applied to the gel (using a Hamilton syringe for 1.5 mm gels and a 200 /A Gilson 
pipette for 3 mm gels).
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2.6.2.2. SDS-Polvacrvlamide Gel Electrophoresis
Electrophoresis was carried out using a modification of the method of 
Hashimoto et al, 1983, using the discontinuous buffer system of Laemmli (Laemmli, 
1970). The linear slab gels were 8-12 % acrylamide and were made as shown in table 
2. Electrophoresis was carried out using a Protean II system (BIO-RAD) using 16 cm 
plates. The gels were run at constant current (25 mA for a 3 cm gel and 12 mA for 
a 1.5 cm gel) for approximately 15 hr, until the bromophenyl blue tracking dye had 
just run off the gel.
Buffers
The following stock solutions were made and stored for up to one month at 0-4 °C. 
Resolving gel buffer : 1.5 M Tris-HCl, 0.4 % (w/v) SDS, pH 8.8 
Stacking gel buffer : 0.5 M Tris-HCl, 0.4 % (w/v) SDS, pH 6.8 
Acrylamide stock solution : Obtained by dissolving 60 g acrylamide, 60 g sucrose 
and 1.6 g N 'N methylene bis acrylamide in 150 ml of double distilled water (final 
volume = 250 ml). This solution was stored in a dark bottle.
Electrophoresis running buffer : 0.025 M Tris-HCl, 0.1 % (w/v) SDS, 0.2 M 
glycine, pH 8.3
Ammonium Persulphate : 100 mg/ml, was freshly made for each gel.
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Table. 2 Quantities required for one 3 mm gel
Stock solution Resolving Gel Stacking Gel
8 % 10 % 12 %
Acrylamide stock solution (ml) 20 25 30 2
Resolving gel buffer (ml) 25 25 25 -
Stacking gel buffer (ml) - - - 3.75
Double-distilled water (ml) 22 17 12 9.75
Ammonium persulphate (ml) 0.5 0.5 0.5 0.1
TEMED (/A) 40 40 40 20
2.6.2.3. Tricine Gel System
The Tricine gel system (Schagger & Von Jagow, 1987) was used for good 
separation of labelled glucose transporter fragments. Electrophoresis was carried out 
using a Protean II system (BIO-RAD) using 20 cm plates. Gels were run on constant 
voltage, 30 V for approximately 1 hr, until everything had entered the stacking gel, 
then 95 V for approximately 15 hr, until the bromophenyl blue tracking dye had just 
reached the bottom of the gel but had not run off the gel.
Buffers
The following stock solutions were made and stored for up to one month at 0-4 °C. 
Acrylamide solution 1 (49 % T, 3 % C) : 48 g acrylamide and 1.5 g N 'N  methylene 
bis acrylamide were dissolved in double distilled water (100 ml final vol.). The
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solution was stored in a dark bottle.
Acrylamide solution 2 (49.5 % T, 6 % C) : 46.5 g acrylamide and 3 g of N 'N  
methylene bis acrylamide were dissolved in double distilled water (100 ml final vol.) 
and stored in a dark bottle.
Gel buffer : 3 M Tris-HCl, 0.3 % (w/v) SDS, pH 8.45 
Anode buffer : 0.2 M Tris-HCl, pH 8.9
Cathode buffer : 0.1 M Tris-HCl, 0.1 M Tricine, 0.1 % (w/v) SDS, pH 8.25 
Ammonium Persulphate : 100 mg/ml, was freshly made for each gel.
Table. 3 Quantities required for one 3 mm gel
Stock solution
Acrylamide sol" 1 (ml) 
Acrylamide sol" 2 (ml) 
Gel buffer (ml)
Separating Gel Spacer Gel





d.d. water (ml) 30 including glycerol













The stacking gel was 2 cm long and the spacer gel was 3 cm long. The 
separating and stacking gels were poured within 2 min of each other (but it was 
essential that the separating gel had polymerized first). The Anode buffer was put in 
the lower compartment and cathode buffer was put in the upper compartment of the
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electrophoresis apparatus.
2.6.2.4. Molecular Weight Standards For Electrophoresis
Molecular weight standards were: myosin (205 kDa), B-galactosidase (116 
kDa), phosphorylase B (97.4 kDa), bovine albumin (66 kDa), Ovalbumin (44 kDa), 
and carbonic anhydrase (29 kDa). 1 vial of standards (SDS-6H, Sigma) was dissolved 
in 2 ml of electrophoresis sample buffer and then divided into aliquots (100 ft 1) and 
stored at - 20 °C. Prestained standards (Sigma): triosephosphate isomerase (26.6 
kDa) and B-galactosidase (116 kDa) were applied when gels were to be transferred for 
western blotting. Prestained standards (one vial of each) were dissolved in a total of 
3 ml of electrophoresis sample buffer and stored at - 20 °C in 100 fA aliquots.
2.6.2.5. Processing of Gels
Gels were stained in 0.02 % Coomassie blue, 30 % methanol, 10 % acetic 
acid, to fix the protein and to allow the lanes to be clearly seen. The lanes were 
sliced (0.33 or 0.66 cm/slice) and dried in scintillation vials for 2 hr at 80 °C, then 
dissolved for approximately 2 hr at 80 °C in hydrogen peroxide (30 % v/v), 2 % 
ammonium hydroxide (with vial lids on). Samples were counted in 8 ml of scintillant 
(Optiphase Safe, LKB) in a Packard 1500 TRI-CARB or 1600 TR liquid scintillation 
counter at an efficiency of about 30 %.
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2.6.3. Chloroform/Methanol Precipitation of Protein
1 ml of methanol and 250 fA of chloroform were added to 250 fA of protein 
sample in a 10 ml polypropylene centrifuge tube and this suspension was centrifuged 
at 9,000 g in an Ole Dich bench centrifuge for 10 sec. 750 fA of water was added 
and the sample was respun at 9,000 g for 1 min. The upper phase was removed, and 
750 fA of methanol was added to the rest of the lower chloroform phase and the 
interphase with the precipitated protein. The sample was respun at 9,000 g for 2 min 
and the supernatant was discarded. The protein pellet was dried under an air stream.
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CHAPTER 3 : RESULTS
3.1. Production of Antibodies
3.1.1. Preparation of Anti-GLUTl and Anti-GLUT4 Antibodies
Anti-C terminal peptide antibodies were produced to the GLUT1 and GLUT4 
glucose transporter isoforms. The anti-GLUTl antibodies did not bind to the GLUT1 
C-terminal peptide in an ELISA. This was probably due to the peptide binding very 
tightly to the ELISA plate. The anti-GLUTl antibodies did bind to protein-depleted 
erythrocyte membranes and a good titre of antibodies was obtained from each rabbit 
used. Fig. 8 shows the increase in antibody titre obtained in one rabbit over 20 
weeks. 30 ml bleeds were generally taken monthly after a good titre of specific 
antibodies had been obtained.
The anti-GLUT4 antibodies bound to the GLUT4 C-terminal peptide in an 
ELISA and were produced in high yields by all rabbits. We were therefore able to 
use these antibodies in immunoprecipitation and Western blotting experiments.
No cross-reactivity was observed between the two antibodies. This was tested 
by ELISA, checking anti-GLUT4 antiserum binding to protein-depleted membranes 
and GLUT1 peptide and anti-GLUTl antiserum binding to GLUT4 peptide (results not 
shown). Also when one particular isoform was immunoprecipitated from detergent 
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o Week 20
Fig. 8. Anti-GLUTl antibody screening by ELISA. Rabbits were immunized 
with GLUT1 C-terminal peptide conjugated to KLH and the antisera was monitored 
for specific antibodies by ELISA. Plates were coated with 5 fig of protein-depleted 
membranes/well and bound antibody was detected with a peroxidase conjugate.
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3.1.2. Purification of Anti-Peptide Antibodies
GLUT1 and GLUT4 C-terminal peptides were coupled to activated agarose to 
give anti-peptide antibody affinity columns for GLUT1 and GLUT4 antibodies. The 
column eluant at each stage was monitored for specific anti-peptide antibodies using 
ELISA. Fig. 9 shows that after recycling of the antiserum 3 times through the 
column, virtually all antipeptide antibodies had bound and so were removed from the 
serum. A small amount of antipeptide antibody was removed during the 2 M sodium 
chloride wash which was meant to only remove loosely bound antibodies. However 
virtually all the specific antibody was removed from the column with sodium 
thiocyanate (NaSCN). The NaSCN eluant was then rapidly dialysed and concentrated 
to a volume similar to that of the starting serum and shown by ELISA to contain 
functional antibodies. We would routinely obtain approximately 250 fig of specific 
antibodies per 1 ml of antisera. The antibodies were stored at -80 °C. Although 
affinity purified antibodies were initially used successfully in a large number of 
experiments, they seemed to only remain stable in solution at -80 °C for a few 
months. As purifying the antibodies was also a time consuming process, we decided 
to try using whole antisera in immunoprecipitations and western blots. Antisera 
proved to be just as efficient as the affinity purified antibodies and therefore whole 
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o Purified Antibody
Fig. 9. M onitoring o f the affinity purification o f anti-G LU Tl antibodies by 
ELISA. GLUT1 peptide was coupled to reactigel to make an affinity column. 
Fractions collected from the column were monitored by ELISA. Serum (▼) was 
passed through the column at least 3 times to allow retention of specific antibody by 
the column and leaving very little in the antisera ( • ) .  The column was washed with 
PBS and then 2 M NaCI to remove weakly bound protein (A). Specific antibodies 
were then eluted with 3.5 M NaSCN and rapidly dialysed against PBS (O ).
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3.2. Studies on the Ervthrocvte Glucose Transporter
The glucose transporter in erythrocytes has been extensively studied as 
erythrocytes are easy to obtain in large quantities and contain large levels of the 
glucose transporter protein (Allard & Lienhard, 1985). Also, it was not until the first 
glucose transporter (GLUT1) was cloned, sequenced and its tissue distribution 
investigated (Mueckler et al, 1985), that it was realised that there are a number of 
glucose transporter isoforms. Even though there are now known to be at least six 
different glucose transporter isoforms, they display a high degree of sequence 
homology, and so it is thought that a common mechanism for facilitation of transport 
is likely. The transport of sugars is generally thought to occur via a conformational 
change mechanism in which binding sites are alternately exposed to the outside and 
inside solutions (Barnett et al, 1973a,b). However, detailed information on the 
kinetics and conformational changes involved in the transport of sugars is still not 
known. With the use of specific external and internal ligands ATB-BMPA and 
cytochalasin B, anti-C-terminal peptide antibodies and proteinases, the studies 
described in this thesis aimed to investigate some of the conformational changes that 
take place within the transporter upon ligand binding and transport.
3.2.1. Photolabelling the Glucose Transporter in Intact Erythrocytes using ATB- 
BMPA
The azidosalicoyl derivative of bis-mannose (ASA-BMPA) was used by 
Holman et al, (1986) to label the external binding site of the erythrocyte glucose
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transporter. Although ASA-BMPA was specific for the glucose transporter in intact 
erythrocytes, it also labelled a band 3 protein and spectrin when used to label the 
glucose transporter in isolated erythrocyte membranes. Therefore a diazirine 
derivative of BMPA (ATB-BMPA) was made in an attempt to get increased specificity 
in isolated membranes.
When erythrocytes were irradiated in the presence of ATB-[2-3H]BMPA, and 
the resulting membranes were analysed by electrophoresis on a 10 % acrylamide gel, 
a single broad peak was observed which ran between the 45 and 66 kDa molecular 
weight markers (Fig. 10). Photochemical decomposition of ATB-BMPA in water has 
been shown to have a half time of approximately 30 sec (Clark & Holman, 1990). 
Increasing the irradiation time from 30 sec to 60 sec increased the incorporation of 
ATB-BMPA into the glucose transporter (Fig. 10). Therefore to achieve maximum 
incorporation whilst trying to avoid damaging the cells, for most future experiments 
a 60 sec irradiation time was used. This labelling was fully inhibited by 300 mM D- 
glucose but not 300 mM D-mannitol (Fig. 10). 50 /uM cytochalasin B, an inside 
specific inhibitor of the glucose transporter, also fully inhibited ATB-BMPA labelling 
of the transporter in intact erythrocytes (Fig. 20).
3.2.2. Photolabelling the Glucose Transporter in Ervthrocvte Membranes using ATB- 
BMPA
It was necessary to be able to label glucose transporter protein specifically in 
isolated membranes as proteolytic cleavage studies on the erythrocyte glucose 
transporter had to be done on membranes. When erythrocyte membranes were
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Fig. 10. Photolabelling o f erythrocytes with ATB-BMPA. Human erythrocytes 
were washed with PBS then 600 /il of a 20 % erythrocyte suspension containing 300 
mM D-glucose (4) or 300 mM D-mannitol (O  , • )  was mixed with 10 /tCi of ATB-[2- 
3H]BMPA. The erythrocyte suspension was transferred to 1 mm-pathlength cuvettes 
and irradiated for 30 sec O) or 60 sec ( • ) .  Erythrocyte membranes were obtained 
by osmotic lysis and analysed by electrophoresis on a 10 % acrylamide gel.
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irradiated with the photolabel ATB-[2-3H]BMPA, just one peak was observed on SDS- 
PAGE of approximate molecular weight 45-66 kDa (Fig. 11). This peak was fully 
displaceable by 300 mM D-glucose (Fig. 11) and 50 fiM cytochalasin B (results not 
shown).
3.2.3. Determining the Affinity of the Erythrocyte Glucose Transporter for ATB- 
BMPA
The affinity constant (or half maximal inhibition constant, Kj) of the 
erythrocyte glucose transporter for ATB-BMPA was determined in two ways.
[14C] Galactose uptake in erythrocytes was measured at a range of nonlabelled 
ATB-BMPA concentrations. The reciprocal of the uptake rate constant (s/v) was 
plotted against the ATB-BMPA concentration (Fig. 12). The Kj (as determined by 
non-linear regression fitting to Equation 1) was 297 ± 53 fiM at 20 °C.
ATB-BMPA inhibition of ASA-3H-BMPA binding to intact erythrocytes was 
also determined at 0 °C and 20 °C. The free/bound ratio was calculated by 
comparison with [l4C]sucrose as described (section 2.3.6.2.). The free/bound ratio 
in the presence of ATB-BMPA was multiplied by the bound/free ratio in the absence 
of the inhibitor (n) and was plotted against the ATB-BMPA concentration (Fig. 13) 
The Kj was calculated by non-linear regression fitting to Equation 2. These K} values 
were 368 ± 59 juM and 338 ± 37 fiM at 0 °C and 20 °C respectively.
Therefore the Ki was not found to be affected by a change in temperature of 
the membranes and the K/s for ATB-BMPA inhibition of ASA-BMPA binding at 20 













Fig. 11. Photolabelling o f erythrocyte membranes With ATB-BMPA. Human 
erythrocytes were washed in PBS, then the membranes were obtained by osmotic lysis 
and centrifugation at 20,000 g. 300 fil of erythrocyte membranes at 1 mg/ml 
containing 300 mM D-glucose ( • )  or 300 mM D-mannitol were mixed with 60 f i d  
of ATB-[2-3H]BMPA and irradiated for 60 sec. Membranes were washed 2 times in 
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Fig. 12. Inhibition o f  D-galactose uptake with ATB-BMPA. The uptake of 100 
fiM D-galactose by erythrocytes was measured at a range of ATB-BMPA 
concentrations. The reciprocal of the uptake rate constant (s/v) was plotted against 
the ATB-BMPA concentration. The Kj was determined by non-linear regression 
fitting to Equation 1. The Kj was 297 +  53 /zM (from two experiments with triplicate 
observations at each inhibitor concentration); results are means and the bars represent 
the S.E.M. of the six observations at each concentration.
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Fig. 13. Inhibition o f ASA-BMPA binding by ATB-BMPA. The binding of 0.1 
f i d  (10 pmol) of ASA-[2-3H]BMPA to 200 fx\ of an 80 %-cytocrit erythrocyte 
suspension was measured over a range of ATB-BMPA concentrations. The 
free/bound ratio was calculated by comparison with [14C] sucrose as described in the 
methods section. The free/bound ratio in the presence of ATB-BMPA was multiplied 
by the bound/free ratio in the absence of inhibitor (n) and was plotted against the 
ATB-BMPA concentration. The Kj was calculated by non-linear regression fitting to 
Equation 2. At 20 °C ( • )  the Kj =  368 ±  59 nM (from observations at 16 ATB- 




3.2.4. Efficiency of ATB-BMPA Labelling of Erythrocyte Membranes
Using the half maximal inhibition constant of the erythrocyte glucose 
transporter for ATB-BMPA, the efficiency of labelling could be calculated. 90 pmol 
of transporter (calculated assuming 600 pmol/mg of membrane protein (Allard & 
Lienhard, 1985))incorporated 5.7 pmol of ATB-BMPA, and therefore 6.3 % of the 
sites were labelled. The concentration of ATB-BMPA in the reaction was 20 juM, 
which means that, as the half-saturation constant was approximately 350 fiM, the sites 
were 5.4 % saturated. The efficiency of labelling was therefore calculated as 117 %. 
Another experiment showed labelling to be 177 % efficient. These values seem 
higher than expected, but suggest that if all the sites were occupied by ligand, then all 
the sites would covalently cross-link with the ATB-BMPA. Subsequent studies by 
Palfreyman et al, (1992) and Nishimura et al, (1993) also suggested that the labelling 
by ATB-BMPA was * 100 % efficient.
3.2.5. Immunoprecipitation of GLUT1 from Erythrocyte Membranes
An anti-GLUTl antibody was produced by immunizing a rabbit with a KLH- 
conjugated peptide corresponding to the C-terminal 13 amino acids of the erythrocyte 
(GLUT1) glucose transporter (section 3.1.1.). Erythrocyte glucose transporters were 
labelled with ATB-BMPA and then the erythrocyte membranes were solubilized in 0.5
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% Mega 10 with 2 mM DTT in 5 mM phosphate buffer. This detergent buffer was 
found to successfully solubilize the erythrocyte membrane proteins without interfering 
with the antibody-glucose transporter binding. Fig. 14 shows that incubation of 
solubilized labelled erythrocyte membranes for 1 hr with anti-GLUTl antibodies 
coupled to protein A-Sepharose pulled down 64 % of the labelled glucose transporters. 
A second 1 hr incubation with more antibody pulled down another 20 % of the 
labelled GLUT 1 leaving only 16 % in the supernatant. Under identical conditions, 
immunoprecipitation with preimmune antiserum pulled down no labelled transporter, 
leaving it all in the supernatant (Fig. 15). This suggested that most if not all the 
labelled glucose transporters in erythrocytes membranes were the GLUT1 isoform. 
Subsequent studies showed that immunoprecipitation of GLUT1 using a single 
precipitation from Thesit-solubilized membranes was ~ 80-90 % efficient.
3.2.6. Trypsin Cleavage of the Erythrocyte Glucose Transporter
Trypsin cleaves the native glucose transporter on the cytoplasmic face only, 
to give two membrane-embedded fragments (Cairns et al, 1987). Cleavage of the 
ASA-BMPA-labelled glucose transporter by trypsin yields a labelled 19 kDa fragment 
(Holman et al, 1986). When the ATB-BMPA-labelled glucose transporter was treated 
with 100 units/ml of trypsin, a labelled peak at approximately 18 kDa was produced 
which could be resolved from the 50 kDa native glucose transporter peak using a 12 
% SDS-polyacrylamide gel (Fig. 16).
The ATB-BMPA-labelled glucose transporter was cleaved with trypsin and then 
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Fig. 14. Immunoprecipitation o f ATB-BMPA labelled erythrocyte membranes.
Erythrocyte membranes were labelled with ATB-[2-3H]BMPA, then solubilized in 0.5 
% Mega 10 detergent buffer. Solubilized membranes (75 fig) were mixed at 0-4 °C 
for 1 hr with 180 fig of purified anti-GLUTl antibody attached to 30 fil protein A- 
Sepharose (A). Supernatant from the first immunoprecipitate was transferred to a 
second GLUT1 antibody-protein A-Sepharose conjugate for another 1 hr (y) then the 
immunopellets were washed and analysed along with the remaining supernatant ( • )  
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Fig. 15. Immunoprecipitation o f ATB-BMPA labelled erythrocyte membranes 
with preimmune serum. Erythrocyte membranes were labelled with ATB-[2- 
3H]BMPA then solubilized in 0.5 % Mega 10 detergent buffer. Solubilized 
membranes (75 ng) were mixed at 0-4 °C for 1 hr with 180 n 1 of preimmune serum 
attached to 30 /xl protein A-Sepharose (A).  Supernatant from the first 
immunoprecipitate was transferred to a second preimmune serum-protein A-Sepharose 
conjugate for another 1 hr (O ). Then the immunopellets were washed and analysed 

















Fig. 16. Immunoprecipitation o f trypsin-treated ATB-BMPA labelled 
erythrocyte glucose transporters. Erythrocyte membranes (1 mg/ml) were labelled 
with ATB-[2-3H}BMPA then treated with trypsin (100 u/ml) for 30 min at 20 °C. 
The trypsin was removed by washing in phosphate buffer then the membranes were 
solubilized in 0.5 % Mega 10 detergent buffer and subjected to immunoprecipitation 
with anti-GLUTl antibodies bound to protein A-Sepharose. The immunopellet ( • )  
and the supernatant (A) were analysed by electrophoresis on a 12 % acrylamide gel.
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peptide antibodies attached to protein A-Sepharose. Both the immunoprecipitated 
protein and the protein left in the supernatant were analysed by 12 % SDS-PAGE 
(Fig. 16). The labelled 45-66 kDa peak corresponding to the transporter that still 
retains most or all of its structure and the C-terminal 18 kDa labelled fragment that 
has lost its N-terminal half are shown. Approximately 50 % of the ATB-BMPA 
labelled transporter was converted to the labelled 18 kDa fragment. A large 
percentage (82 %) of the 45-66 kDa glucose transporter peak was still in the 
supernatant. If this is compared to the 36 % for the non-treated glucose transporter 
(Fig. 14) then the result suggests that some of the glucose transporter must lack its C- 
terminal (antibody binding fragment). There was also a small amount (35 %) of the 
18 kDa fragment immunoprecipitated on the antibody pellet suggesting that some of 
the 18 kDa fragment still retained its C-terminal. Therefore, the two regions of 
GLUT1 in which trypsin cleaves (the central loop and cytoplasmic C-terminal) do not 
appear to vary markedly in their susceptibility to trypsin cleavage.
3.2.7. Effect of ATB-BMPA Labelling on Trypsin Cleavage of the Erythrocyte 
Glucose transporter
Proteolysis by trypsin was used to investigate the conformational changes 
involved when the erythrocyte glucose transporter bound the outside-specific ligand 
ATB-BMPA. The erythrocyte glucose transporter was labelled with ATB-BMPA and 
the resulting membranes were treated with trypsin. Approximately 50 % of the 
labelled transporter was converted to the 18 kDa fragment (Fig. 16). The unlabelled 
glucose transporter was treated with trypsin (under identical incubation conditions as
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those used for the labelled transporter) and then the resulting fragments were labelled 
with ATB-BMPA. In this case, virtually all the glucose transporters were cleaved to 
give an 18 kDa peak (Fig. 17). ATB-BMPA labelling of the trypsin fragment was 
also fully displaced with 300 mM D-glucose (Fig. 17). Therefore labelling of the 
glucose transporter with the outside binding ligand ATB-BMPA makes it more 
resistant to cleavage by trypsin.
3.2.8. Effect of ATB-BMPA and Cvtochalasin B Labelling on Thermolysin Cleavage 
of the Erythrocyte Glucose Transporter
Proteolysis by thermolysin was also used to investigate conformational changes 
involved when ligands bind to the internal and external surface of the erythrocyte 
glucose transporter. Erythrocyte membranes were labelled with the exofacial ligand 
ATB-BMPA and with cytochalasin B which binds to the inside binding site. The 
labelled membranes were then treated with thermolysin which cleaves proteins on the 
amino side of hydrophobic residues. Thermolysin (0.4 units/ml) cleaved cytochalasin 
B labelled membranes giving almost total conversion to a labelled 18 kDa fragment 
(Fig. 18). Treatment of ATB-BMPA labelled membranes with 6 times as much 
thermolysin (2.4 units/ml) resulted in no cleavage of the transporter (Fig. 18).
When the thermolysin treated ATB-BMPA labelled membranes were 
immunoprecipitated with anti-C terminal peptide antibodies, all the labelled transporter 
was found on the immunopellet leaving virtually none in the supernatant (Fig. 19). 
As the ATB-BMPA labelled glucose transporter was fully immunoprecipitated after 
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Fig. 17. Trypsin treatment o f erythrocyte membranes followed by 
photolabelling with ATB-BMPA. Erythrocyte membranes (1 mg/ml) were treated 
with trypsin (100 u/ml) for 30 min at 20 °C. The trypsin was removed by washing 
in phosphate buffer then the membranes were labelled with ATB-[2-3H]BMPA in the 
presence of 300 mM D-glucose ®  or 300 mM D-mannitol ( • ) .  The membranes were 
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Fig. 18. Thermolysin treatment o f labelled erythrocyte membranes. Erythrocyte 
membranes (300 fig) were labelled with either 30 f i d  of ATB-[2-3H]BMPA and 
treated with 2.4 units/ml of thermolysin (A) or with 1.6 f i d  of [3H]cytochalasin B in 
the presence of 100 /xM cytochalasin E and treated with 0.4 units/ml of thermolysin 
( • )  for 30 min at 20 °C. Thermolysin was removed by washing the membranes in 
phosphate buffer with 27 mM EDTA, then the samples were analysed by 
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Fig. 19. Immunoprecipitation o f thermolysin-treated ATB-BMPA-labelled 
erythrocyte glucose transporters. Erythrocyte membranes (1 mg/ml) were labelled 
with ATB-[2-3H]BMPA then treated with 2.4 units/ml of thermolysin for 30 min at 
20 °C. After washing in phosphate buffer with 27 mM EDTA, the membranes were 
solubilized in 0.5 % Mega 10 detergent buffer and immunoprecipitated with purified 
GLUT1 antibody attached to protein A-Sepharose for 1 hr at 0-4 °C. The 
immunopellet (A) was washed and analysed along with the supernatant ( • )  by 
electrophoresis on a 12 % acrylamide gel.
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Therefore, binding of ATB-BMPA to the glucose transporter must stabilize a 
conformation that is resistant to thermolysin cleavage at both the cytoplasmic loop and 
the C-terminal cleavage sites. In comparison, binding of the inside ligand seems to 
stabilize a conformation that is very susceptible to thermolysin cleavage. Therefore 
the inside and outside ligands must be stabilizing different conformations of the 
glucose transporter protein.
3.2.9. Affinity of the Native and Trvpsin-Treated Glucose Transporter for ATB- 
BMPA
The affinity of the native glucose transporter and the trypsin produced 18 kDa 
fragment for the external ligand ATB-BMPA were compared. Erythrocyte membranes 
were labelled with ATB-BMPA without trypsin treatment (Fig. 11) and after trypsin 
treatment (Fig. 17). Trypsin treated membranes showed 10-12 fold less labelling (2 
experiments), which suggests that the affinity for ATB-BMPA is markedly reduced 
in the trypsin fragment.
3.2.10. Investigation of D-Glucose Displacement of ATB-BMPA in The Native 
Glucose Transporter and in the 18 kDa Trypsin Fragment
In order to further investigate the differences in the native glucose transporter 
and the 18 kDa trypsin fragment, the displacement of the exofacial ligand ATB-BMPA
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by the substrate for the transporter (D-glucose) was investigated. Native and trypsin- 
treated erythrocyte membranes were labelled with ATB-BMPA in the presence of 0- 
100 mM D-glucose or 50 juM cytochalasin B. The membranes were collected and 
separated on 10-12 % gels.
Fig. 20 shows the gel profile for the native transporter. Labelling was 
completely displaced by 50 juM cytochalasin B, whereas some labelling was still 
obtained even in the presence of 100 mM D-glucose. The ratio of the areas of the 
photolabelled peaks obtained in the presence and absence of D-glucose (A/A0) were 
plotted against the D-glucose concentration (Fig. 22), giving a Kj of about 10 mM. 
This could be due to D-glucose combining with two sites (curve 2) or a single site 
(curve 3).
Glucose displacement of labelling of the intact transporter was then compared 
with the displacement by D-glucose of ATB-BMPA labelling of the trypsin fragment 
(Fig. 21). With the trypsin fragment, a much lower concentration of D-glucose was 
needed to fully displace all the ATB-BMPA labelling. 10 mM D-glucose gave 
virtually total displacement of labelling, resulting in a gel profile similar to that of 50 
juM cytochalasin B. When we plotted A/Aq against D-glucose concentration for the 
trypsin fragment a Kj of about 1.5 mM was obtained (Fig. 22). This apparent 
increase in the affinity of the trypsin fragment for glucose may be associated, at least 
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Fig. 20. Displacement of ATB-BMPA labelling o f the erythrocyte glucose 
transporter by D-glucose. Intact erythrocytes were labelled with ATB-[2-3H]BMPA 
in the absence of D-glucose ( • )  and at 1 mM (O), 5 mM (A), 25 mM (■) and 100 
mM (A) D-glucose. Labelling was also determined in the presence of 50 /xM  
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Fig. 21. Displacement o f ATB-BMPA labelling o f the trypsin fragment by D- 
glucose. Erythrocyte membranes were treated with trypsin (100 u/ml) for 30 min at 
20 °C then labelled with ATB-[2-3H]BMPA in the presence of 0 mM ( • ) ,  2 mM Q  
or 10 mM fa) D-glucose or 50 /*M cytochalasin B. The membranes were washed in 
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Fig. 22. Displacement by D-glucose o f ATB-BMPA labelling to the native and 
trypsin-treated glucose transporter. A comparison of D-glucose displacement of 
ATB-BMPA from the native transporter and from the trypsin fragment (Figs 20 & 
21). The ratio of the areas of the photolabelled peaks obtained in the presence and 
absence of D-glucose (A/Ao) was plotted against the D-glucose concentration. The 
ATB-BMPA labelling that was not displaced by cytochalasin B was subtracted. 
Displacement by D-glucose of ATB-BMPA labelling of the intact transporter ( • )  gave 
a of 10 mM when results were fitted to the equation A/A* =Ki/(Ki+G) where G 
is the D-glucose concentration. Displacement of ATB-BMPA from the trypsin 
fragment (4) gave a K* of about 1.5 mM [curve 1, A/Ao =  1.5/(1.5+G)]. Curve 2 
was obtained from the equation for a two-site model:
A/A0 =  1A[1.5/(1.5+G)]-f?t[26/(26+G)]. Curve 3 was obtained from the single-site 
model [A/A.= 10/(10=G)].
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3.2.11. NTCB Cleavage of the ATB-BMPA-Labelled Purified Glucose Transporter
Treatment of proteins with NTCB followed by incubation at alkaline pH results 
in cleavage of proteins at cysteines (Cairns et al, 1984). The erythrocyte (GLUT1) 
glucose transporter sequence contains 6 cysteine residues (Mueckler etal, 1985). Fig. 
23 shows the location of the 6 cysteines in GLUT1 and the potential NTCB cleavage 
fragments. The NTCB treatment was carried out in a buffer containing 1.7 % SDS, 
which would at least partially denature the glucose transporter protein and so allow 
cleavage of the cysteines buried within the transmembrane segments. The ATB- 
BMPA labelled, purified glucose transporter was chosen for use in these experiments, 
as it was a much more concentrated source of labelled glucose transporters than 
erythrocyte membranes. NTCB treatment of erythrocyte membranes resulted in 
similar fragmentation patterns to those seen with the purified glucose transporter 
(results not shown).
The ATB-BMPA labelled glucose transporter was treated with NTCB and then 
the resultant fragments were immunoprecipitated by antibodies to the GLUT1 C- 
terminal and the GLUT1 cytoplasmic loop (residues 231-246). NTCB treatment 
produced a number of ATB-BMPA labelled fragments (Fig. 24) of approximate 
molecular weight: 6 kDa, 14 kDa, 23 kDa, 29 kDa and 50 kDa. The cytoplasmic 
loop antibody immunoprecipitated ATB-BMPA labelled fragments of approximate 
molecular weight: 14 kDa, 23 kDa, 29 kDa and 50 kDa. The anti-C-terminal 
antibody immunoprecipitated ATB-BMPA labelled fragments of approximate 
molecular weight: 14 kDa, 29 kDa and 50 kDa.
Therefore, a 6 kDa fragment labelled by ATB-BMPA was not immuno­
precipitated by either the C-terminal or loop antibodies. As ATB-BMPA has already
Fig. 23. Location of the six cysteines in GLUT1. The GLUT1 amino acid sequence contains six cysteines 
(Mueckler et al, 1985). The location of the six cysteines in the putative two-dimensional model of GLUT1 
(Proposed by Mueckler et al, 1985) are shown.
been shown to bind to the C-terminal half of the glucose transporter (section 3.2.6.), 
the only possible fragment is that produced by cleavage at cysteines 347 and 421 or 
429, comprising the top half of TM9, TM10 and most of TM11. A labelled 14 kDa 
fragment was immunoprecipitated by both antibodies. The C-terminal antibody must 
be immunoprecipitating the fragment from the C-terminal to cysteine 347, which 
would locate the site of ATB-BMPA labelling to somewhere in TM9 to TM12. 
However the loop antibody must be immunoprecipitating the fragment produced by 
cleavage at cysteines 201 or 207 and 347, suggesting that there is also extensive 
labelling somewhere between TM6 and TM9. Therefore, ATB-BMPA may be 
labelling more than one residue in the C-terminal half of GLUT1. Subsequent studies 
in collaboration with Baldwins group (Davies et al, 1992) suggested that the major site 
of labelling was TM8.
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Fig. 24. NTCB cleavage o f the ATB-BMPA labelled, purified glucose 
transporter. ATB-BMPA labelled, purified erythrocyte glucose transporter (in Tris- 
acetate buffer, pH 8.0, containing 1.7 % SDS) was gassed with nitrogen then 
incubated with 10 mM NTCB for 30 min at 37 °C. An equal volume of borate 
buffer, pH 9.3, was added and the pH adjusted to between pH 9 and 10, then the 
mixture was incubated for 45 hr at 37 °C, with regular readjustment of the pH back 
to pH 9 to 10. After addition of 2-mercaptoethanol (30 /zl/ml), the mixture was 
desalted by filtration through a centricon 10 microconcentrator and dilution with 1 
mM Tris-HCl, pH 6.8. The mixture was divided into 4, one sample was not 
immunoprecipitated (Fig. 24a) and three samples were solubilized in 2 % Thesit 
detergent buffer, then immunoprecipitated with preimmune serum, anti-GLUTl 
cytoplasmic loop antibody (Fig. 24b) and anti-GLUTl C-terminal antibody (Fig. 24c). 
The resulting labelled peaks were separated by electrophoresis using the Tricine gel 
system.
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3.3. Studies on GLUT1 Mutants Expressed In CHO-K1 Cells
This work was done in collaboration with Hashiramoto and colleagues in Kobe, 
Japan who did all the mutagenesis on GLUT1 and expressed the mutants in CHO-K1 
cells. They also carried out some of the transport and labelling studies. The CHO-K1 
cell line was chosen because of its low endogenous glucose transport activity 
(Hasegawa et al, 1990). Wild-type and mutant GLUT1 expression levels were 
monitored by labelling cell-surface carbohydrate with 3H-borohydride and then 
immunoprecipitating the labelled GLUT1 with anti-GLUTl antibodies. Glucose 
transport activity was then compared in the wild-type and mutant clones. In order to 
investigate whether particular amino acid residues are involved in the binding of 
ligands or in the changes in conformation of GLUT1, binding of the external ligand, 
ATB-BMPA and the internal ligand, cytochalasin B to the mutant glucose transporters 
were compared. ATB-BMPA is known to bind to the external surface of GLUT1 in 
the region of TM8 (Holman & Rees, 1987, Davies et al, 1992, section 3.2.11.). 
Cytochalasin B is thought to bind at the internal surface of the glucose transporter in 
the region of TM10 and TM11 (Holman & Rees, 1987, Davies et al, 1992).
3.3.1. Mutation of Asparagine and Glutamine Residues in Transmembrane Segments 
7 and 8
Sequence alignment of the glucose transporter sequences (Dr P. Hodgson, 
University of Bath) has shown that asparagine and glutamine residues are highly 
conserved and so may therefore be important for glucose transporter structure and
Fig. 25. Location o f the residues in GLUT1 that have been investigated by site-directed mutagenesis. The
location in the putative two-dimensional membrane topology of GLUT1 (proposed by Mueckler et al, 1985) of 
Gln282, Asn288, Asn317, Tyr292, Tyr293 and Pro385. Also the 25th amino acid from the C-terminal of GLUT1
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function. Since asparagine (Asn) and glutamine (Gin) residues can participate in 
hydrogen bonding to sugars (Quiocho, 1986), they may form part of a channel through 
the protein. Substitutions at glutamine 282 and asparagine 288, which are predicted 
to occur in TM7 and at asparagine 317, which is predicted to occur in TM8, (Fig. 25) 
were investigated to determine whether any of these residues were important for 
glucose transporter structure and function. The amide residues were substituted with 
the aliphatic residues, leucine (Leu) and isoleucine (lie) which could not participate 
in hydrogen bonding.
The results are shown in table 4. Although borohydride labelling of CHO-K1 
cells labels any cell-surface exposed carbohydrate, the anti-GLUTl antibody was 
specific enough to immunoprecipitate only the GLUT1 glucose transporter (Fig. 26). 
All 3 mutants (Gln282-Leu, Asn288-Ile, Asn317-Ile) could be detected at the cell 
surface of CHO-K1 cells by borohydride labelling to a level comparable to that of 
wild-type GLUT1. Labelling in the Gln282-Leu, Asn288-Ile and Asn317-Ile clones 
was 97 ± 14.8 % (n=4), 57.7 % (n = 2) and 166 ± 32 % (n=4) of the wild-type 
level, respectively. Non-transfected CHO-K1 cells showed levels of endogenous 
GLUT1 that were only approximately 5 % of the labelling found in the wild-type 
clone (Fig. 26).
Uptake of 2-deoxy-D-glucose was measured in the wild-type and mutant 
clones. The wild-type clone had a large increase (5.2-fold) in transport activity 
compared to non-transfected CHO-K1 cells. Glucose transport activity in each of the 
mutant clones, Gln282-Leu, Asn288-Ile and Asn317-Ile was comparable to activity in 
the wild-type clone and was 92.2 ± 6.1, 51.0 ± 3.8 and 70.0 ± 16.1 % (n = 5) of 
the wild-type value, respectively.
Transport activity in the wild-type and Gln282-Leu mutant was further
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Table 4. Transport activity and labelling levels in wild-type, asparagine m utant 
and glutamine m utant clones. All values are expressed as the percentage of the 
level in the wild-type clone. The results are the mean ± S.E.M. from 4-5 experiments, 






6 0 0 0
5 0 0 0









X X X JX
8 10
Gel Slice Number
Fig. 26. Immunoprecipitadon o f borohydride-labelled GLUT1 in non- 
transfected, wild-type and Gln282-Leu CHO-K1 clones. Cells of the wild-type 
(O ), GIn282-Leu ( • )  and non-transfected CHO-K1 (▲) clones were grown to 
confluence in 35 mm culture dishes. Cells were treated with 10 units of galactose 
oxidase and 1 unit of neuraminidase in 1 ml of PBS for 30 min at 18 °C. After 
washing in PBS, the cells were incubated with 2 mCi of tritiated sodium borohydride 
in 1 ml PBS for 10 min. After washing in PBS, the cells were solubilized in 2 % 
Thesit detergent buffer and immunoprecipitated with anti-GLUTl antibody. The 
immunoprecipitates were then analysed by electrophoresis on a 10 % acrylamide gel.
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investigated and they were found to have similar K™ and values for 2-deoxy-D- 
glucose net influx. The K̂ , and Vmax values calculated from these data were 1.83 ± 
0.2 mM and 1458 ± 97 pmol/min/mg of protein for the wild-type and 1.07 ± 0.38 
mM and 735 ± 1 3 6  pmol/min/mg of protein for the Gln282-Leu clone, respectively 
(Fig. 27). Thus at low concentrations of substrate, where the transport rate constant 
is equal to V ^ /K ^  the wild-type and Gln282-Leu values are similar (the V^/IC,,, 
ratios were 0.8 and 0.69 nmol/min/mg of protein/mM for the wild-type and Gln282- 
Leu cells, respectively). Some nonlinearity was observed in the reciprocal kinetic plot 
of 2-deoxy-D-glucose transport in the Gln282-Leu mutant, and at high substrate 
concentrations this mutated transporter showed approximately 2-fold slower net influx.
Binding of the internal ligand cytochalasin B was then examined. All three 
mutants were able to bind cytochalasin B giving labelling significantly greater than that 
in non-transfected cells. The mutants, Gln282-Leu, Asn288-Ile and Asn317-Ile, 
showed levels of labelling that were 55.5 ± 9.4 % (n=4), 184 % (n = 2) and 55.2 ± 
3.4 % (n=4) of wild-type levels, respectively (Fig. 28). Therefore, substitution of 
leucine for glutamine 282 and isoleucine for asparagine 288 and 317 did not greatly 
perturb binding of cytochalasin B to the inside site of the glucose transporter.
The two asparagine mutants both bound the external ligand ATB-BMPA, 
giving levels of labelling that were comparable to the labelling seen in the wild-type 
clone (Fig. 29). However the Gln282-Leu mutant showed very little labelling by 
ATB-BMPA, the labelling being only approximately 5 % of the wild-type level and 
similar to that of non-transfected cells. This result suggests that glutamine 282 is 
important for binding of ligands to the outside site.
To further investigate this inability of the Gln282-Leu mutant to bind outside 
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Fig. 27. 2-Deoxy-D-glucose net uptake in wild-type and Gln282-Leu mutant 
GLUT1 clones. Cells of the wild-type (O ) and Gln282-Leu ( • )  clones were grown 
to confluence in 35 mm culture dishes. The net uptake of 2-deoxy-D-[2,6-3H]glucose 
was measured for 1 min at the indicated extracellular concentrations. Results shown 
are from a single experiment representative of two similar experiments. K* and V *  
values were determined by nonlinear regression (weighted for relative error) of the 
Michaelis-Menten equation. The K* and values calculated from these data were 
1.83 ±  0.2 mM and 1458 +  97 pmol/min/mg of protein for the wild-type and 1.07 

















Fig. 28. Cytochalasin B labelling o f GLUT1 in non-transfected, wild-type and 
Gln282-Leu CHO-K1 clones. Cells of the wild-type (O ), Gln282-Leu ( • )  and non- 
transfected CHO-K1 (t) clones were grown to confluence in 90 mm culture dishes and 
then fractionated to yield a crude plasma membrane fraction. 200 fig of plasma 
membranes in 400 fil of TES and 100 fiM cytochalasin E were labelled with 1.4 /xCi 
of [4-3H]cytochalasin B by irradiation. The membranes were washed twice and then 










Fig. 29. ATB-BMPA labelling o f GLUT1 in non-transfected, wild-type and 
mutant CHO-K1 clones. Cells of the wild-type (O ), Gln282-Leu ( • ) ,  Asn288-Ile 
($), Asn317-Ile (■) and non-transfected CHO-K1 (4) clones were grown to confluence 
in 35 mm culture dishes. Cells were labelled with 100 f i d  of ATB-[2-3H]BMPA in 
250 /xl of PBS at 18 °C by irradiation. After washing five times in PBS, the cells 
were solubilized in 2 % Thesit detergent buffer and precipitated with 

















10 20 30 40 500
[Ethylidene-O-Glucose] (mM)
Fig. 30. 4,6-O-ethylidene-D-glucose inhibition o f  transport activity in wild- 
type and Gln282-Leu mutant GLUT1 clones. Cells of the wild-type (O ) and 
Gln282-Leu ( • )  clones were grown to confluence in 35 mm culture dishes. The net 
uptake of 2-deoxy-D-[2,6-3H]glucose was measured for 10 min at the indicated 
concentrations of 4,6-O-ethylidene-D-glucose. Results shown are from a single 
experiment representative of two similar experiments. The Ki was determined by 
nonlinear regression (weighted for relative error) of the equation V/V0 =  K/(Kj +  I). 
The values calculated from these data were 11.7 ±  0.77 mM for the wild-type and 
121 +  20 mM for the GIn282-Leu cells.
124
binds to the outside site of the glucose transporter, to inhibit 2-deoxy-D-glucose 
transport. Fig. 30 shows that 4,6-O-ethylidene-D-glucose is a potent inhibitor of 
transport activity in the wild-type clone, giving an apparent Kj of 11.7 ± 0.77 mM. 
This value is similar to that reported for the inhibition of glucose transport activity in 
erythrocytes (Barnett et al, 1973a,b), where GLUT1 is the predominant isoform. 
However, in the Gln282-Leu mutant clone, 4,6-O-ethylidene-D-glucose was a very 
poor inhibitor of transport and the apparent K; was increased by 10-fold to 121 ± 20 
mM.
3.3.2. Mutation of Tyrosines 292 and 293 in Transmembrane Segment 7
The substitution of leucine for glutamine 282, which is predicted to occur in 
transmembrane segment 7, has been shown to perturb binding of ligands to the outside 
binding site of GLUT1 (section 3.3.1.). Therefore, it is thought that TM7 may move 
up and down in the membrane to accept inside or outside binding ligands. To further 
investigate the role of TM7, tyrosine's (Tyr) 292 and 293 which are predicted to occur 
at the top of TM7 (Fig. 25), were substituted with the aromatic residue, phenylalanine 
(Phe) and the aliphatic residue, isoleucine (lie). The motif Q^QXSGXNXXXYY293 
is present in all mammalian glucose transporters and is highly conserved in members 
of the wider glucose transporter superfamily.
The results are shown in table 5. All the mutants were found to be expressed 
at the cell surface to a level comparable to that of wild-type GLUT1. The amount of 
borohydride-labelled Tyr292-Ile, Tyr293-Ile, Tyr292-Phe and Tyr293-Phe mutant 













































Table 5. Transport activity and labelling levels in wild-type and tyrosine 
m utant clones. All values are expressed as the percentage of the level in the wild- 
type clone. The results are the mean ± S.E.M. from 3-5 experiments.
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and 137.3 ± 18.5 % (n = 4) of the wild-type level, respectively.
The uptake of 2-deoxy-D-glucose was measured in these tyrosine mutants. The 
Tyr292-Ile, Tyr292-Phe and Tyr293-Phe mutants all retained a high level of transport 
activity which was 73.8 ± 4.72 % (n = 5), 55.8 ± 4.84 % (n = 5) and 89.2 ± 6.10 
% (n = 5) of the wild-type activity, respectively. Substitution of tyrosine 293 for 
isoleucine resulted in a markedly decreased transport activity which was only 15.0 ± 
3.36 % (n = 5) of that observed in the wild-type clone and was similar to the transport 
activity seen in non-transfected CHO-K1 cells (24.4 ± 4.72 % (n = 5) of the wild-type 
clone).
This reduction in transport activity of the Tyr293-Ile mutant was accompanied 
by an inability to bind the internal ligand. The cytochalasin B labelling in the Tyr293- 
Ile mutant was only 4.5 ± 2.1 % (n=4) of that of the wild-type clone (Fig. 31) and 
was comparable to the labelling in the non-transfected CHO-K1 cells (18.2 ± 2.3 % 
(n = 4) of the wild-type clone) (Fig. 31). Cytochalasin B labelling in the other mutants 
(Tyr292-Ile, Tyr292-Phe and Tyr293-Phe) was comparable to wild-type GLUT1 with 
levels that were 53.8 ± 7.3 % (n=4), 103.5 ± 8.6 % (n = 4) and 107.3 ± 8.1 % 
(n=4) of wild-type levels, respectively.
Although substitution of tyrosine 293 with isoleucine perturbed binding of the 
internal ligand, binding of the external ligand ATB-BMPA was unaffected. All four 
mutants were labelled with ATB-BMPA to a similar extent to the wild-type clone. 
The levels of ATB-BMPA labelling in the Tyr292-Ile, Tyr293-Ile, Tyr292-Phe and 
Tyr293-Phe mutants were 118.7 ± 15.8 % (n = 3), 126.2 ± 34.9 % (n = 3), 147.6 ± 
60.7 % (n = 3) and 105.8 ± 27.1 % (n = 3) of that of the wild-type clone, 
respectively.

















Fig. 31. Cytochalasin B labelling o f GLUT1 in non-transfected, wild-type and 
mutant CHO-K1 clones. Cells of the wild-type ($, Tyr293-Ile (O ), Tyr292-Ile ( • ) ,  
Tyr293-Phe Tyr292-Phe (ft and non-transfected CHO-K1 (A) clones were grown 
to confluence in 90 mm culture dishes and then fractionated to yield a crude plasma 
membrane fraction. 100 /xg of plasma membranes in 400 /xl of TES and 100 /zM 
cytochalasin E were labelled with 1.4 /xCi of [4-3H]cytochalasin B by irradiation. The 
membranes were washed twice and then analysed by electrophoresis on a 10 % 
acrylamide gel.
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phenylalanine, can be tolerated by GLUT1. Whereas, when it is substituted with the 
aliphatic residue, isoleucine, 2-deoxy-D-glucose transport activity is markedly 
decreased and internal ligand binding is perturbed.
3.3.3. Mutation of Proline 385 in Transmembrane Segment 10
Molecular modelling studies suggest that the putative transmembrane segment 
10 can undergo remarkably large conformational changes that may alternately expose 
the hexose binding site to the external and internal solutions (Hodgson, Osguthorpe 
& Holman, manuscript in preparation). Molecular dynamic simulations suggest that 
proline 385 in GLUT1 is particularly important in producing a pivotal point for this 
conformational change (Hodgson, Osguthorpe & Holman, manuscript in preparation). 
The amino acid motif F378FEVGPGPIPW388, predicted to occur in TM10 (Fig. 25), 
is present in all mammalian glucose transporters (GLUT'S 1, 2, 3, 4 & 7) with some 
conservative changes in GLUT5. Proline 385 is conserved in all but the SNF3 
galactose transporter from Saccharomyces cerevisiae, where glycine is present at this 
position (Celenza et a l, 1988). The effect of replacing proline 385 in GLUT1 with 
glycine and isoleucine, on glucose transport activity and external and internal ligand 
binding was investigated.
The results are shown in table 6. Both the Pro385-Gly and Pro385-Ile GLUT1 
mutants were found to be expressed at the cell surface to a level comparable to that 
of wild-type GLUT1. The amount of borohydride-labelled Pro385-Gly and Pro385-Ile 
mutant GLUT1 was 82.1 ± 9.4 % (n=4) and 92.6 ± 9.1 % (n=4) of the wild-type 
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Table 6. Transport activity and labelling levels in non-transfected, wild-type 
and Proline m utant clones. All values are expressed as the percentage of the 
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Fig. 32. Immunoprecipitation of borohydride-labelled GLUT1 in non- 
transfected, wild-type and proline mutant CHO-K1 clones. Cells of the wild-type 
(O ), Pro385-Gly (A), Pro385-Ile ( • )  and non-transfected CHO-K1 (A) clones were 
grown to confluence in 35 mm culture dishes. Cells were treated with 10 units of 
galactose oxidase and 1 unit of neuraminidase in 1 ml of PBS for 30 min at 18 °C. 
After washing in PBS, the cells were incubated with 1 mCi of tritiated sodium 
borohydride in 1 ml PBS for 10 min. After washing in PBS, the cells were 
solubilized in 2 % Thesit detergent buffer and immunoprecipitated with anti-GLUTl 
antibody. The immunoprecipitates were then analysed by electrophoresis on a 10 % 
acrylamide gel.
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The uptake of 2-deoxy-D-glucose was measured in these proline mutants. The 
Pro385-Gly mutant retained a high level of transport activity which was 121.8 ± 7 . 6  
% (n=4) of the wild-type activity. However, substitution of proline 385 for 
isoleucine resulted in a markedly decreased transport activity which was only 39.5 ± 
3.6 % (n=4) of that observed in the wild-type clone and was similar to the transport 
activity seen in non-transfected CHO-K1 cells (25.7 ± 5.3 % (n = 4) of the wild-type 
clone).
Next, we determined whether this decreased transport activity in the Pro385-Ile 
clone was accompanied by a decrease in binding of the internal and/or the external 
ligands cytochalasin B and ATB-BMPA. The Pro385-Gly mutant was labelled with 
both cytochalasin B and ATB-BMPA to a level comparable to that of the wild-type 
clone (Fig. 33,34). Cytochalasin B and ATB-BMPA labelling was 146 ± 13.6 % 
(n = 6) and 53.5 ± 1.8 % (n=4) of wild-type levels, respectively.
The Pro385-Ile mutant was also labelled with cytochalasin B to a level that was
106.2 ± 4.2 % of that of the wild-type clone. However, substitution of proline 385 
for isoleucine, completely prevented labelling by the external ligand ATB-BMPA, 
giving labelling that was only 3.4 ± 0.8 % of the wild-type level and similar to the 
labelling in non-transfected CHO-K1 cells (5.8 ± 0.3 % (n=4) of the level in the 
wild-type clone) (Fig. 34).
Therefore, substitution of glycine for proline 385 can be tolerated by GLUT1 
and causes only small changes in ligand binding and transport activity. However if 
proline 385 is substituted for the bulkier residue isoleucine, external ligand binding is 
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Fig. 33. Cytochalasin B labelling of GLUT1 in non-transfected, wild-type and 
proline mutant CHO-K1 clones. Cells of the wild-type (O ), Pro385-Gly (A), 
Pro385-lle ( • )  and non-transfected CHO-K1 (▲) clones were grown to confluence in 
90 mm culture dishes and then fractionated to yield a crude plasma membrane 
fraction. 200 fig of plasma membranes in 400 fil of TES and 100 fiM cytochalasin 
E were labelled with 1.4 fiCi of [4-3H]cytochalasin B by irradiation. The membranes 
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Fig. 34. ATB-BMPA labelling of GLUT1 in non-transfected, wild-type and 
proline mutant CHO-K1 clones. Cells of the wild-type (O ), Pro385-Gly (A ), 
Pro385-Ile ( • )  and non-transfected CHO-K1 (A) clones were grown to confluence in 
35 mm culture dishes. Cells were labelled with 100 ^Ci of ATB-f2-3H]BMPA in 250 
/xl of PBS at 18 °C by irradiation. After washing five times in PBS, the cells were 
solubilized directly in electrophoresis sample buffer and analysed by electrophoresis 
on a 10 % acrylamide gel.
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3.3.4. C-Terminal Deletion Mutants of GLUT1
Upon removal of the C-terminal 37 amino acids, GLUT1 loses the ability to 
transport glucose and to bind the external ligand ATB-BMPA, although it can still 
bind the internal ligand cytochalasin B (Oka et a l, 1990). However, GLUT1 is still 
fully functional after removal of the C-terminal 12 amino acids (Lin et al, 1992). In 
order to determine how many of the GLUT1 C-terminal amino acids had to be 
retained for exofacial ligand binding, a number of C-terminal deletion mutants were 
produced and assayed for their ability to bind ATB-BMPA and cytochalasin B.
The results are shown in table 7. The ability to bind the external ligand ATB- 
BMPA was lost after deletion of the C-terminal 25 amino acids (CD25). The CD24 
mutant showed a level of ATB-BMPA labelling that was 50.67 ± 2.4 % (n=4) of the 
wild-type level but on deletion of the 25th residue the level of labelling decreased to 
6.0 ± 1.73 % (n = 3) which was comparable to labelling in non-transfected CHO-K1 
cells (4.0 ± 0.58 % (n = 3) of the wild-type level).
The CD24 and CD25 mutants could both still bind cytochalasin B to a level 
comparable to that of the wild-type clone (78.4 ± 11.1 % and 77.8 ± 13.5 % (n = 5) 

























100 50.7 ±2.4 
(n = 4)
6 .0±1 .7  
(n = 3)
Table 7. Transport activity and labelling levels in non-transfected, wild-type 
and C-terminal deletion m utant clones. All values are expressed as the 
percentage of the level in the wild-type clone. The results are the mean ± S.E.M. 
from 3-5 experiments.
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3.4. Studies on the Regulation of Glucose Transport in the Rat Adipocvte
3.4.1. Preparation of Isolated Rat Adipocytes
Great care was taken when isolating rat adipocytes. Each new batch of insulin, 
collagenase and BSA was thoroughly tested to ensure that they produced viable, non- 
leaky cells which exhibited a low basal transport and a good insulin stimulation of 
transport. To avoid mechanical effects which increase the basal transport activity, the 
cells were maintained at 37 °C and were not centrifuged until after transport 
measurement or ATB-BMPA labelling.
3.4.2. Basal and Insulin-Stimulated Glucose Transport
Basal and insulin-stimulated 3-O-methyl-D-glucose transport was determined 
for each rat adipose cell preparation. The rate constant for influx of 3-0-[14C]methyl- 
D-glucose into basal cells was 0.0061 ± 0.0013 s'1 (n = 12), and into insulin- 
stimulated cells was 0.213 ± 0.020 s'1 (n = 12) giving an average insulin stimulation 
of 35 fold.
3.4.3. Photolabelling of Rat adipocytes with ATB-BMPA
If ATB-BMPA could be used to label glucose transporters in the plasma 
membrane of isolated rat adipocytes without any labelling of the internal pool of
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transporters, this would be an important technique for estimating levels of the separate 
pool of cell-surface transporters. Isolated rat adipocytes at a 40 % cytocrit were 
irradiated for 60 sec with ATB-[2-3H]BMPA to allow total activation of the diazirine 
group and to get maximum incorporation. Initially the adipocytes were resuspended 
after 30 sec irradiation and before being irradiated for a second 30 sec but this was 
later found to be unnecessary and so a single 60 sec irradiation was used.
Fig. 35 shows the gel profile when insulin stimulated isolated rat adipocytes 
were irradiated in the presence of ATB-BMPA and the resulting plasma membranes 
run on a 10 % SDS-polyacrylamide gel. A peak corresponding to the glucose 
transporter runs between the 45 and 6 6  kDa markers at approximately 50 kDa. A 
second non-specific peak runs at approximately 75 kDa. The non-specific peak was
2.2 ± 0.1 (n = 8 ) times the size of the specific glucose transporter peak. The exact 
nature of this non-specifically labelled protein is not known. Labelling of the 50 kDa 
protein but not the 75 kDa protein was fully displaced when the rat adipose cells were 
labelled in the presence of 300 mM D-glucose or 50 /uM cytochalasin B (Fig. 36).
It was important that the ATB-BMPA was impermeant and could not label 
intracellular transporters. After labelling of insulin-stimulated cells with ATB-BMPA 
the low density microsome fraction was isolated and analysed by SDS-PAGE. 
Virtually no labelled glucose transporters were found in the low density microsome 
fraction (= 4 % of the plasma membrane level).
The effect of a 60 sec irradiation on the cells was checked to ensure that they 
were not being damaged by the UV light. Cells were irradiated and then transport 
activity was measured. Irradiation did not affect basal and insulin-stimulated glucose 
transport activity.
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Fig. 35. ATB-BMPA labelling of basal and insulin-stimulated rat adipose cells.
Isolated rat adipose cells (1 ml of 40 % cytocrit) were incubated with ( • )  or without 
(O ) 10 nM insulin for 20 min at 37 °C in 1 % albumin/Hepes buffer. They were 
then mixed with 333 f i d  of ATB-[2-3H]BMPA in 35 mm polystyrene dishes and 
irradiated for 2 x 30 sec. The cells were fractionated to obtain a crude plasma 
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Fig. 36. Displacement of ATB-BMPA labelling o f the adipocyte glucose 
transporter by cytochalasin B. Isolated adipose cells (1 ml of a 40 % cytocrit) were 
treated with 10 nM insulin for 20 min at 37 °C then photolabelled with 250 / i d  of 
ATB-|2-3H]BMPA for 2 x 30 sec with (A) or without (O ) 50 cytochalasin B. 
Plasma membranes were isolated and analysed by electrophoresis. Only the peak 
corresponding to the glucose transporter is shown. Cytochalasin B does not reduce 
the non-specific 75 kDa peak area.
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3.4.4. Photolabelling of Basal and Insulin-Stimulated Rat Adipocytes
When basal and insulin-stimulated cells were photolabelled with ATB-BMPA 
and the plasma membranes isolated, a large (> 7 fold) difference in the number of 
glucose transporters in the plasma membrane of basal and insulin-stimulated cells was 
observed (Fig. 35). The size of the non-specific peak remains the same in basal and 
insulin-stimulated cells suggesting that the large increase in the glucose transporter 
peak in insulin-stimulated cells is specific and not due to inaccurate loading of protein 
onto the gel.
3.4.5. Immunoprecipitation of GLUT1 and GLUT4 from Basal and Insulin-Stimulated 
Rat Adipocytes
Anti-GLUTl and anti-GLUT4 antibodies (section 2.2.) were used together with 
ATB-BMPA to investigate cell-surface levels of the two transporter isoforms in basal 
and insulin-stimulated rat adipocytes. A 0.5%Mega 10 detergent buffer had been used 
to solubilize proteins from erythrocyte membranes. This proved to be unsuccessful 
with rat adipocytes so alternative detergents were tried. A detergent buffer composed 
of 2 % Thesit (Q 2E9) and proteinase inhibitors in phosphate buffer was found to 
solubilize the proteins in rat adipose cells and did not interfere with antibody-glucose 
transporter binding.
After incubation of the adipocytes with Thesit solubilization buffer for 20 min 
at room temperature, the unsolubilized material was spun down and found to contain 
virtually no labelled glucose transporter (Fig. 37a). The solubilized fraction was
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incubated with anti-GLUTl and anti-GLUT4 antibodies to remove the glucose 
transporters and chloroform/methanol precipitation of the supernatant showed that 
virtually all the labelled 50 kDa peak had been removed leaving the non-specific peak 
in the supernatant (Fig. 37b).
No peak is observed on SDS-PAGE if insulin-stimulated rat adipocytes are 
photolabelled with ATB-BMPA in the presence of cytochalasin B, then 
immunoprecipitated with anti-GLUTl and anti-GLUT4 antibodies (results not shown). 
Therefore, only protein that is labelled by ATB-BMPA in a cytochalasin B inhibitable 
fashion is immunoprecipitated by the antibodies.
The solubilized fraction was immunoprecipitated successively with anti-GLUTl 
then anti-GLUT4 antibodies or anti-GLUT4 then anti-GLUTl antibodies. As Fig. 38 
shows, the amount of a particular isoform was not dependant on the order of 
immunoprecipitation. The GLUT4 isoform was shown to be the most abundant 
isoform in the plasma membrane of both basal and insulin-stimulated cells. After 
insulin treatment GLUT4 accounted for 89.8 ± 1.2 % (n=4) of the total plasma 
membrane glucose transporters. The amount of GLUT1 in basal cells was 
approximately 5 fold (19.9 ± 2.4 %, n=4) less than in insulin-stimulated cells. 
Insulin increased the amount of plasma membrane GLUT4 approximately 20 fold 
(basal cells contained 4.9 ± 0.39 %, n = 6  compared to insulin-treated cells). This 
corresponded to an average transport stimulation with insulin of 35 fold (section
3.4.2.). Therefore there was still an approximate 1.5-2 -fold discrepancy between 
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Fig. 37. Immunoprecipitation o f glucose transporters from Thesit-solubilized 
rat adipocytes. Isolated rat adipocytes (1 ml of a 40 % cytocrit) were stimulated 
with 10 nM insulin and then photolabelled with ATB-BMPA. The unbound label was 
removed by washing in 1 % albumin/Hepes buffer. The cells were then directly 
solubilized in 2 % Thesit detergent buffer for 20 min at 18 °C. The unsolubilized 
material was then removed by centrifugation at 2 0 , 0 0 0  g for 1 0  min and was found 
to contain virtually no labelled glucose transporter (Fig. 37a). The solubilized 
material was incubated with anti-GLUTl and anti-GLUT4 antibodies attached to 
protein A-Sepharose (GLUT4 peak =  3500 Dpm, GLUT1 peak =  400 Dpm). The 
supernatant after immunoprecipitation was chloroform/methanol precipitated and the 
labelled protein content was analysed. Virtually all the labelled glucose transporter 

















Fig. 38. Immunoprecipitation of GLUT1 and GLUT4 from ATB-BMPA labelled 
rat adipose cells. Isolated rat adipose cells (1 ml of a 40 % cytocrit) were incubated 
with (#,4) or without (O A  10 nM insulin for 20 min then photolabelled with 1 mCi 
ATB-[2-3H]BMPA (2 x 30 sec irradiation). A crude plasma membrane fraction was 
prepared and divided in half, then solubilized in 2 % Thesit detergent buffer. Each 
half was then subjected to successive immunoprecipitation with anti-GLUTl and anti- 
GLUT4 antibodies and analysed by electrophoresis. In a, GLUT1 was 
immunoprecipitated before GLUT4 (M ; 340 dpm with insulin, 96 dpm basal or after 
GLUT4 (0 ,0 ); 300 dpm with insulin, 48 dpm basal. In b, GLUT4 was 
immunoprecipitated before GLUT1 (4,A); 3764 dpm with insulin, 136 dpm basal or 
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3.4.6. Trvpsin-Treatment of Immunoprecipitated GLUT4
GLUT1 has a number of possible trypsin cleavage sites, but under native 
conditions GLUT1 is only cleaved within its cytoplasmic central loop and C-termini 
to give an 18 kDa ATB-BMPA-labelled fragment (section 3.2.6.). Comparison of the 
GLUT1 and GLUT4 amino acid sequences shows that GLUT4 has a similar pattern 
of possible cleavage sites to GLUT1, but GLUT4 also has an arginine in the exofacial 
loop between TM9 and TM10, which is not found in GLUT1. To examine the 
susceptibility of the GLUT4 isoform to trypsin cleavage, we first immunoprecipitated 
GLUT4 from ATB-BMPA-labelled rat adipocyte membrane fractions, then treated the 
immobilized GLUT4 with trypsin. This allowed removal of the non-specifically 
labelled 75 kDa protein that could also be trypsin-susceptible and so complicate the 
results.
Fig. 39 shows that when GLUT4 from plasma membranes and low density 
microsomes were treated with trypsin, a labelled 18 kDa fragment was produced from 
both fractions. The fact that labelled 18 and 50 kDa peaks were visible after trypsin 
cleavage shows that the GLUT4 is not in a denatured form after 2 % Thesit 
solubilization and immunoprecipitation as all the other possible cleavage sites have not 
become accessible.
When immunoprecipitated GLUT4 was treated with trypsin and the 
immunopellet and supernatant analysed separately, all the 18 kDa trypsin fragment 
was found in the supernatant (Fig. 40). The majority of the remaining 50 kDa 
glucose transporter was still attached to the immunopellet, but a small amount was 
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Fig. 39. Trypsin treatment o f plasma membrane and low density microsome 
GLUT4. Plasma membrane (0 , PM) and low density microsome (A, LDM) fractions 
were prepared from insulin-stimulated rat adipocytes as described in section 2.5.7.. 
150 fig of membrane was labelled with 250 /iCi ATB-[2-3H]BMPA then solubilized 
in 2 % Thesit detergent buffer. The solubilized membrane was then incubated 
overnight with 5 ng purified anti-GLUT4 antibody attached to 12 /xl protein A- 
Sepharose. The immunoprecipitates were washed then treated with 10 units of trypsin 
for 45 min. Electrophoresis sample buffer was then added and the released protein 
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Fig. 40. Trypsin treatment of immunoprecipitated rat adipocyte GLUT4.
insulin-stimulated isolated rat adipocytes (1 ml of a 40 % cytocrit) were labelled with 
250 f i d  of ATB-[2-3H]BMPA then washed and directly solubilized in 2 % Thesit 
detergent buffer. After immunoprecipitation of the GLUT4, trypsin (100 units/ml) 
was added for 30 min then the immunopellet (A) and the supernatant ( • )  were analysed 
by electrophoresis on a 12 % acrylamide gel.
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3.4.7. Localisation of GLUT4 in Basal and Insulin-Stimulated Cells by ATB-BMPA 
Labelling of Subcellular Fractions
In order to determine where GLUT4 is localised in basal and insulin-stimulated 
cells, plasma membrane and low density microsome fractions were isolated as 
described (section 2.5.7.), then photolabelled with ATB-[2-3H]BMPA and 
immunoprecipitated with anti-GLUT4 antibodies. The results were calculated as a 
percentage of the radioactivity in the insulin-treated plasma membrane sample (Fig. 
41). The increase in plasma membrane GLUT4 after insulin-stimulation was 
determined by this method to be only approximately 3-fold, compared to an average 
transport stimulation of 35-fold. The increase in GLUT4 in the plasma membrane in 
the insulin-stimulated state was accompanied by a decrease in the low density 
microsomes, the total being similar in basal and insulin-stimulated cells. The 
difficulties in fractionating rat adipocytes reproducibly resulted in large standard 
errors. The amount of the GLUT4 isoform in the basal plasma membrane was only 
approximately 10 % of the total in basal cells. Therefore even a small contamination 
of the plasma membrane fraction by low density microsomes would increase the 
apparent number of basal plasma membrane glucose transporters and so underestimate 
the stimulation due to insulin.
3.4.8. GLUT4 Distribution in Basal and Insulin-Stimulated Cells by Western Blotting
Basal and insulin-stimulated cells were subfractionated into 



















Ins PM Bas PM Ins LDM Bas LDM Ins Tot Bas Tot
Fig. 41. Immunoprecipitation of GLUT4 from ATB-BMPA-labelled membrane 
fractions isolated from rat adipose cells. Basal and insulin-treated isolated rat 
adipocytes were fractionated and plasma membrane and low density microsome 
fractions (200 ng) were labelled with 200 ^Ci of ATB-[2-3H]BMPA. The membranes 
were solubilized in 2 % Thesit detergent buffer and immunoprecipitated with anti- 
GLUT4 antibody attached to protein A-Sepharose. The immunoprecipitated material 
was subjected to electrophoresis. The total radioactivity per sample was calculated 
as a percentage of the radioactivity in the insulin-treated plasma membrane sample. 
The results are the means ± S.E.M. from three experiments.
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microsome fractions. 10 fig of each fraction was run on SDS-PAGE then transferred 
to nitrocellulose and probed with anti-GLUT4 antibody then 125I-protein A. The 125I 
band corresponding to the glucose transporter was excised and counted and the counts 
(after a nonspecific background was removed) were multiplied by the total protein to 
give the amount of GLUT4 in each fraction. An approximate 5 fold increase in 
plasma membrane GLUT4 after insulin-stimulation was measured by this method and 
there was a corresponding decrease of GLUT4 from the low-density microsome 
fraction (Fig. 42). In insulin-stimulated cells approximately 45 % of the GLUT4 was 
found to be at the plasma membrane. The 5 fold increase observed with this method 
is still small compared to the approximate 2 0  fold increase seen with 
immunoprecipitation of ATB-BMPA labelled glucose transporters from isolated 
adipocytes (section 3.4.5) and compared to the average 35-fold transport stimulation. 
As with ATB-BMPA labelling of membrane fractions (section 3.4.7.), the main reason 
for this small increase in GLUT4 is likely to be an artificially high basal due to 
contamination of plasma membrane with high and low-density microsomes. 85 % of 
the GLUT4 in the basal state was located in the microsomal fraction, so even a small 
contamination of the plasma membrane with this fraction would increase the basal 
considerably. A small amount of GLUT4 was detected in the HDM fraction and the 
mitochondria/nuclei fraction, which is probably in part due to a contamination with 
low density microsomes and plasma membrane.
3.4.9. Inhibition of Glucose Transporter Translocation by Potassium Cyanide










-  300 -
h-
E  2 0 0  -
CL
Q
100  -  
0  -
Bas Ins Bas Ins Bas Ins Bas Ins 
PM HDM LDM Mit/Nuc
Fig. 42. Western blotting of basal and insulin-stimulated rat adipocyte
membrane fractions with anti-GLUT4 antibody. Isolated rat adipocytes (2 ml of
a 40 % cytocrit) were incubated with or without insulin (10 nM, 20 min) then
fractionated into plasma membrane (PM), mitochondria/nuclei (Mit/Nuc), high density
microsomes (HDM) and low density microsomes (LDM) as described (section 2.5.7.).
10 fig of each fraction was separated on a 1.5 mm, 10 % acrylamide gel and then
transferred to nitrocellulose. The nitrocellulose was blotted with anti-GLUT4
antibody then 0.1 ^Ci/ml 125I-protein A. It was then exposed to film and cut and
counted. The counts obtained for 10 fig were multiplied by the total protein per
fraction, which did not vary significantly between basal and insulin-stimulated
samples. The results are expressed as the mean and standard error (n=4) of
Dpm/total protein.
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and can be inhibited by KCN (Kono et al, 1981). The effect of KCN on glucose 
transporter translocation in isolated rat adipocytes upon addition and removal of 
insulin was investigated.
Cells were stimulated with insulin in the presence or absence of 2 mM 
potassium cyanide, then assayed for 3-0-methyl-D-glucose transport activity and 
labelled with ATB-BMPA to determine plasma membrane glucose transporter levels. 
KCN added 2 min prior to the addition of insulin blocked the insulin-stimulation of 
glucose transport activity keeping the activity close to basal levels. The rate constants 
for 3-O-methyl-D-glucose transport were: in basal cells k = 0.0021 s’1, in KCN and 
insulin-treated cells k = 0.0021 s'1 and in insulin-treated cells k = 0.198 s'1.
The addition of KCN before insulin also appeared to totally block translocation 
of the glucose transporter as cell surface glucose transporter levels were found to be 
similar to basal levels (Fig. 43a). To check that cyanide did not interfere with ATB- 
BMPA labelling of the glucose transporter, rat adipose cells were fully stimulated with 
insulin then incubated with or without 2 mM cyanide for 2 min before being labelled 
with ATB-BMPA. Fig. 43b shows that the addition of cyanide does not affect 
labelling of insulin-stimulated cells by ATB-BMPA. Addition of cyanide after full 
insulin stimulation also had no effect on glucose transport activity.
It has been reported that cyanide also blocks fully the effects of removing 
insulin from fully stimulated cells (Kono et al, 1981). The effect of cyanide on the 
reversal of insulin-stimulated glucose transport activity in isolated rat adipocytes was 
investigated. It was found that 2 mM KCN only partially blocked the decrease in 
glucose transport activity due to removal of insulin. Transport activity in KCN-treated 
cells was still approximately 50 % of the fully insulin-stimulated level. KCN was also 












Fig. 43. Effect of KCN on glucose transporter translocation and ATB-BMPA 
labelling. The effect of KCN when added before and after insulin treatment was 
investigated, a) Isolated rat adipose cells (1 ml of a 40 % cytocrit) were untreated 
( • )  or treated with 10 nM insulin alone (4) or with 2 mM KCN for 2 min then 10 nM 
insulin for 20 min (O ). After labelling with 333 /xCi ATB-BMPA a crude plasma 
membrane fraction was isolated and analysed by electrophoresis, b) Insulin-stimulated 
isolated rat adipocytes (1 ml of a 40 % cytocrit) were incubated with (O ) or without 
(A) 2 mM KCN for 2 min before labelling with 500 f i d  ATB-BMPA. Cells were 
then washed, solubilized in 2 % Thesit detergent buffer and immunoprecipitated with 
anti-GLUT4 antibody. The immunoprecipitated protein was then analysed by 
electrophoresis and cutting and counting gel slices.
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3.4.10. The Time Course For Activation of Insulin-stimulated Glucose Transport
The time course for insulin-stimulated glucose transport activity in rat 
adipocytes was compared with the time course of appearance of the GLUT1 and 
GLUT4 isoforms at the plasma membrane (as determined by their ability to bind 
ATB-BMPA). Rat adipose cells were stimulated with insulin and then at various times 
KCN was added to stop further translocation and photolabelling was carried out 
immediately.
Stimulation of 3-O-methyl-D-glucose transport with 2 nM insulin was rapid at 
37 °C, giving a maximum stimulation after only approximately 10 min (Fig. 44a). 
A log plot of the data (Fig. 44b) had a positive intercept on the time axis suggesting 
there was a lag time for activation. The lag time, calculated as the intercept on the 
time axis, was 47.1 ± 9.5 sec (n = 5). As the intercept on the time axis was positive, 
the W2 was not calculated from the slope of this plot in the normal way, but was 
calculated as t = (ln2 -c)/m, where c is the intercept on the y axis and m is the slope. 
This gave a tV2 of 3.2 ± 0.2 min (n = 5).
Fig. 44a also shows the time course of appearance of the glucose transporter 
isoforms, GLUT1 and GLUT4 at the plasma membrane. Like transport, the 
appearance at the cell surface was very rapid with maximum levels by 10 min. The 
log plot of this data (Fig. 44b) showed no detectable lag and the half-times for the 
appearance of GLUT1 and GLUT4 at the plasma membrane were calculated from the 
slope to be 2.32 ± 0.30 min and 2.17 ± 0.18 min respectively, (n = 3). Therefore
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Fig. 44. Time course for the insulin-stimulation o f glucose transport and for the 
appearance o f cell-surface transporters. Isolated rat adipocytes were treated with 
2 nM insulin for the indicated times. After addition of 2 mM KCN, 3-O-methyl-D- 
glucose transport ( • )  was measured and cell-surface glucose transporters were 
photolabelled with ATB-BMPA. Following labelling, the cells were washed and 
directly solubilized in 2 % Thesit detergent buffer, then immunoprecipitated with 
antibodies to GLUT1 (■) and to GLUT4 (□). The immunoprecipitates were then 
analysed by electrophoresis. The results in a) were calculated as a fraction of the 
fully stimulated level of transport or labelling, with subtraction of the levels found in 
basal cells, and are the mean ±  S.E.M. from three to five experiments. In b) the 
lines were derived from regression (weighted for relative error) of the combined 
GLUT1 and GLUT4 labelling or transport. Insulin-stimulation of glucose transport 
( • )  showed a lag time of 47.1 ±  9.5 sec (n=5) and a half time of 3.2 + 0.2 min 
(n=5). The appearance of GLUT1 (■) and GLUT4 (□) at the cell surface occurred 
with half times of 2.32 +  0.30 min and 2.17 ±  0.18 min respectively (n=3).
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the transporters appeared at the plasma membrane with no significant lag and their 
appearance slightly preceded the full transport stimulation.
The experimental errors involved in the determination of cell-surface 
transporters were found to be greater than those involved in the determination of 
transport activity. Although the mean values (from 3-5 experiments) for the 
transporter levels and the transport rate were different, at some points the S.E.M. 
values for these estimates overlapped. The maximum difference between transporter 
appearance and transport stimulation (which was only approximately 2  fold) occurred 
only at short times after insulin addition. This small difference was less evident when 
insulin concentrations higher than 2 nm were used. This result, along with the two­
fold discrepancy observed between transport stimulation and transporter appearance 
may be due to insulin also producing a small change in the intrinsic activity of the 
glucose transporters as well as its major effect on their translocation to the plasma 
membrane.
3.4.11. Reversal of Insulin-Stimulated Glucose Transport
Cells were fully stimulated with insulin and then either the cells were washed 
at least 4 times to remove the insulin or alternatively, the insulin was removed by 
digestion with a low concentration (0.25 mg/ml) of collagenase. At each time point, 
translocation was stopped by the addition of 2 mM potassium cyanide, and this was 
followed quickly by transport and ATB-BMPA photolabelling assays. Fig. 45a shows 
that reversal of insulin-stimulated glucose transport was less rapid than activation. 
Removal of insulin caused an approximate 90 % decrease in transport, the transport
level returning to near basal levels. The t l/z for the reversal of transport (tV2 = 10.9 
± 1 . 4  min, n = 3) was similar to the half-time for the decrease in cell-surface GLUT1 
and GLUT4 levels, tVz = 11.7 ± 2.7 min (n = 3) for GLUT1 and tVz = 12.3 ± 3.0 
min (n = 2) for GLUT4 (Fig. 45b). Therefore there was no detectable lag between 
loss of transport activity and removal of the transporters from the cell surface.
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Fig. 45. Time course for the decrease in glucose transport activity and cell- 
surface transporters upon removal o f insulin. Isolated rat adipocytes were fully 
stimulated with 1 nM insulin for 30 min then the insulin was removed by washing or 
by the addition of collagenase (0.25 mg/ml). At the indicated times after insulin 
removal, 2 mM KCN was added and 3-O-methyl-D-glucose transport ( • )  was 
measured and the remaining cell-surface transporters were labelled with ATB-BMPA. 
Following labelling, the cells were washed and directly solubilized in 2 % Thesit 
detergent buffer, then immunoprecipitated with antibodies to GLUT1 (O ) and GLUT4 
( • ) .  The immunoprecipitates were then analysed by electrophoresis. The results were 
calculated as a fraction of the frilly stimulated level of transport or labelling, with 
subtraction of the levels found in basal cells, and are the mean ±  S.E.M. from two 
to three experiments. Half times were calculated from semi-log plots of these data. 
The half times for reversal of transport and cell-surface GLUT1 and GLUT4 were 
10.9 ±  1.4 min (n=3), 11.7 ±  2.7 min (n=3) and 12.3 ±  3.0 min (n=2) 
respectively.
















CHAPTER 4 : DISCUSSION
4.1. Photolabelling the Erythrocyte Glucose Transporter with ATB-BMPA
ASA-BMPA, a 4-azidosalicylate derivative of the bis-mannose compound (1,3- 
bis-(D-mannos-4-yloxy)-2-propylamine, BMP A) has been used by Holman et al (1986) 
to label the erythrocyte glucose transporter. Holman et al, (1986) found that ASA- 
BMPA specifically labels this glucose transporter protein when labelling is carried out 
on intact erythrocytes. However, when labelling of the glucose transporter with ASA- 
BMPA is carried out on erythrocyte membranes, ASA-BMPA also labels other 
proteins that are unrelated to the glucose transporter (Holman, G. D., Parkar, B. A. 
& Midgley, P. J. W. unpublished data). The diazirine derivative of BMPA (2-N-(l- 
azi-2,2,2-trifluoroethy 1) benzoyl-1,3 -bis- (D-m annos-4-y loxy) -2-propylamine, ATB- 
BMPA) is used in this study to label the erythrocyte glucose transporter. Diazirines 
are photoactivated to give reactive carbenes. Nitrenes undergo similar reactions to 
those of carbenes but the reactivity of nitrenes is considerably lower (Bayley & 
Knowles, 1977). The results described in this thesis show that ATB-BMPA labels the 
erythrocyte glucose transporter to give a single broad peak on SDS-PAGE at ~ 50 
kDa. ATB-BMPA is also shown to label only the glucose transporter protein, but no 
other proteins, when labelling is carried out on erythrocyte membranes. The labelling 
of the glucose transporter by ATB-BMPA is displaceable by D-glucose. The 
displacement of ATB-BMPA-labelling by a transported substrate of the glucose 
transporter, suggests that ATB-BMPA may bind to the transporter at or near the 
external ligand-binding site. ATB-BMPA labelling of the glucose transporter is also 
displaced by cytochalasin B. Davies et al, (1992) have localised the site of
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cytochalasin B labelling in the erythrocyte glucose transporter to the region 
phenylalanine 389 to tryptophan 412 at the bottom of TM10 and TM11. The finding 
that cytochalasin B binding to the internal surface of the transporter inhibits the 
binding of ATB-BMPA to the external surface suggests that the transporter can not 
bind internal and external ligands simultaneously.
Results described in this thesis show that GLUT1 is the major isoform in 
erythrocytes. An antibody has been produced against a peptide corresponding to the 
C-terminal 13 amino acids of the HepG2/GLUTl sequence reported by Mueckler et 
al (1985). The anti-GLUTl antibody immunoprecipitates over 80 % of the ATB- 
BMPA-labelled glucose transporter protein from solubilized erythrocyte membranes.
The efficiency of ATB-BMPA-labelling of erythrocyte GLUT1 is calculated 
to be * 100 %. This is calculated assuming the concentration of glucose transporter 
protein in the erythrocyte plasma membrane to be 600 pmol/mg of membrane protein 
(Allard & Lienhard, 1985). 90 pmol of transporter incorporates 5.7 pmol of ATB- 
BMPA. Therefore 6.3 % of the glucose transporter sites are labelled with ATB- 
BMPA. The affinity constant (or half maximal inhibition constant, Kj) of erythrocyte 
GLUT1 for ATB-BMPA is calculated to be * 350 pM. Therefore, at the ATB-BMPA 
concentration used (20 pM) the sites will be 5.4 % saturated. The efficiency of 
labelling is therefore calculated as 117 %. Similar studies in 3T3-L1 adipocytes and 
rat adipocytes also suggest the labelling by ATB-BMPA is approximately 100 % 
efficient (Palfreyman et al, 1992, Nishimura et al, 1993). Therefore, if all the sites 
are occupied by ligand, then all the sites would covalently cross-link with the ATB- 
BMPA.
The affinity of the erythrocyte glucose transporter for ATB-BMPA has been 
determined in two ways: either from the inhibition of the uptake of 100 pM D-
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galactose by ATB-BMPA or from the inhibition of the reversible binding of the 
exofacial label ASA-BMPA. The affinity constant (Kj) is determined from transport 
inhibition experiments to be * 297 pM at 20 °C. The Kj is determined from the 
binding experiments to be « 368 pM at 0 °C and ~ 338 pM at 20 °C. Therefore, the 
two methods give similar Kj values for the affinity of GLUT1 for ATB-BMPA. ATB- 
BMPA binding to GLUT1 does not show any marked temperature dependence. The 
Kj obtained for GLUT1 binding of ATB-BMPA is similar to the value obtained by 
Jordan & Holman (1992) for the affinity of the liver transporter for ATB-BMPA (Kj 
« 250 pM), where GLUT2 is the major glucose transporter isoform. Also Holman 
et al (1990) reported a Kj of * 247 pM for ATB-BMPA binding in basal and insulin- 
stimulated rat adipocytes where GLUT4 is the major isoform. Therefore GLUT1, 
GLUT2 and GLUT4 appear to have a similar affinity for the external ligand ATB- 
BMPA. By contrast, Hellwig & Joost (1991) have reported that GLUT1, GLUT2 and 
GLUT4 vary markedly in their affinities for transported substrates and for inside- 
specific ligands, cytochalasin B and forskolin.
A lack of temperature dependence for ATB-BMPA binding to erythrocyte 
GLUT1 is described in this thesis. Midgley et al, (1985b) have reported a similar lack 
of temperature-dependence for the bis-mannose derivative nitroazidophenyl-BMPA 
binding to the erythrocyte glucose transporter. The Kj is dependent on the equilibrium 
dissociation constant:
Kj = . (1+A)
(where A is the asymmetry in the unloaded carrier distribution; that is, the rate 
constant for empty carrier movement from outside to inside over the rate constant for 
empty carrier movement from inside to outside). Lowe and Walmsley, (1986) have 
studied the temperature-dependence of erythrocyte glucose transporter kinetics. Their
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results show a large decrease in the Vmax of the transporter as the temperature 
decreases from 20 °C to 0 °C. Little temperature-dependence of was observed. 
Lowe & Walmsley (1986) reported a large decrease in the proportion of both 
unloaded- and loaded-outward-facing carriers as the temperature was decreased from 
50 °C to 0 °C. Therefore a lowering of temperature, which apparently increases A, 
would have to produce a corresponding decrease in so that there is no overall 
effect on the K*. There is no evidence presently available to suggest that the 
dissociation constant is temperature-dependent. This apparent discrepancy 
between the observed lack of temperature effects on ligand binding and the marked 
temperature effect on glucose transport activity requires further investigation.
Erythrocyte GLUT1 has six cysteine residues at positions 133, 201, 207, 347, 
421 and 429 (Mueckler et al, 1985). Fragmentation of the ATB-BMPA-labelled 
purified erythrocyte glucose transporter at cysteine residues, by NTCB, is shown in 
this thesis to produce ATB-BMPA-labelled fragments on SDS-PAGE of approximate 
molecular weight 6  kDa, 14 kDa, 23 kDa, 29 kDa and 50 kDa. The labelled 
fragments have been further identified by using antibodies to the C-terminal and to the 
central cytoplasmic loop of GLUT1. The immunoprecipitation of a 14 kDa labelled 
fragment by the antibody to the central loop of GLUT1 suggests that ATB-BMPA 
must label the region between cysteines 201 or 207 and cysteine 347. The C-terminal 
antibody also immunoprecipitates a 14 kDa fragment suggesting that ATB-BMPA 
labels between cysteine 347 and the C-terminal of GLUT1. Therefore, these results 
suggest that ATB-BMPA may label more than one site in the C-terminal region of 
GLUT1. A subsequent study in collaboration with Baldwin’s group has used anti­
peptide antibodies, generated against all the cytoplasmic loop regions of GLUT1, to
more accurately identify ATB-BMPA-labelled fragments produced after chemical and 
proteolytic cleavage of the glucose transporter (Davies et al, 1992). The results of this 
study suggest that the major site of labelling of GLUT1 by ATB-BMPA is around 
TM8  between alanine 301 and arginine 330. Holman & Rees, (1987) have identified 
TM9 in GLUT1 as the site of labelling of ASA-BMPA. The identification of the 
labelled fragments in their study was based solely on the molecular weight of the 
fragments as seen on SDS-PAGE. The differences observed between the sites of 
labelling of ATB-BMPA and ASA-BMPA may be due to inaccuracies in identifying 
the labelled fragments in the various methods used. However, the differences in the 
structures of the photoactivatable groups (ATB and ASA) on the bis-mannose ligands 
may result in the compounds fitting into the GLUT1 substrate binding site in slightly 
different orientations. Upon activation of the ligands, the reactive carbene and nitrene 
groups may be facing different regions of the binding site and so label different 
transmembrane segments. In addition, it is known that azides and diazirines show 
reactivity towards different types of amino acid side chains (Bayley & Knowles, 
1977).
4.2. Investigation of Glucose Transporter Conformational Changes Using Proteinases
ATB-BMPA is shown in this thesis to bind to the C-terminal half of GLUT1. 
Photolabelling of erythrocyte GLUT1 with ATB-BMPA, followed by trypsin- or 
thermolysin-treatment of the transporter, produces a labelled fragment on SDS-PAGB 
of * 18 kDa. The 18 kDa fragment is derived from the C-terminal half of GLUT1 as 
the fragment can be immunoprecipitated by an anti-GLUTl C-terminal peptide
antibody. The effect of binding of the external ligand (ATB-BMPA) and the internal 
ligand (cytochalasin B) on the susceptibility of the glucose transporter to proteolysis 
is reported in this thesis. When ATB-BMPA-labelled-GLUTl is treated with trypsin 
~ 50 % of the native transporter is converted to an 18 kDa tryptic fragment. Some 
of the 18 kDa tryptic fragment is still immunoprecipitatable with the GLUT1 anti-C- 
terminal peptide antibody. Therefore, some of the ATB-BMPA-labelled tryptic 
fragment must still retain its C-terminal antibody-binding fragment. By contrast, when 
unlabelled GLUT1 is treated with trypsin, almost complete conversion of the native 
transporter to an 18 kDa fragment is observed. Therefore, ATB-BMPA stabilizes a 
conformation of GLUT1 that is more resistant to proteolysis by trypsin than the 
unlabelled transporter. The protection from thermolysin-cleavage by ATB-BMPA 
binding to GLUT1 is even more pronounced. Thermolysin-treated ATB-BMPA- 
labelled GLUT1 is fully immunoprecipitated as a 50 kDa protein, demonstrating that 
neither the central loop nor the C-terminal regions of GLUT1 have been cleaved. 
Cairns et al, (1987) showed that trypsin and thermolysin cleaved the native glucose 
transporter solely at the cytoplasmic face. Therefore, this protection from proteolysis 
of GLUT1 by the outside-binding ligand can not be due to steric hindrance. The 
outside-specific ligand is thought to stabilize an outward-facing conformation in which 
the proteolytic cleavage sites are not accessible. These results support those of a 
number of other investigators. Holman & Rees, (1987) found that thermolysin cleaved 
the cytochalasin B-labelled transporter and not the ASA-BMPA-labelled transporter. 
The rate of tryptic cleavage of the erythrocyte glucose transporter was shown by Gibbs 
et al (1988) to be slower in the presence of the outside ligands, phloretin or 4,6-0- 
ethylidene-D-glucose.
At a concentration of thermolysin that is 6  times lower than that which
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produces no cleavage of the ATB-BMPA-labelled transporter, virtually complete 
cleavage of cytochalasin B-labelled GLUT1 is observed. Therefore, cytochalasin B 
appears to stabilize a conformation that is more susceptible to proteolysis than the 
conformation stabilized by the outside binding ligand, ATB-BMPA. This is consistent 
with the comparison of the ASA-BMPA- and cytochalasin B-labelled glucose 
transporters (Holman & Rees, 1987). King et al, (1991) have also reported that the 
non-covalent binding of the inside-specific hexose, propyl glucoside, to GLUT1 
renders the transporter more susceptible to proteolysis.
The results described in this thesis show that the native erythrocyte glucose 
transporter (GLUT1) and the tryptic fragment differ markedly in their affinities for the 
external ligand ATB-BMPA and for the transported substrate D-glucose. Trypsin- 
treated erythrocyte membranes show 10-12-fold less ATB-BMPA-labelling than the 
native transporter. This suggests that the affinity for ATB-BMPA is markedly reduced 
in the trypsin fragment. By contrast, the D-glucose affinity is increased * 6-fold. 
Results presented here are therefore consistent with those of Cairns et al (1987) who 
have shown that the Kj for D-glucose inhibition of cytochalasin B-binding to the 
tryptic fragment is reduced by approximately 10-fold compared to the Kj for D- 
glucose inhibition of cytochalasin B-binding to the unproteolysed transporter. Binding 
of the inside-specific ligand, cytochalasin B, to the trypsin fragment has been shown 
to be only slightly less efficient than binding of cytochalasin B to the native glucose 
transporter (Karim et al, 1987, Cairns et al, 1987).
Oka et al, (1990) have shown that deletion of the C-terminal 37 amino acids 
of GLUT1 produces a mutant transporter that still binds cytochalasin B efficiently, 
shows poor binding of the exofacial ligand ATB-BMPA, and loss of the ability to
167
transport glucose. Lin et al, (1992) have shown that deletion of the C-terminal 12 
amino acids of GLUT1 produces a mutant glucose transporter which retains its ability 
to bind the external and internal ligands and its ability to transport glucose. To further 
explore the region of the C-terminal that is required for ligand binding, additional C- 
terminal deletion mutants have been investigated here. The results described in this 
thesis show that the ability of GLUT1 to bind ATB-BMPA is lost upon deletion of 
the 25th residue at the C-terminal of the protein. A mutant GLUT1 lacking the C- 
terminal 24 amino acid residues still binds ATB-BMPA efficiently. The ability to 
bind cytochalasin B is retained when 24 or 25 amino acids are deleted from the C- 
terminal of GLUT1. Therefore, upon deletion of 25 amino acids from the C-terminal 
of GLUT1, the transporter may adopt a similar conformation to that adopted by the 
GLUT1 tryptic fragment as they both have a reduced affinity for the external ligand, 
ATB-BMPA. In addition, it has been reported that both the GLUT1 tiyptic fragment 
(Baldwin et al, 1980) and a GLUT1 deletion mutant lacking the 37 C-terminal amino 
acids (Oka et al, 1990) lose the ability to transport glucose.
The truncated mutant and the GLUT1 tryptic fragment may be adopting an 
inward-facing conformation. This inward-facing conformation could expose the inside 
binding site and so enable the mutant GLUT1 to bind cytochalasin B. The alternating 
conformational change that exposes the external site may involve TM12 moving up 
in the membrane. The truncation of the C-terminal segment of TM12 may prevent 
this upward movement. May, (1989) has shown that the binding of cytochalasin B 
to GLUT1 results in a decrease in the cell-surface accessibility, to permeable thiol 
reagents, of the top of TM12. This observation is consistent with the possibility that 
this segment moves down in the membrane when cytochalasin B is bound. The 
binding of exofacial ligands such as maltose increase the accessibility to the treatment
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with the thiol reagent, which is consistent with TM12 moving up in the membrane 
(May, 1989).
The susceptibility of the GLUT4 glucose transporter isoform to proteolysis is 
also shown here to be dependant on the liganded state of the transporter protein. Oka 
et al (1988) and Yano & May (1993) have reported that no low molecular weight 
fragments are detected on SDS-PAGE after trypsin-treatment of cytochalasin B- 
labelled GLUT4. These authors suggest that trypsin cleaves GLUT4 more extensively 
than is observed with GLUT1. Additional cleavage of GLUT4 within the C-terminal 
half of the transporter would reduce the 18 kDa fragment normally observed with 
GLUT1 cleavage to smaller fragments that are not detectable on SDS-PAGE. The 
results in this thesis show that trypsin-treatment of ATB-BMPA-labelled GLUT4 from 
rat adipocytes produces a labelled 18 kDa fragment. ATB-BMPA-labelled GLUT4 
has been immunoprecipitated from Thesit-solubilized adipocyte membranes with anti- 
GLUT4 antibody and subsequently treated with trypsin. The trypsin-treatment of 
GLUT4 results in complete removal of the C-terminal antibody-binding fragment of 
the transporter. The ATB-BMPA-labelled 18 kDa GLUT4 fragment no longer 
precipitates with the antibody-protein A-Sepharose conjugate. The finding that 
cleavage of ATB-BMPA-labelled GLUT4 by trypsin produces a significant amount of 
an 18 kDa fragment suggests that the ATB-BMPA-labelled GLUT4 is cleaved less 
extensively than cytochalasin B-labelled GLUT4. Yano & May, (1993) have reported 
that cleavage of GLUT4 by thermolysin is retarded by the exofacial ligand, 4,6-0- 
ethylidene-D-glucose. Therefore ATB-BMPA, and other external ligands, may be 
stabilizing a conformation in which a number of sites in the C-terminal half of 
GLUT4 are protected from proteolysis. Cytochalasin B binding to GLUT4 may
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expose these cleavage sites. The structure of the GLUT4 glucose transporter could 
be further investigated using a number of other proteinases and chemical cleavage 
reagents. The GLUT1 and GLUT4 isoforms may differ in their susceptibility to 
various proteinases and chemical cleavage reagents and produce different proteolytic 
fragments. A difference between GLUT1 and GLUT4 cleavage by trypsin has already 
been observed. These different proteolytic patterns may help to identify differences 
in the conformations of GLUT1 and GLUT4. A difference between the conformations 
of the glucose transporters in the basal and insulin-stimulated states may be identified.
4.3. The Structure-Function Relationship of GLUT1
There are presently known to be six different mammalian glucose transporter 
isoforms (GLUT’S 1-5 & 7, this is reviewed in section 1.1.). These glucose 
transporter isoforms have now been sequenced from a number of different species 
including human, rat, mouse, pig and rabbit. A number of other sugar transporters 
have been sequenced and display some sequence identity with the mammalian glucose 
transporter family. These include sugar transporters from bacteria, yeast, 
cyanobacteria and protozoa. Some of the sugar transporters in this superfamily 
cotransport protons or possibly other ions during the sugar transport process. All these 
sugar transporters are thought to have a similar structure to that proposed for GLUT1 
(Mueckler et al, 1985). Sequence alignment of the members of the glucose transporter 
family identifies residues that are highly conserved in all or most of the transporters.
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This should provide information on which residues may be important or essential for 
maintenance of the common structure and function. The residues that are predicted 
to be important can then be studied using site-directed mutagenesis, followed by 
expression of these mutated glucose transporters in cells such as CHO cells or 
Xenopus oocytes.
29 sequences of members of the sugar transporter superfamily have been 
sequenced aligned by Dr. P Hodgson (University of Bath). The alignment is shown 
in Table 8. The sequence alignment shows that asparagine (N) and glutamine (Q) 
residues are highly conserved especially around the top of TM’s 7 and 8. Asparagine 
(Asn) and glutamine (Gin) residues can participate in hydrogen bonding, both as 
hydrogen donors and as hydrogen acceptors. Therefore, these residues may be 
involved in hydrogen bonding to a sugar molecule in the external or internal binding 
sites or they may be involved in the transport of the sugar through the glucose 
transporter protein. Studies described in this thesis examine the importance of Gln282 
and Asn288 in TM7 and Asp317 in TM8 of GLUT1 in the ability of GLUT1 to bind 
ligands and to transport 2-deoxy-D-glucose. The amide residues are substituted with 
the aliphatic residues leucine (Leu) and isoleucine (lie), residues which can not 
participate in hydrogen bonding. The GLUT1 mutants are expressed at the cell- 
surface of CHO-K1 cells as detected by Western blotting or by borohydride-labelling 
of cell-surface carbohydrate followed by specific immunoprecipitation of labelled 
GLUT1. None of the Asn or Gin mutants lose the ability to transport 2-deoxy-D- 
glucose or to bind the internal ligand, cytochalasin B. Therefore, none of these 
residues are an absolute requirement for transport or for binding of cytochalasin B. 
This may seem surprising considering the degree of conservation of these residues. 
A number of these residues may be involved in the transport of sugars through the
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HUMGLUT1 (282-294) Q Q L S G I N A V F Y Y S
RATGLUT1 (282-294) Q Q L S G I N A V F Y Y S
MUSGLUT1 (282-294) Q Q L S G I N A V F Y Y S
RABGLUT1 (282-294) Q Q L S G I N A V F Y Y S
PIGGLUT1 (241-253) Q Q L S G I N A V F Y Y S
HUMGLUT2 (314-326) Q Q F S G I N G I F Y Y S
RATGLUT2 (312-324) Q Q F S G I N G I F Y Y S
MUSGLUT2 (313-325) Q Q F S G I N G I F Y Y S
HUMGLUT3 (280-292) Q Q L S G I N A V F Y Y S
HUMGLUT4 (298-310) Q Q L S G 1 N A V F Y Y S
RATGLUT4 (298-310) Q Q L S G I N A V F Y Y S
MUSGLUT4 (300-312) Q Q L S G I N A V F Y Y S
HUMGLUT5 (288-300) Q Q L S G V N A I Y Y Y A
HUMGLUT7 (312-324) Q Q T S G V N G I F Y Y H
HUMGLUT1 (378-389) F F E V G P G P I P W F
RATGLUT1 (378-389) F F E V G P G P I P W F
MUSGLUT1 (378-389) F F E V G P G P I P W F
RABGLUT1 (378-389) F F E V G P G P I P W F
PIGGLUT1 (337-348) F F E V G P G P I P W F
HUMGLUT2 (410-421) F F E I G P G P I P W F
RATGLUT2 (408-419) F F E I G P G P I P W F
MUSGLUT2 (409-420) F F E I G P G P I P W F
HUMGLUT3 (376-387) F F E I G P G P I P W F
HUMGLUT4 (394-405) F F E I G P G P I P W F
RATGLUT4 (394-405) F F E I G P G P I P W F
MUSGLUT4 (396-407) F F E I G P G P I P W F
HUMGLUT5 (386-397) G H A L G P S P I P A L
HUMGLUT7 (408-419) F F E I G P I P I P F F
Table 8. Sequence alignment o f GLUT’S 1-7 around transmembrane segments 7 
and 10. Sequences of GLUT’S 1-7 were sequence aligned by Dr P. Hodgson. The 
sequence alignments around transmembrane segments 7 and 10 are shown. Mutation 
of the residues Gln282, Tyr293 and Pro385 (from GLUT1) resulted in perturbation 
of GLUT1 function.
protein and the mutation of just one residue may be compensated for by the presence 
of the other residues. Although no change in transport or internal ligand binding is 
observed with these mutants, substitution of Gln282 with a leucine residue selectively 
perturbs binding of the external ligand, ATB-BMPA. In the predicted 2-dimensional 
model for GLUT1 (Mueckler et al, 1985) Gln282 is located towards the centre of 
TM7. Therefore, TM7 may move up in the membrane to accept exofacial ligands. 
The mutagenesis results are consistent with the studies using proteases described 
above. The upward-movement of TM7 may move a region at the bottom of TM7, 
possibly including a proteolytic cleavage site, further into the membrane. This could 
be investigated further by studying the extent of proteolysis of the wild-type GLUT1 
and the Gln282-Leu mutant. If the Gln282-Leu is locked in an inward-facing 
conformation, the Gln282-Leu mutant might be expected to be more extensively 
cleaved than the wild-type GLUT1 if the proteolysis is carried out in the absence of 
internal or external ligands. If the Gln282-Leu mutant can adopt an outward-facing 
conformation but this conformation can not be stabilized by binding of the external 
ligand ATB-BMPA, the ATB-BMPA-bound wild-type GLUT1 may be less susceptible 
to trypsin-cleavage than the Gln282-Leu mutant.
Maiden et al (1987) have suggested that the two halves of the glucose 
transporter protein may be arranged in a similar manner as there is a high degree of 
duplication of sequences in the N- and C-terminal halves of the protein. Mueckler et 
al (1985) have suggested that as transmembrane segments 7, 8 and 11 are predicted 
to be amphipathic, they may form part of a hydrophilic channel. The results described 
here suggest that both TM7 and TM12 may move up in the membrane to accept 
exofacial ligands. The six transmembrane segments of the C-terminal half of GLUT1 
may be arranged concentrically, with TM7 next to TM12, to form a channel. The
outside site would be occupied by upward movement of TM7 and TM12. In this 
conformation of the protein, the binding of a nontransported ligand may be very 
dependent on glutamine 282. However, a transported substrate such as 2-deoxy-D- 
glucose would be rapidly relayed from the exofacial site to the inside site by a cluster 
of hydrogen-bonding residues in the centre of the protein. In this position in the 
centre of the protein, a single amino acid substitution might be less critical. 
Therefore, 2-deoxy-D-glucose binding and transport would be less dependent on 
glutamine 282. However, as substitution of glutamine 282 alters the specificity of the 
exofacial site, the transport of hexoses other than 2-deoxy-D-glucose may be 
perturbed. Therefore, the transport properties of other glucose analogues in the 
glutamine 282 mutant clone may provide important information regarding the 
interactions involved in the transport of sugars through the glucose transporter. 
Further investigation of the importance of these Gin and Asn residues could involve 
the study of a mutant in which two or three of these residues has been substituted.
To investigate further the role of TM7 in the transport of hexoses by GLUT1, 
the tyrosine (Tyr) residues 292 and 293, which are predicted to be at the top of TM7 
(Mueckler et al, 1985), have been studied. The motif Q^QXSGXNXXXYY293 is 
present in all mammalian glucose transporters and is widely conserved in members of 
the wider glucose transporter superfamily (Dr. P Hodgson, University of Bath, Table 
8). Barnett et al, (1973a,b) have studied the binding of D-glucose analogues to the 
inside and outside binding sites of the erythrocyte GLUT1 transporter. Studies with 
C6 analogues of D-glucose led Barnett et al (1973a) to propose that hydrogen bonding 
and hydrophobic binding may contribute to the binding of glucose analogues to the 
external binding site. The authors suggested that either a tryptophan or a tyrosine
residue suitably placed with respect to the C6 position of the sugar could fulfil both 
of these functions. Tyrosine’s 292 and 293 at the top of TM7 may form part of the 
proposed hydrophobic region at the exofacial substrate binding site. The effects of 
substituting Tyr292 and Tyr293 by phenylalanine (Phe) and isoleucine (lie) on 
GLUT1 transport activity and ligand-binding properties are reported here. 
Phenylalanine has a similar aromatic side chain to that of tyrosine but it lacks a 
hydroxyl and is unable to participate in hydrogen bonding. Isoleucine is a smaller, 
less bulky residue than tyrosine and is unable to participate in hydrogen bonding. 
Substitutions of Tyr292 by either phenylalanine or isoleucine are tolerated by GLUT1 
and the mutant glucose transporters show no reduction in glucose transport activity 
or in external or internal ligand binding. The mutant Tyr293-Phe is also fully 
functional as a glucose transporter. However, when tyrosine 293 is substituted by 
isoleucine the ability of the mutant GLUT1 to transport glucose and to bind the 
internal ligand cytochalasin B is lost. By contrast, the ability of the Tyr293-Ile 
mutant to bind ATB-BMPA is retained. These results suggest that the hydrogen 
bonding properties of tyrosines 292 and 293 are not essential for glucose transporter 
function. However, the size of tyrosine residue must be important as well as its 
hydrophobicity as the relatively small but hydrophobic residue, isoleucine, affects the 
functioning of the transporter whereas the large hydrophobic residue, phenylalanine 
does not. The Tyr293-Ile mutant may be unable to undergo the conformational 
change that transports the sugar from outside to inside and that subsequently exposes 
the inside site and possibly a proteolytic cleavage site.
This could be investigated further by examining the susceptibility to 
proteolysis of the wild-type and the Tyr293-Ile mutant. If the Tyr293-Ile mutant is 
locked in an outward-facing conformation it may be less susceptible to cleavage by
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trypsin than the unliganded wild-type GLUT1.
The conformational changes involved in external and internal ligand binding 
and transport by GLUT1 are likely to involve other transmembrane segments as well 
as TM7 and TM12. Molecular modelling studies (Hodgson, Osguthorpe & Holman, 
manuscript in preparation) suggest that the putative TM10 can undergo remarkably 
large conformational changes that may alternately expose the hexose binding site to 
the external and internal solution. These authors (Hodgson, Osguthorpe & Holman, 
manuscript in preparation) suggest that proline 385 in GLUT1 is particularly important 
in producing a pivotal point for these conformational changes. Proline 385 is situated 
in a proline rich region. The amino acid motif F378FEVGPGPIPW388 which is 
predicted to occur in TM10 (Mueckler et al, 1985) is widely conserved in all 
mammalian glucose transporters (Dr. P Hodgson, University of Bath, Table 8). 
Mutagenesis of tryptophan 388 in GLUT1 has been shown to result in reduced binding 
of cytochalasin B (Katagiri et al, 1991, Garcia et al, 1992). The authors suggest that 
tryptophan 388 may comprise part of the inside binding site. Davies et al, (1992) 
have localised the site of labelling of cytochalasin B to the region phenylalanine 389 
to tryptophan 412 at the bottom of TM10 and TM11. Proline (Pro) is the only 
mammalian imino acid. As such, its side chain is bonded to the tertiary nitrogen in 
a cyclic pyrrolidine ring. Prolines may have both structural and dynamic roles in 
membrane proteins (this topic is reviewed by Williams & Deber, 1991). Structural 
roles include purely static effects such as those arising from a kinked helix, as well 
as electronic effects that stem from increased local polarity. Evidence for a more 
dynamic, transport catalysis role has come from mutagenesis studies on membrane 
proteins in which perturbations of transport occur as a result of proline mutation
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(Williams & Deber, 1991).
The results of the substitution of proline 385 by isoleucine (lie) and glycine 
(Gly) on the transport and ligand-binding abilities of GLUT1 are described here. 
Isoleucine is a large aliphatic residue, whereas glycine is smaller with only a single 
hydrogen on its side chain. Substitution of Pro385 by lie produces a mutant GLUT1 
with greatly reduced transport activity and with no ability to bind the external ligand 
ATB-BMPA. Binding of the internal ligand cytochalasin B is unaffected by the 
mutation of Pro385 to Be. By contrast, substitution of Pro385 by the less bulky 
residue Gly is tolerated and the mutant GLUT1 retains the ability to bind both the 
external and internal ligands and to transport 2-deoxy-D-glucose. Interestingly, proline 
385 is conserved in all members of the wider glucose transporter family other than in 
the SNF3 galactose transporter from Saccharomyces cerevisiae, where glycine is 
present at this position (Celenza et al, 1988).
Therefore, conformational changes of the GLUT1 protein may require the 
flexibility of the proline-rich region around TM10. The effect of the glycine 
substitution, which maintains the transport function of GLUT1, may be because it 
provides a non-hindering atomic environment for rotation around prolines 383 and
387. The substitution of proline 385 by isoleucine clearly perturbs the transport 
function and the ability of GLUT1 to expose a site at the external surface. The 
conformation of the transporter may however be relatively stable as the cytochalasin 
B binding is unperturbed by the isoleucine substitution. Further work could be carried 
out to examine whether the proposed upward movement of TM’s 7 and 12 are part 
of the conformational change that is prevented by the mutation of Pro385 to Be. If 
the Pro385-Ile mutant is locked in an inward-facing conformation it may be more 
susceptible to proteolytic cleavage than wild-type GLUT1 Pro385-fle, if this inward-
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facing conformation involves the downward movement of TM’s 7 and 12.
ATB-BMPA has proved to be an important tool in the study of the structure- 
function relationship of GLUT1. The investigation of a number of other amino acid 
residues in both the N- and C-terminal halves of the glucose transporter protein will 
provide further information about the structure of the protein and the way in which 
it transports sugars. When the glucose transporter protein is successfully crystallised 
and a 3-dimensional structure is obtained, this mutagenesis data should be useful in 
providing additional evidence on how these residues (which have been shown to be 
important by mutagenesis) are involved in transport catalysis. A similar technique 
would also provide information about the insulin-responsive isoform (GLUT4) and the 
other members of the glucose transporter family. Regions of the isoforms that are 
responsible for the differences in substrate specificity, kinetic parameters and 
regulation may then be elucidated.
4.4. Insulin-Stimulation of Glucose Transport in the Rat Adipocyte
Holman et al, (1988) have previously used a benzophenone derivative of 
BMPA to label the glucose transporter in isolated rat adipocytes. However, relatively 
long irradiation times were required to activate the photolabile group and so a new 
compound, ATB-BMPA has been developed in order to get improved labelling of the 
adipocyte glucose transporter using a shorter irradiation time.
The results in this thesis show that ATB-BMPA labels the glucose transporter 
in isolated rat adipocytes in a D-glucose- and cytochalasin B-displaceable manner.
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The labelled glucose transporter runs as a band at approximately 50 kDa in our gel 
system which is clearly separated from a non-specific band at approximately 75 kDa. 
A similar non-specific peak has been reported with the exofacial labels BB-BMPA 
(Holman et al, 1988) and B3GL (Jhun et al, 1992). Midgley et al, (1985a) have 
previously shown that BMPA derivatives are not significandy taken up by either 
adipocytes or erythrocytes, neither via the transporter nor through the lipid bilayer. 
The results described here show that ATB-BMPA is non-permeable to the adipocyte 
plasma membrane. When insulin-stimulated rat adipocytes are labelled with ATB- 
BMPA and the plasma membrane and LDM’s are analysed by SDS-PAGE, the ATB- 
BMPA label recovered in the LDM fraction is only « 4 % of that found in the plasma 
membrane. The lack of labelling of the LDM glucose transporters is not because the 
intracellular transporters are unable to bind ATB-BMPA. Glucose transporters in the 
LDM fraction are labelled with ATB-BMPA if the labelling is carried out on 
membrane fractions. Therefore, ATB-BMPA can be used to selectively label those 
glucose transporters that are present at the cell-surface without labelling those in the 
intracellular pool.
The stimulation of glucose transport by insulin is known to involve the 
translocation of glucose transporters from an internal pool to the plasma membrane 
(Cushman & Wardzala, 1980, Suzuki & Kono, 1980). Large differences have been 
reported between the insulin-stimulated increase in glucose transport activity and the 
extent of transporter translocation to the cell-surface. The quantitation of the insulin- 
stimulated increase in cell-surface glucose transporters was initially based on 
measurements (either cytochalasin B binding or Western blotting) using isolated 
plasma membranes while the large stimulations of glucose transport activity (20-30-
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fold) were measured in intact cells. In 1988, James et al (1988) discovered an insulin- 
responsive glucose transporter isoform in adipocytes. Although the existence of 
GLUT4 readily explains why the original Western blotting studies using anti-GLUTl 
antibodies were so discrepant, a substantial disparity remains between glucose 
transport activity and the translocation of the GLUT4 isoform as measured by 
cytochalasin B binding to plasma membrane fractions.
The results described here show that labelling of adipocyte membrane fractions 
with ATB-BMPA, followed by immunoprecipitation of GLUT4 from the membrane 
fractions, only results in an approximate 3-fold increase in plasma membrane GLUT4 
in insulin-stimulated cells. The amount of GLUT4 in the basal plasma membrane is 
only approximately 10 % of the total GLUT4 in basal cells. Therefore, even a small 
contamination of the plasma membrane fraction with low density microsomes will 
increase the apparent number of basal plasma membrane glucose transporters and so 
underestimate the stimulation due to insulin. When ATB-BMPA is used to label cell- 
surface glucose transporters in basal and insulin-stimulated adipocytes, a large (~ 7- 
fold) increase in plasma membrane glucose transporters is observed in the insulin- 
stimulated state compared to the basal state. The increase in plasma membrane 
glucose transporters after insulin-stimulation, as detected by the cell-surface labelling 
method is greater than the increases seen using methods involving labelling or 
Western blotting membrane fractions. Use of the exofacial label, ATB-BMPA and 
antibodies to GLUT1 and GLUT4 have enabled a more detailed examination of the 
individual effects of insulin on each glucose transporter isoform which are described 
here. Both the efficiency of labelling and of immunoprecipitation of GLUT4 and 
GLUT1 must be similar if the photolabelling technique is to give a good 
approximation of the relative cell-surface concentrations of GLUT1 and GLUT4. The
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anti-GLUT4 antibody immunoprecipitates 70-80 % of the labelled glucose transporter 
peak obtained in membranes which are isolated from insulin-stimulated cells but are 
not subjected to immunoprecipitation. This is similar to the efficiency of 
immunoprecipitation of GLUT1 from erythrocyte membranes by the anti-GLUTl 
antibody which is discussed above. The affinity of GLUT1 for ATB-BMPA (Kj *  300 
pM) is reported here and is similar to the affinity of GLUT4 for ATB-BMPA (Kj « 
250 pM) as reported by Holman et al (1990).
Immunoprecipitation of GLUT1 and GLUT4 from ATB-BMPA-labelled cells 
shows that the GLUT4 isoform is the most abundant glucose transporter isoform at 
the cell-surface in basal and insulin-stimulated adipocytes. GLUT4 accounts for « 90 
% of the total plasma membrane glucose transporters after insulin-stimulation. This 
result is consistent with those of Zorzano et al (1989) who found that GLUT4 is the 
most abundant isoform at the cell-surface in insulin-stimulated cells. However, these 
authors suggest that GLUT1 is the major isoform in basal cells, whereas the results 
described here suggest that GLUT4 is the major isoform in basal cells also. 
Calderhead et al, (1990) reported that GLUT1 is the most abundant isoform at the 
cell-surface in basal 3T3-L1 adipocytes. This may be associated with the much 
greater proportion of GLUT1 in 3T3-L1 adipocytes where the ratio of GLUT1 to 
GLUT4 has been reported as 1:1 (Yang et al, 1992b). The basal level of GLUT1 in 
the plasma membrane of rat adipocytes may vary depending on the age and the size 
of the cells. The GLUT1 value for 3-O-methyl-D-glucose exchange transport in 
erythrocytes (Barnett et al, 1973a) and in the oocyte expression system (Gould & 
Lienhard, 1989) is 5-fold higher than the GLUT4 in insulin-stimulated rat 
adipocytes (Whitesell & Gliemann, 1979, Taylor & Holman, 1981). The finding that
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the K,,, in basal cells is similar to that in insulin-stimulated adipocytes (Whitesell & 
Gliemann, 1979, Taylor & Holman, 1981) suggests that the GLUT1 K,,, makes only 
a very small contribution to the operational in basal cells.
Kono et al (1981) have shown that reagents such as KCN, which deplete 
cellular ATP levels, block the stimulation of glucose transport by insulin. The effect 
of KCN on the translocation of GLUT4 has been studied and is described here. 
Addition of KCN prior to insulin addition prevents any increase in cell-surface 
GLUT4 levels as no increase in ATB-BMPA-labelling above basal levels is observed. 
KCN treatment does not inhibit ATB-BMPA-labelling of cell-surface glucose 
transporters in fully insulin-stimulated cells. Therefore, ATP must be required for the 
translocation of the glucose transporters to the plasma membrane. Whether ATP is 
also required for the proposed insulin-induced intrinsic activation of the glucose 
transporter still needs to be investigated. In contrast, KCN only partially blocks the 
decrease in glucose transport activity after insulin removal. Therefore, the activation 
of glucose transport by insulin appears to be more sensitive to ATP depletion than the 
inactivation process. Kozka et al, (1991) have reported a similar failure of KCN to 
prevent the reversal of insulin-stimulated glucose transport activity, upon insulin- 
removal, in 3T3-L1 adipocytes.
The time courses for the insulin-stimulation of glucose transport and for the 
reversal of insulin-stimulated glucose transport have been studied and are described 
in this thesis. The time course for activation of glucose transport by insulin shows a 
lag period of 47 sec and a half time of 3.2 min. A similar lag period for activation 
of glucose transport has been reported by others (Haring et al, 1978, Ciaraldi &
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Olefsky, 1979). The activation of glucose transport is preceded by the appearance of 
both GLUT1 and GLUT4 at the cell-surface with half times of * 2.3 min at 37 °C. 
Kamieli et al, (1981) have shown that the appearance of cytochalasin B binding sites 
at the plasma membrane precede transport stimulation. More recently, the appearance 
of GLUT4 at the plasma membrane, as measured by Western blotting, has been 
reported to precede the appearance of ATB-BMPA-accessible GLUT1 and GLUT4 
when the activation by insulin is carried out at 20 °C (Satoh et al, 1993). This 
evidence suggests that insulin-stimulation of glucose transport may involve an 
activation process as well as translocation of the glucose transporters to the plasma 
membrane. This additional activation step is only likely to produce a small 
stimulation in the absence of translocation. It seems unlikely that all the transporters 
in the basal state are intrinsically inactive. Suzuki & Kono, (1980) reconstituted 
glucose transporters from the LDM fraction into phospholipid vesicles where they 
showed glucose transport activity. The results described here show that glucose 
transporters in the LDM fraction can be labelled at the external site by ATB-BMPA. 
In addition, the results described here show that the discrepancy between GLUT4 
transporter abundance and the transport rate is only ~ 1.5-2-fold in the basal state. 
Thus only a small proportion of the plasma membrane transporters are likely to have 
low intrinsic activity, and it may be these transporters that require a subsequent 
covalent or structural activation by insulin.
The time course for the return of glucose transport activity to basal levels after 
insulin-removal, is much slower than that for transport activation which decreases with 
a tlA  of 10.9 min. This correlates closely with the time courses for the loss of cell- 
surface GLUT1 and GLUT4 levels which decrease with half times of * 12 min. Satoh
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et al, (1993) have used ATB-BMPA to tracer-tag GLUT4 in order to investigate 
GLUT4 recycling. The half time for the loss of cell-surface GLUT4 reported in this 
thesis is similar to the half times (reported by Satoh et al, (1993)) for the 
internalization of the ATB-BMPA-tagged GLUT4 both in the absence and in the 
continuous presence of insulin. Satoh et al, (1993) have found that the internalized 
ATB-BMPA-labelled GLUT4 equilibrates with the entire intracellular pool of glucose 
transporters. Upon restimulation by insulin the half times for the reappearance at the 
cell-surface of both non-tagged and ATB-BMPA-tagged GLUT4 are similar and are 
« 3 min (Satoh et al, 1993). The fact that the internalization of GLUT4 is similar in 
both the continuous presence and in the absence of insulin suggests that the effect of 
insulin to increase cell-surface GLUT4 is not due to a significant decrease in the 
endocytosis of GLUT4. Therefore, the main effect of insulin to increase cell-surface 
GLUT4 is likely to be due mainly to an increase in the exocytosis of GLUT4. Yang 
& Holman, (1993) have reported that the main effect of insulin in stimulating glucose 
transport in 3T3-L1 adipocytes is to increase the GLUT1 and GLUT4 exocytosis rate 
constants.
Jhun et al, (1992) have used a bis-glucose derivative (B3GL) to study GLUT4 
recycling in rat adipocytes. They conclude that insulin modifies both the 
internalization and the extemalization steps of GLUT4 recycling in rat adipocytes. 
However, they report only an 11-fold stimulation of glucose transport by insulin 
compared to a typical 20-40-fold stimulation reported here and by others (Taylor & 
Holman, 1981, Satoh et al, 1993). The lower fold insulin response may be due to an 
increased basal rate of glucose transport activity. Also Jhun et al, (1992) report a tV6 
of 3.2 min for the internalization of B3GL-labelled GLUT4. This half time is very 
short compared to the half time for GLUT4 internalization reported here (tV6 * 12
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min) and the half time reported by Satoh et al (1993) for the internalization of ATB- 
BMPA-tagged GLUT4 of * 10 min. Jhun et al, (1992) stop the translocation of 
GLUT4 by cooling the cells to 10 °C. This cooling may mechanically disrupt the 
adipocytes and alter their fractionation properties as at zero time after labelling plasma 
membrane GLUT4, they already recover ~ 25 % of the total labelled GLUT4 in the 
LDM fraction. By contrast, as reported in this thesis, after fractionation of ATB- 
BMPA labelled adipocytes, only * 4 % of the labelled GLUT4 is recovered in the 
LDM fraction. Therefore, Jhun et al (1992) may be underestimating the insulin- 
induced exocytosis of GLUT4 and overestimating the endocytosis of GLUT4.
A possible explanation for the much slower rate of GLUT4 internalization and 
recycling (\ lA ~ 10 min) than the initial stimulation of translocation (tV6 ~ 2-3 min) 
may be that the glucose transporter is recycled through a number of intermediate states 
in the cytosol. Slot et al, (1991a) have identified 11 separate locations of 
immunodetectable GLUT4, eight are cytoplasmic and three are associated with the 
plasma membrane. Satoh et al, (1993) have described a hypothetical mechanism for 
insulin’s stimulatory action on glucose transport based on the original hypothetical 
mechanism described by Kamieli et al (1981) and the histochemical data of Slot et 
al (1991a). The model suggests that the GLUT4 can be in an occluded state (in which 
it can be detected in the plasma membrane by Western blotting only), a partially 
occluded state (in which it can be detected by Western blotting and can bind the 
photolabel ATB-BMPA) and the fully functional state (in which it can be detected by 
blotting and by ATB-BMPA labelling and can also transport glucose).
ATB-BMPA has proved to be a useful tool in the study of the regulation of 
glucose transport in the rat adipocyte. The impermeable nature of ATB-BMPA (which
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has circumvented the need for subcellular fractionation) has allowed a more accurate 
estimate of the effect of insulin on GLUT1 and GLUT4 translocation. Also, the 
ability of ATB-BMPA to label plasma membrane glucose transporters in intact cells 
has allowed a comparison of the time courses for the insulin-stimulation of GLUT1 
and GLUT4 translocation and glucose transport activity. The results have shown that 
the activation of glucose transport by insulin is preceded by the appearance of GLUT1 
and GLUT4 at the cell-surface.
As ATB-BMPA-tagged glucose transporters are recycled in a similar manner 
to non-tagged transporters, ATB-BMPA should be useful in defining the intermediate 
states involved in the recycling process. Further analysis of ATB-BMPA-labelled 
glucose transporter-containing vesicles could identify proteins involved in the 
movement and docking of the intracellular vesicles. The effect of inhibitors of 
signalling pathway intermediates from other cell types on glucose transporter 
translocation, could help identify those intermediates that are involved in the insulin- 
signalling pathway in rat adipocytes.
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